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Summary
The mechanisms involved in osteoblast and adipocyte differentiation from the 
common progenitor, mesenchymal stem cell (MSC) are not fully understood. 
The nucleoside, adenosine, exists in all cells and is known to be involved in 
cell growth, proliferation and apoptosis by interacting with four distinct 
receptors (Ai, A2A, A2b and A3). The aims of this study was to investigate the 
expression and function of adenosine receptors in 1) MSCs and as they 
differentiated into osteoblasts and adipocytes and in 2) mouse 7F2 and 
human osteoblasts and during their transdifferentiation to adipocytes.
Rat MSCs and 7F2 osteoblasts expressed all four adenosine receptors. 
Osteoblast differentiation was associated with increases in A2A and A2b 
receptor expression and their activation stimulated the expression of alkaline 
phosphatase, core binding factor a1 and mineralisation. Adenosine also 
stimulated adipogenesis (lipid accumulation, peroxisome proliferator-activated 
receptor, CCAAT/enhancer binding protein a and lipoprotein lipase 
expression) of MSCs which was accompanied by increased A-i and A2a 
receptor expression.
Transdifferentiation of 7F2 cells to adipocytes was associated with increased 
Ai, but decreased A2a and A2b receptor expression. Loss of A2 receptors in 
adipocytes was supported by reduced cAMP and extracellular signal 
regulated kinase responses to adenosine. Adenosine also stimulated 
transdifferentiation of human osteoblasts to adipocytes by inducing lipoprotein 
lipase and inhibiting alkaline phosphatase and osteocalcin expression. 
Overexpression of Ai receptors in 7F2 cells stimulated adipogenesis (lipid 
accumulation and lipoprotein lipase expression) whereas overexpression of 
A2b receptors stimulated alkaline phophatase expression and inhibited 
adipogenesis.
These results show that adenosine receptor expression and function is 
involved in lineage specific differentiation or transdifferentiation; A2b receptors 
are associated with MSCs and osteoblasts and Ai receptors with adipocytes. 
Targeting adenosine signal pathways may thus be useful as an adjunct 
therapy for the prevention or treatment of conditions in which there is 
insufficient bone or excessive adipocyte formation.
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1.1 Mesenchymal stem cells (MSCs) and osteogenic and adipogenic 
differentiation
1.1.1 Stem cells
Stem cells are non-specialised cells defined by their self-renewal ability and 
differentiation potential. They exist as undifferentiated or poorly differentiated 
cells that lack the functional characteristics of their progeny, and they maintain 
this undifferentiated phenotype until they are exposed to appropriate 
differentiation signals (Fuchs and Segre, 2000; Reya et al., 2001; Thomson et 
al., 1998). They are capable of asymmetric cell division and give rise to two 
daughter cells, one of which remains as a stem cell and the other follows a 
path of proliferation and differentiation. This unique asymmetry enables stem 
cells to undergo continuous self-renewal and indefinite proliferation allowing a 
constant pool of undifferentiated stem cells and subsequent specific lineage 
differentiation to be maintained (Lin, 2008; Morrison and Kimble, 2006). The 
differentiation potency however is not always the same and stem cells are 
classified according to their potential for differentiation, as totipotent, 
pluripotent and multipotent depending on the number of potential cell types 
that can arise (Wagers and Weissman, 2004). Mammalian zygotes are 
considered to be totipotent and these cells have the potential to generate all 
of the cell types in the body (McKay, 2000). Pluripotent cells are descendants 
of totipotent stem cells and give rise to cells of the three embryonic germ 
layers: ectoderm, mesoderm, and endoderm (Thomson et al., 1998). 
Pluripotent cells undergo further specialisation into more developmental^ 
restricted multipotent cells that give rise to a limited number of cell lineages 
within a single germ layer.
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1.1.2 Adult stem cells
Many adult tissues contain multipotent stem cells (adult stem cells) that, as 
opposed to embryonic stem cells, persist throughout life. Adult stem cells are 
responsible for maintaining the integrity and function of tissues by replacing 
the cells that are lost through normal tissue turnover or through apoptosis or 
necrosis following infection or injury (Mimeault and Batra, 2006). They lack 
tissue specific characteristics and remain quiescent until activated by 
appropriate signals to divide and differentiate into specialised cells. These 
cells may be tissue specific, e.g. residing in the brain (neuronal stem cells), 
skin (epidermal stem cells), eye (retinal stem cells) and gut (intestinal crypt 
stem cells) or may be located in other tissues that serve as stem cell 
reservoirs e.g. bone marrow which harbour multiple populations of stem cells 
with different properties (Li and Xie, 2005; Moore and Lemischka, 2006; 
Spradling et al., 2001). The bone marrow contains both haemopoietic stem 
cells (HSC) and MSCs. HSC have been used for many years in a therapeutic 
setting as a basis for bone marrow transplantation (Dupont, 1997) and MSCs 
contribute to the regeneration of multiple mesodermal tissue types (Pittenger 
et al., 1999). MSCs have been studied extensively in recent years and have 
been used in clinical settings (Granero-Molto et al., 2008; Horwitz et al., 2002; 
Koc et al., 2000; Krampera et al., 2006).
1.1.3 MSCs
The existence of cells with multilineage mesenchymal differentiation capacity 
was first demonstrated by Friedenstein and co-workers, who described the 
osteogenic potential of small population of cells in the bone marrow
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(Friedenstein et al., 1966). Moreover, they demonstrated that in vitro 
cultivation of bone marrow cells at low density in a liquid medium containing 
serum gave rise to colonies of plastic-adherent cells with a fibroblastic 
appearance, which they defined as colony forming unit-fibroblasts (CFU-Fs). 
These cells had high proliferative capacity in vitro and when transplanted 
resulted in the generation of bone (Friedenstein et al., 1970; Friedenstein et 
al., 1974; Owen and Friedenstein, 1988). As a result of these observations the 
concept of multipotent stem cells capable of differentiating into mesenchymal 
lineages including myocytes, chondrocytes, adipocytes, osteoblasts and 
tendonocytes was proposed by Caplan (1991) who was the first to use the 
term mesenchymal stem cell (Caplan, 1991). These investigations formed the 
basis of further studies which demonstrated that bone marrow derived stromal 
cells were able to form a mixture of osseous and cartilaginous tissue in vivo or 
to differentiate into osteoblasts, chondrocytes and adipocytes in vitro (Awad et 
al., 1999; Bruder et al., 1998; Kadiyala et al., 1997; Krampera et al., 2006; 
Pittenger et al., 1999). Recent studies, however, questioned the ability of 
indefinite self-renewal and the multipotent properties of MSCs, and for this 
reason, The International Society for Cellular Therapy (ISCT) proposed that 
MSCs should be called multipotent stromal cells (Horwitz et al., 2005).
1.1.3.1 Source of MSCs
MSCs represent a very small percentage (0.0001 - 0.01%) of nucleated cells 
in the bone marrow, but can be expanded using standard cell culture 
techniques (Pittenger et al., 1999; Sakaguchi et al., 2005). Human MSCs are 
often obtained from aspirates of bone marrow harvested from the superior
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iliac crest of the pelvis (Pittenger et al., 1999; Risbud et al., 2006). They have 
also been isolated from the tibial and femoral marrow compartments and 
thoracic and lumbar spine (D'lppolito et al., 2002; Murphy et al., 2002). Apart 
from human MSCs, other well characterised MSC models include those of rat 
and mouse origin. MSCs from cow, pig, horse and sheep have also been 
investigated, particularly in possible therapeutic applications (Baddoo et al., 
2003; Bosnakovski et al., 2005; Moscoso et al., 2005; Santa Maria et al., 
2004). In rodents, bone marrow is typically obtained from the mid-diaphysis of 
the tibia or femur, whereas in large animals it is often harvested from the 
superior iliac crest of the pelvis. In addition to bone marrow, MSCs or MSC- 
like cells have been isolated from a number of tissues including; adult skeletal 
muscle, adipose tissue, lung, dental pulp, amniotic fluid and fetal lung and 
liver (Anker et al., 2003; Campagnoli et al., 2001; Gronthos et al., 2000; 
Williams et al., 1999; Zuk et al., 2001; Zvaifler et al., 2000).
1.1.3.2 Isolation and characterisation of MSCs
Traditionally, MSCs have been isolated utilising their physical property of 
selective adherence (compared to haemopoietic cells) to plastic surfaces 
(Luria et al., 1971). Whilst this eliminates many types of cells, macrophages, 
endothelial cells, lymphocytes, and smooth muscle cells may also adhere to 
plastic (Deans and Moseley, 2000). Further purification can be obtained by 
serial passaging, the resulting cultures are, however, still morphologically and 
functionally heterogeneous and commonly contain undifferentiated stem cells 
and lineage restricted precursors with varying differentiation capacities (Colter 
et al., 2000; Javazon et al., 2001). Considerable efforts have been made to
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isolate a more homogenous MSC population using centrifugation over a 
Percoll gradient which allows the enrichment of nucleated cells and 
subsequent selection using MSC specific cell surface markers which are 
absent from haemopoietic cells (Pittenger et al., 1999; Simmons and Torok- 
Storb, 1991). However, such attempts are hampered by the lack of MSC 
specific markers. To date, there is no established phenotypic definition for 
MSCs; they do express a number of cell surface molecules, such as CD44, 
CD105, CD106, CD166, CD29, CD73, CD90, CD117, STRO-1 and Sca-1 
none of which individually or in combination has been shown to be specific for 
MSCs (Bobis et al., 2006; Tare et al., 2008). On the other hand, MSCs do not 
express markers typical for haemopoietic cell lineages including, CD11b, 
CD31, and CD45 (Bobis et al., 2006; Tare et al., 2008). MSCs are thus best 
characterised using a combination of phenotypic and functional studies and, 
as suggested by the International Society for Cellular Therapy (ISCT), they 
should be defined by their property of plastic adherence, their phenotype and 
their capacity to differentiate into osteoblasts, adipocytes and chondrocytes 
(Dominici et al., 2006).
1.1.3.3 MSCs - commitment and differentiation
The commitment of MSCs to differentiate into different cell lineages is 
mediated by a complex interaction of extracellular mediators. The 
mechanisms are not fully understood, but a number of growth factors and 
hormones such as bone morphogenic proteins (BMPs), wingless type MMTV 
integration site (Wnt) proteins, hedgehog (Hh) proteins, fibroblastic growth 
factors (FGFs), insulin, insulin-like growth factors (IGFs) appear to be involved
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(see section 1.3). These factors are thought to regulate the changes in the 
expression and activation of lineage specific transcription factors that act as 
master switches to drive the differentiation of uncommitted precursors down a 
specific lineage (figure 1.1). For example Sox 5, 6  and 9 regulate chondrocytic 
differentiation and myogenic regulatory factors (MRFs) (including MyoD, 
myogenin, myogenic factor 5 and MRF 4) and myocyte enhancer factor 2 
(MEF2) regulate myogenic differentiation (Blais et al., 2005; Frith and 
Genever, 2008). Factors that regulate MSC differentiation into adipocytes and 
osteoblasts will be discussed in section 1.1.3.4 and 5.
Mesenchymal 
Stem cell
Self-renewal
Commitment
Pre-chondrocytes Pre- osteoblasts Pre-adipocytes Myoblasts
Cbfal
osx
MRFs
MEF2
C/EBPp & 6
PPARy
C/EBPa
SOX 5.6.9
Differentiation
Chondrocytes Osteoblasts Adipocytes Myocytes
Figure 1.1 Differentiation potential of MSCs. Modified from Harada and 
Rodan (2003).
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1.1.3.4 Adipocyte differentiation
The nuclear receptor peroxisome proliferators activated receptor (P P A R y) is 
the key transcription factor involved in adipogenesis (Gimble et al., 1996). 
P P A R y  is expressed as two isoforms P P A R y l and P P A R y2  that are formed as 
a result of alternative splicing; P P A R y2  is the main isoform in adipocytes 
(Tontonoz et al., 1994). P P A R y2  is expressed early in the adipocyte 
differentiation process and at high levels in fat tissue (Kersten et al., 2000; 
Rosen and Spiegelman, 2001) and its requirement in adipogenesis has been 
demonstrated by both gain and loss of function studies. Activation of P P A R y2  
is sufficient to induce adipocyte differentiation of many cell types but its 
absence results in complete lack of adipogenesis in vitro, indicating an 
absolute requirement of P P A R y2  for adipocyte formation (Ren et al., 2002; 
Tontonoz et al., 1994). The roles of P P A R y  in regulation of adipogenesis have 
also been demonstrated by gene knockout strategies in several mouse 
models (Barak et al., 1999; Mueller et al., 2002; Rosen et al., 1999; Zhang et 
al., 2004b). These studies suggest that both P P A R y l and P P A R y2  are 
involved in adipogenic differentiation, but P P A R y2  is the most potent isoform.
CCAAT/enhancer binding proteins (C /E B P ) are also important transcription 
factors involved in adipocyte differentiation. Amongst the C /E B P  family, 
C /E B P a , C /E B P p  and C /E B P 6  are known to promote adipogenesis while 
C /E B P y  is found to inhibit adipogenesis (Darlington et al., 1998). C /E B P p  and 
C /E B P 5  are early markers of adipogenesis and are able to activate expression 
of P P A R y  and C /E B P a  (Clarke et al., 1997; Yeh et al., 1995). When activated,
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C /E B P a  induces expression of several adipogenic genes that are involved in 
the maturation of adipocytes and is also necessary for insulin dependent 
glucose uptake. C/EBPs are therefore important contributors at both the 
commitment and differentiation phases of adipogenesis (Lefterova and Lazar, 
2009; Rosen and MacDougald, 2006).
1.1.3.5 Osteoblast differentiation
The essential regulators of osteoblast lineage cells are the core binding 
protein from the runt family of transcription factors (Runx2) and osterix (OSX). 
Runx2 is also known as osteoblast specific factor 2 (Osf2) or core binding 
factor a1 (Cbfal). Cbfal directs mesenchymal cells to differentiate into 
osteoblasts and inhibits their differentiation into adipocytes (Toshihisa, 2006). 
The role of Cbfal in osteoblast differentiation has been demonstrated in null- 
mutation mice which show a complete lack of both intramembranous and 
endochondral ossification due to the absence of osteoblast differentiation 
(Komori et al., 1997; Otto et al., 1997). Although cartilage is present in Cbfal 
null mice, these animals show a defect in chondrocyte maturation and a lack 
of hypertrophic chondrocytes (Inada et al., 1999). On the other hand 
overexpression of Cbfal induces osteoblast differentiation, bone formation 
and the expression of bone associated markers and matrix mineralisation 
both in vitro and in vivo (Ducy et al., 1997; Zheng et al., 2004).
Mice lacking the OSX gene also show a complete lack of osteoblastic 
differentiation and mineral bone matrix formation. However, unlike Cbfal-null 
mice, MSCs in OSX-null mice maintain their full potential to differentiate into
9
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chondrocytes (Day et al., 2005; Hu et al., 2005; Nakashima et al., 2002). OSX 
may thus be important for directing precursor cells away from the chondrocyte 
lineage and towards the osteoblast lineage. Furthermore, OSX is not 
expressed in Cbfal-null mice, whereas the expression of Cbfal is normal in 
OSX-null mice, indicating that OSX is expressed downstream of Cbfal (Day 
et al., 2005; Hu et al., 2005; Nakashima et al., 2002). Other transcription 
factors involved in differentiation of osteoblasts include those of the Dlx and 
Msx homeodomain families that are homologues of the Drosophila Distal-less 
and muscle specific homeobox genes, respectively (Ichida et al., 2004; Kim et 
al., 2004; Shirakabe et al., 2001; Tadic et al., 2002).
1.2 Inter-relationships between osteoblasts and adipocytes
1.2.1 Transcription factors
Recent studies have shown that transcription factors such as P P A R y  may 
have a dual role in the conversion of MSCs into osteoblasts or adipocytes. 
These studies suggest that a large degree of plasticity exists between 
osteoblasts and adipocytes and that they can form a reciprocal relationship. In 
vitro studies have shown that several P P A R y  agonists, i.e. netoglitazone, 
rosiglitazone and thiazolidinedione, not only induce the differentiation of 
murine and human bone marrow MSCs into adipocytes, but also negatively 
regulate osteoblast differentiation by repressing Cbfal (Ali et al., 2005; 
Lazarenko et al., 2006; Rzonca et al., 2004). Overexpression of P P A R y  in 
MSCs has been shown to preferentially induce adipogenesis rather than 
osteoblastogenesis. When expressed in osteoblasts, P P A R y  suppresses the 
mature osteoblast phenotype and induces expression of genes that are
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associated with an adipocyte-like phenotype, such as adipose protein 2 (aP2), 
fatty acid synthase (FAS), and lipoprotein lipase (LPL) (Lecka-Czernik, 1999).
In vivo studies showed that PPARy function was respectively stimulated or 
inhibited in animal models of bone loss and bone formation. Treatment of 
mice with rosiglitazone increased the volume of bone marrow adipose tissue 
while reducing bone mineral content, bone formation rates, and trabecular 
bone area (Ali et al., 2005; Rzonca et al., 2004). Similar results were observed 
when ovariectomised rats received rosiglitazone (Sottile et al., 2004). A less 
potent ligand, troglitazone, increased bone marrow adipose volume without 
significantly reducing bone mass and trabecular volume (Tornvig et al., 2001). 
Furthermore, mice with congenital mutations in PPARy displayed enhanced 
bone formation (Cock et al., 2004). This increased bone mass was associated 
with a 2  fold increase in osteoblast formation and in vitro studies showed 
there was a similar decrease in adipocyte formation from bone marrow 
derived MSCs (Akune et al., 2004). Consistent with these findings was the 
observation that primary cultured marrow cells lacking PPARy expressed 
several osteoblast markers and key molecules for osteoblast differentiation, 
including Cbfal and OSX (Kawaguchi et al., 2005). On the other hand, Cbfal 
deficient calvarial cells spontaneously differentiate into adipocytes indicating 
that Cbfal has an inhibitory effect on adipocyte differentiation (Kobayashi et 
al., 2000). Together these data suggests that specific expression of lineage 
specific transcription factors has a dual role, favouring the differentiation of 
MSCs toward one cell type and inhibiting differentiation to other cell types.
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1.2.2 Osteoblasts and adipocytes in health and disease
A large body of clinical evidence supports the notion that there is an inverse 
relationship between adipocytes and osteoblasts. For example, ageing which 
has negative effects on bone mass and osteoblast production is also 
associated with an increase in marrow adiposity (Duque, 2008; Gimble J M et 
al., 2006). With advancing age, the number of adipocytes in the bone marrow 
increases, resulting in the appearance of fatty marrow. This is most 
pronounced in the long bones, where up to 90% of the marrow cavity is 
occupied by adipocytes. Marrow adiposity is recognised to be a significant risk 
factor for the long-term capability of maintaining mechanical strength in the 
skeleton (Byers et al., 2001).
In contrast to the elderly, healthy teenagers and young adults have high levels 
of bone in the axial and appendicular skeleton but low levels of adipocytes in 
the marrow. However even in healthy young individuals, the amount of bone 
in the axial and appendicular skeleton have been shown to be inversely 
related to marrow adiposity (Di lorgi et al., 2008). Reduced bone mass is thus 
likely to be partly due to an imbalance in the production of bone-forming and 
fat-forming cells in the marrow. Evidence for this was shown many years ago 
when histomorphometric and radiological examination of bone indicated that 
changes in bone marrow stromal cell dynamics with age could result in 
osteoporosis as a result of replacing the osteoprogenitor cell population with 
adipose tissue in the marrow (Meunier et al., 1971; Moore and Dawson, 
1990). More recently, it has been shown that ageing is associated with 
changes in the intrinsic differentiation potential and the specific marrow
12
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microenvironment necessary for differentiation of MSCs. MSCs derived from 
aged rats have reduced expression of Cbfal, Dlx5, collagen type I and 
osteocalcin and show increased adipogenesis in response to rosiglitazone 
when compared with MSCs isolated from adult animals. Similarly, conditioned 
media from bone marrow cultures of aged animals induced a greater degree 
of adipogenesis (Moerman et al., 2004). Sera from aged individuals have also 
been shown to inhibit the expression of Cbfal, alkaline phosphatase (ALP), 
collagen type I and osteocalcin (Abdallah et al., 2006).
Adipocyte recruitment at the expense of a reduction in osteoblast number may 
also contribute to bone loss in postmenopausal women. After the menopause, 
the rate of bone remodelling increases due to sex steroid deficiency 
(Manolagas, 2000) which is accompanied by an increase in the number of 
early osteoclast and osteoblast progenitors (Jilka et al., 1998). Reduction in 
the number of osteoblast progenitors due to adipocyte recruitment could 
therefore result in an imbalance between formation and resorption and leads 
to progressive bone loss. In fact, several groups have reported an inverse 
relationship between trabecular bone loss and increased marrow adiposity in 
postmenopausal osteoporosis (Griffith et al., 2006; Shen et al., 2007; Verma 
et al., 2002; Yeung et al., 2005). Similar findings have been seen in 
glucocorticoid treatment, increased cortisol production and immobilisation 
(Ahdjoudj et al., 2002; Valentin et al., 2007; Wang et al., 1977).
Together, these observations strengthen the premise that there is a reciprocal 
relationship between adipocyte and osteoblast differentiation. The bone loss
13
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seen in osteoporosis could therefore be an outcome of preferential 
differentiation of mesenchymal cells into the adipocyte at the expense of 
osteoblasts. Inhibiting marrow adipogenesis with a parallel increase in 
osteoblastogenesis could be a useful therapeutic strategy to either prevent or 
treat conditions where there is insufficient bone formation or excessive 
marrow adipogenesis.
1.3 Factors involved in osteoblast and adipocyte differentiation and 
function
Many compounds, including growth factors and hormones have been shown 
to be involved in the differentiation of MSCs to osteoblasts and adipocytes, 
some of the more important are described below. In addition I have focused 
on adenosine signal pathways in the context of differentiation as this is largely 
an unexplored area and the subject of my thesis.
1.3.1 Growth factors
Osteoblasts produce a range of growth factors including the IGFs, platelet 
derived growth factors (PDGF), basic fibroblast growth factors (bFGF), 
transforming growth factor-p (TGF-fc) and BMPs (Nakamura, 2007). These 
factors can act in an autocrine and paracrine fashion and are involved in the 
different stages of the osteoblast differentiation process.
Amongst these factors, BMPs are capable of initiating osteoblastogenesis 
from uncommitted progenitor cells (Katagiri et al., 1994) by stimulating the 
transcription of genes that encode Cbfal and Dlx5 (Abe et al., 2000; Leboy, 
2006; Newberry et al., 1998; Termaat et al., 2005). BMPs are essential for
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osteoblasts to achieve a mature phenotype, characterised by expression of 
ALP, collagen type I, and osteocalcin and the formation of collagen-based 
extracellular matrix and mineral deposition. Inhibition of the BMP signalling 
pathway by noggin (a natural antagonist) has been shown to suppress the 
osteoblast phenotype by inhibiting mineralisation in vitro and in vivo (Abe et 
al., 2000; Devlin etal.,2003).
TGF-p, an abundant molecule in the bone matrix, plays a stage-dependent 
role in osteoblast differentiation. It stimulates bone formation by recruiting 
osteoblast progenitors and stimulating their proliferation, whilst inhibiting 
osteoblast maturation, differentiation and mineralisation. Blocking the 
expression of phenotype-specific genes, such as osteocalcin and ALP 
increases the population of committed osteoblasts (Banerjee et al., 2001; Lee 
et al., 2000). TGF-p and BMPs also influence adipogenic differentiation. TGF- 
p inhibits adipocyte differentiation by blocking the induction of the adipogenic 
transcription factor C/EBPa via interaction with Smad3, Smad6  and Smad7 
proteins (Choy and Derynck, 2003; Choy et al., 2000). In contrast, BMPs, 
under selected culture conditions, stimulate adipocyte differentiation (Hata et 
al., 2003; Sottile and Seuwen, 2000).
Other factors such PDGF, IGFs, and the FGF family can all stimulate 
osteoblast differentiation (Varghese et al., 2000; Zhao et al., 2000). However, 
similar to TGF-p, these factors are only able to influence the replication and 
differentiation of committed osteoblast progenitors towards the osteoblastic
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lineage and are unable to induce osteogenesis in uncommitted mesenchymal 
pluripotent cells.
1.3.2 Leptin
Leptin, an adipocyte-derived hormone that regulates appetite and energy 
expenditure, is also found to have complex effects on bone. The actions of 
leptin on bone can be explained by its ability to act positively and directly, or 
negatively, via stimulation of growth hormone secretion and its effects on the 
hypothalamic pituitary axis (Thomas, 2004). The direct effects of leptin on 
bone appear to be mediated primarily via effects on MSCs (Thomas et al.,
1999). Leptin has been shown to stimulate the proliferation of bone marrow 
MSCs (a murine cell line) and osteoblasts isolated from fetal rats (Steppan et 
al., 2000; Takahashi et al., 1997). It also increased osteoblastic differentiation 
of a conditionally immortalised stromal cell line from human bone marrow, rat 
calvarium cells, and human osteoblasts in long-term cell cultures (Takahashi 
et al., 1997). At the same time, leptin decreases adipocyte differentiation of 
stromal precursors (Hamrick et al., 2005). These findings suggest that leptin 
may regulate the reciprocal differentiation of MSCs along the osteoblast and 
adipocyte lineages. On the other hand some studies have shown that high 
concentrations of leptin induce apoptosis of bone marrow MSCs, decrease 
bone formation, and increase bone resorption (Kim et al., 2003; Martin et al., 
2007). An excess of marrow adipogenesis could therefore result in a very high 
local concentration of leptin in the bone marrow microenvironment and 
contribute to bone loss.
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1.3.3 Wnt signalling
Writs are a large family of secreted glycoproteins that activate the family of 7- 
membrane-spanning frizzled (FZD) receptors to regulate cell growth, 
differentiation, function, and death in many organs and tissues, including bone 
and fat. Wnt signalling can be subclassified as either canonical or non- 
canonical, depending on whether p-catenin is involved (Clevers, 2006). The 
canonical Wnt/p-catenin pathway appears to be important in bone 
development. It is thought to favour differentiation of progenitor cells into 
osteoblasts as opposed to adipocytes, stimulate osteoblast proliferation and 
induce osteoblastogenesis (Baron and Rawadi, 2007; Muruganandan et al., 
2009). In humans, mutations in the Wnt co-receptor low-density lipoprotein 
receptor related protein 5 (LRP5) are shown to be associated with alterations 
in bone mass. Whereas loss of function mutations in the LRP5 gene resulted 
in low bone mass and skeletal fractures, gain of function mutations of LRP5 
have been found to be associated with increased bone density (Gong et al., 
2001; Hofbauer et al., 2002; Little et al., 2002). Similar findings were observed 
by knocking out LRP5 or introducing gain of function mutations in mice (Babij 
et al., 2003; Clement-Lacroix et al., 2005; Kato et al., 2002). In these animals, 
bone resorption was unaffected suggesting Wnt signalling pathways only 
targeted the osteoblasts.
Furthermore, a defect in the p-catenin gene in mesenchymal precursor cells 
was associated with a lack of skeletal bone (Hu et al., 2005). Similarly, a 
spontaneous conversion of various cell types to adipocytes was observed 
following inhibition of p-catenin signalling (Bennett et al., 2002). Activation of
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Wnt/p-catenin signalling pathways in mesenchymal precursors has also 
shown to repress adipogenesis and stimulate osteoblastogenesis. For 
example, overexpression of WntlOb increases bone mass and strength, whilst 
inhibiting adipogenesis and blocking the induction of key adipogenic 
transcription factors C /E B P a  and P P A R y (Bain et al., 2003; Bennett et al., 
2002; Rawadi et al., 2003; Ross et al., 2000).
1.3.4 Transcriptional co-activator with PDZ-binding motif (TAZ)
TAZ is a transcriptional modulator that regulates the functional interaction of 
specific transcription factors with chromatin (Hong et al., 2005; Kanai et al.,
2000). Recently, TAZ has been implicated in the regulation of differentiation of 
MSCs into osteoblasts and adipocytes. It is believed that TAZ directly 
interacts with the regulatory regions of Cbfal and P P A R y  and promote 
osteoblastic differentiation by co-activating Cbfal, whilst inhibiting 
adipogenesis by repressing P P A R y. Binding of TAZ to Cbfal is found to 
increase the expression of osteoblast related genes during terminal osteoblast 
differentiation. In contrast, binding to P P A R y markedly inhibits its ability to 
induce the expression of adipocyte genes such as aP2. In addition, siRNA 
inhibition of TAZ in preadipocytes and MSCs is shown to induce adipogenesis 
at the expense of osteoblastogenesis (Hong et al., 2005). TAZ expression 
appears to increase during osteoblast differentiation and decrease during 
adipocyte differentiation (Hong and Yaffe, 2006).
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1.3.5 Hh signalling
Hh signalling is another pathway that is thought to be involved in the 
regulation of osteoblastogenesis vs adipogenesis. In MSCs activation of Hh 
signalling appears to promote osteoblast rather than adipocyte differentiation. 
Overexpression of Hh signalling is shown to inhibit the expression of the 
adipocyte markers aP2, leptin, C/EBPa and PPARy whilst inducing the 
osteoblast markers osteocalcin and Cbfal in C3H10T1/2 cells (Spinella- 
Jaegle et al., 2001). Furthermore, disruption of the Hh signalling pathway 
resulted in failure of cells to undergo osteoblast differentiation (Long et al., 
2004). In preadipocytes, Hh signalling induced an almost complete inhibition 
of adipocyte differentiation as shown by Oil Red O staining and adipocyte 
marker gene expression (Suh et al., 2006). Hh signalling has also shown to 
inhibit maturation of human MSCs via the targeting of C/EBPa and PPARy 
genes (Fontaine et al., 2008). On the other hand, in preosteoblasts, 
recombinant human sonic Hh potently increases osteoblastic differentiation as 
demonstrated by increased ALP activity, mineralisation and expression of 
osteoblast marker genes (Geertje van der et al., 2003).
1.3.6 Cyclic adenosine monophosphate (cAMP) signalling
cAMP is a secondary messenger in intracellular signal cascades that is 
activated by a wide variety of cellular actions in response to a large number of 
extracellular agents. In the context of bone, parathyroid hormone (PTH) up 
regulates cAMP whereas adenosine can both stimulate and inhibit cAMP via 
different receptor systems. cAMP is produced by adenylate cyclases from 5- 
AMP in the adenosine triphosphate (ATP) metabolic pathway and is rapidly
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degraded by cyclic nucleotide phoshodiesterases (PDEs) that hydrolyse the 
3’-phoshphoester bond to the inactive noncyclic nucleotide 5’-AMP (Fimia and 
Sassone-Corsi, 2001). Changes in cAMP levels are translated into 
intracellular responses through activation of effector proteins, the most 
important of them being cAMP-dependent protein kinase or protein kinase A 
(PKA). PKA is a heterotetrameric holoenzyme consisting of two catalytic 
subunits and one regulatory subunit. cAMP binds to and causes the release of 
the free active catalytic subunits which subsequently migrate into the nucleus 
where they phosphorylate and activate transcriptional activators including the 
cAMP responsive element binding protein (CREB). Subsequently CREB binds 
the cAMP response enhancer element (CRE) typically found in the promoter 
of many cAMP responsive genes to activate transcription (Daniel et al., 1998; 
Sands and Palmer, 2008). Activation of this signalling pathway is involved in 
many cell activities including growth and differentiation.
The importance of the cAMP/PKA/CREB pathway in the induction of 
adipocyte differentiation and maturation has been known for many years. 
Indeed, agents that increase cAMP, such as isobutylmethylxanthine (IBMX) 
have been used, in vitro, as a component of cell culture medium to initiate 
adipogenic differentiation (Farmer, 2006). Activation of the cAMP pathway 
stimulates adipogenesis in murine preadipocytes (3T3-L1) and in human 
MSCs by increasing the expression of many adipocytic genes (Petersen et al., 
2008; Reusch et al., 2000; Watanabe et al., 2003; Yang et al., 2008). A 
remarkable observation is the finding that adipocyte differentiation in mouse 
embryonic fibroblasts from CREB'7' mice is impaired (Zhang et al., 2004a) and
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siRNA mediated depletion of CREB and the closely related activating 
transcription factor-1 (ATF1) in 3T3-L1 cells results in loss of adipogenic 
differentiation (Fox et al., 2006). Overexpression of constitutively active CREB 
is sufficient for initiation of adipogenesis as determined by triacylglycerol 
storage, cell morphology, and the expression of adipocyte marker genes, 
whereas expression of a dominant-negative form of CREB blocks 
adipogenesis (Reusch et al., 2000). Furthermore, the cAMP/CREB pathway 
appears to be associated with a number of events during adipocyte 
differentiation. Activation of cAMP in preadipocytes suppresses Wnt10b and 
Sp1, both of which are negative regulators of adipogenesis (Bennett et al., 
2002; Tang et al., 1999). On the other hand, cAMP/CREB is thought to induce 
C/EBPp and PPARy expression and the production of endogenous PPARy 
ligands (Bennett et al., 2002; Petersen et al., 2008; Tzameli et al., 2004; Yang 
et al., 2008; Zhang et al., 2004a).
The cAMP pathway also has a positive effect on osteoblastogenesis although 
some of the findings are conflicting. Activation of cAMP pathway through PTH 
has been shown to regulate a number of osteoblastic differentiation genes 
such as osteopontin, collagen type I, bone sialoprotein and osteocalcin 
(Boguslawski et al., 2000; Ogata et al., 2000; Yang and Gerstenfeld, 1996). 
PTH has also shown to enhance BMP signalling through cAMP and promote 
osteoblastic function and anabolic actions of new bone formation (Nakao et 
al., 2009). PKA appears to participate synergistically in BMP-2-induced 
osteoblastic differentiation (Sugama et al., 2006; Zhao et al., 2006) and 
inhibiting PKA in murine premyoblast C2C12 cells been shown to repress
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OSX and collagen type I expression and ALP enzyme activity. On the other 
hand, stimulation of cAMP with 8 -Br-cAMP, dibutyryl-cAMP or forskolin 
accelerates BMP-2 induced ALP activity and osteocalcin expression 
(Tsutsumimoto et al., 2002; Zhao et al., 2006) and increases osteoblast 
differentiation in vitro and bone formation in vivo (Siddappa et al., 2008).
The cAMP pathway has also been shown to be involved in the induction of in 
vitro vascular calcification by enhancing osteoblast-like differentiation of 
calcifying vascular cells (Tintut et al., 1998). Moreover, PDE inhibitors that 
cause elevation of the intracellular cAMP have been reported to induce 
osteoblastic differentiation and inhibit osteoclastic differentiation in vitro 
(Tsutsumimoto et al., 2002; Waki et al., 1999). PDE silencing also induced 
osteoblastogenesis as shown by upregulation of several osteogenic genes 
and increased mineralisation (Pekkinen et al., 2008). These data are 
supported by in vivo studies, in which PDE inhibitors have been shown to 
increase bone mass in mice by mainly promoting bone formation (Kinoshita et 
al., 2000). In addition, CRE binding sites have been reported in promoter 
regions of osteoblast associated genes (Huang et al., 2005; Pearman et al., 
1996) and PKA is shown to phosphorylate Cbfal via a PKA phosphorylation 
site (Selvamurugan et al., 2000).
In contrast to a stimulatory role for cAMP in osteoblastogenesis, other 
researchers have suggested a negative action of cAMP on bone formation. 
For example, in the osteoblastic cell line, MC3T3-E1, treatment with cAMP 
elevating agents resulted in degradation of Cbfal and inhibition of
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osteoblastic differentiation (Tintut et al., 1999). Parathyroid hormone-related 
peptide (PTHrP) also inhibits Cbfal expression through the PKA pathway (Li 
et al., 2004). In human MSCs, cAMP reduces the expression of Cbfal and 
osteopontin (Yang et al., 2008) whereas in rodent cells, it inhibits ALP, 
osteocalcin, and collagen type I (Siddappa et al., 2009).
1.3.7 Nucleotides
Nucleotides, such as ATP, adenosine diphosphate (ADP), uridine 
triphosphate (UTP) and uridine diphosphate (UDP) are important extracellular 
signalling molecules that act through cell surface receptors, designated 
purinergic (P)2 receptors. The P2 receptors are grouped into the P2X ligand- 
gated ion channels and P2Y G-protein coupled receptors (GPCRs). Currently, 
there are seven known P2X subtypes (P2Xi_7) and eight P2Y subtypes P2Yi, 
P2Y2, P2Y4, P2Y6, P2Yh, P2Yi2, P2Yi3 and P2YU. Each of these receptors 
has been cloned, characterised and display distinct tissue expression and 
pharmacology (Burnstock, 2007; Ralevic and Burnstock, 1998). Multiple P2 
receptors have been localised to bone, where they elicit a range of responses 
including osteoblast proliferation, bone formation activities and osteoclast 
formation and resorptive capacity (Gallagher, 2004). At least eight different P2 
receptors (P2X2, P2X4, P2X5, P2X7, P2Yi, P2Y2, P2Y4 and P2Y6) are present 
in human osteoblasts and osteoblastic cell lines, but the functional roles for 
these have not been completely clarified (Alqallaf et al., 2009; Gallagher and 
Buckley, 2002; Hoebertz et al., 2003; Hoebertz et al., 2000).
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The P2X5 receptor has been implicated in the stimulation of DNA synthesis 
and thought to be involved in the regulation of osteoblast proliferation 
(Nakamura et al., 2000). The P2X7 receptor is involved in skeletal responses 
to mechanical loading and in cell membrane blebbing in response to high 
concentrations of ATP (Li et al., 2005; Panupinthu et al., 2007). In addition 
studies of mice lacking the P2X7 showed increased bone resorption by 
osteoclasts and decreased bone formation by osteoblasts (Ke et al., 2003). 
Activation of P2Yi and P2Y2 receptors has been shown to modulate the 
actions of systemic factors such as PTH (Bowler et al., 1999; Buckley et al., 
2001). Activation of P2Y2 or P2Y4 with UTP and ATP strongly inhibits 
mineralisation (Orriss et al., 2006; Orriss et al., 2007).
In contrast to the reports of P2 receptor signalling in bone, little is known 
about its receptors in MSCs and adipocytes. A recent study by Coppi et al 
(2007) suggest that ATP is released by undifferentiated human MSCs, 
affecting their proliferation and cell fate (Coppi et al., 2007). ATP and its 
receptors have also been shown to mediate lipogenesis, which regulate fat 
stores independently from insulin stimulated glucose transport (Schodel et al., 
2004). ATP has also been shown to stimulate aP2 expression, without having 
effect on differentiation in 3T3-L1 preadipocyte cells (Omatsu-kanbe et al., 
2006). Expression of the P2Yn receptor in adipocytes on the other hand 
appears to be involved in the inhibition of insulin-stimulated leptin production 
and stimulation of lipolysis (Lee et al., 2005). Many of the effects of ATP are 
however caused by its breakdown product, adenosine, which has been known 
for a long time to be involved in the activities of adipocytes (see section 1.4.9).
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1.4 Adenosine signalling pathway
1.4.1 Adenosine
Adenosine is an endogenous purine ribonucleoside consisting of adenine (the 
purine base) in glycosidic linkage with the sugar, ribose. Besides its role as a 
structural element in building nucleic acids and in energy metabolism, 
adenosine also modulates a variety of physiological responses by interacting 
with specific cell surface receptors. Adenosine was first documented as a 
physiological regulator in the cardiovascular system by Drury and Szent- 
Gyorgyi (1929); later Sattin and Rail (1970) postulated that the regulatory 
effects of adenosine are due to their interaction with specific receptors on the 
cell surface. It is now established that there are four different adenosine 
receptor subtypes; Ai, A2A, A2b and A3. These are also known as P1 receptors 
and have been cloned and pharmacologically characterised from several 
species including human, rat and mouse (Fredholm et al., 2001; Linden, 
2001). Adenosine activates adenosine receptors with different affinities; the 
high affinity A1 (3 - 30 nM) and A2a (1 - 2 0  nM) receptors are activated by 
physiological concentrations and the low affinity A2B (5000 - 20000 nM) and A3 
(>1000 nM) receptors require higher concentrations of adenosine. High 
concentrations of adenosine are found to occur in extreme or pathological 
conditions (Latini and Pedata, 2001; Yuzlenko and Kiec-Kononowicz, 2006).
1.4.2 Adenosine metabolism
Adenosine is normally present in both intracellular and extracellular spaces 
although extracellular levels under cellular resting conditions are low. It is 
established that adenosine is produced by two different pathways that involve
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different substrates, i.e. adenosine monophosphate (AMP) and S- 
adenosylhomocysteine (SAH) (Schrader et al., 1981; Zimmermann, 2000) 
(Figure 1.2). Under basal conditions, intracellular adenosine is mainly formed 
from the sequential dephosphorylation of ATP by a cascade of phosphatases 
(Zimmermann, 2000). The other possible intracellular source of adenosine 
involves the hydrolysis of SAH by SAH hydrolase. This pathway is responsible 
for about one-third of adenosine production under normoxic conditions but 
does not appear to be important in hypoxic conditions (Latini and Pedata, 
2001). Adenosine can also be formed in the extracellular space by breakdown 
of ATP, ADP and AMP that have been transported out of the cell. Under basal 
conditions, adenosine levels in cells and tissue fluids are low (30 - 300 nM). 
When cells become stressed such as during hypoxic events, inflammation and 
tissue injury, increased metabolic activity due to high cellular energy demands 
and low oxygen supply, induces a rise in the dephosphorylation of ATP to 
adenosine (Latini and Pedata, 2001; Pastor-Anglada et al., 2001). In addition 
there is marked efflux of ATP, ADP and AMP into the extracellular space. 
These processes bring about a marked increase in cytoplasmic adenosine 
concentrations and an accumulation of adenosine in the extracellular space 
(Hyde et al., 2001; Pastor-Anglada et al., 2001). Such conditions may lead to 
several hundred fold increases in extracellular adenosine and reach 
concentrations of up to 30 pM (Latini and Pedata, 2001; Pastor-Anglada et al., 
2001). Increased adenosine re-stabilises the ratio of energy supply and 
demand, stimulates vasodilatation and exerts protective effects on the heart 
and brain (Fredholm et al., 2001; Jacobson and Gao, 2006). The half-life of 
adenosine is however short and extracellular adenosine is rapidly converted
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into inosine by adenosine deaminase (ADA) and/or removed by nucleoside 
transporters from the outside to the inside of the cells where it is
phosphorylated back to AMP by adenosine kinase (AK).
Inosine
E-NTPDasesADA
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•Adenosine AMP ADP ATP
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•  •
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Figure 1.2 Pathways of adenosine synthesis and metabolism. Modified
from Blackburn (2003). Adenosine is produced intracellularly from the 
dephosphorylation of AMP by cytosolic-5’ nucleotidases (cyto-5’NT) or by hydrolysis 
of S adenosylhomocysteine (SAH) by SAH hydrolase. Adenosine can also form 
extracellularly by breakdown of ATP, ADP and AMP that have been transported out 
of the cell. Extracellular ATP and ADP are catabolized by a cascade of 
ectonucleoside triphosphate diphosphohydrolase (ENTPDases) to AMP and ecto-5’- 
nucleotidase (CD73) in turn, rapidly dephosphorylates AMP to adenosine. 
Extracellular adenosine can signal via adenosine receptors or it can be deaminated 
to inosine by adenosine deaminase (ADA) or be transported into cells via nucleoside 
transporters (NT). Intracellular adenosine can be secreted or converted back to AMP 
via adenosine kinase (AK). Alternatively it can be deaminated to inosine by ADA.
1.4.2.1 Enzymes involved in metabolism of adenosine
A variety of surface-located enzymes are involved in the extracellular 
hydrolysis of ATP; these, include the ecto-nucleoside triphosphate 
diphosphohydrolase family (E-NTPDase) 1, 2, 3 and 8  that break down ATP
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to ADP and AMP. E-NTPDase1 (CD39) hydrolyses ATP to ADP at the same 
rate as ADP to AMP, whereas NTPDase2 (CD39L1), NTPDase3 (CD39L3) 
and NTPDase8  (ecto-ATPase) show a preference for ATP over ADP as 
substrate and hydrolyse ATP up to thirty times faster than ADP (Kukulski et 
al., 2005; Robson et al., 2006; Zimmermann, 2001).
The rate limiting step in extracellular ATP hydrolysis is the conversion of AMP 
to adenosine which is mediated by ecto-5’-nucleotidase (CD73), a glycosyl 
phosphatidylinositol (GPI)-linked, membrane-bound glycoprotein (Dunwiddie 
et al., 1997; Strater, 2006). It is interesting to mention that CD73 is expressed 
and is used as one of the positive markers for selection of MSCs (Bobis et al., 
2006; Tare et al., 2008). The activity of CD73 controls the levels of ATP/ADP 
versus adenosine by altering the balance of expression and whether P2 or P1 
receptors become activated. Similar enzymes are also involved in the 
intracellular hydrolysis of ATP to adenosine, a notable difference however is 
that CD73 is replaced by structurally unrelated cystolic-5-nucleotidase 
(Strater, 2006).
The important enzymes that catabolise adenosine are, as mentioned above, 
ADA and AK; ADA is a high capacity and high Km (70 juM) enzyme that acts 
mainly on extracellular adenosine whereas AK is a low capacity and low Km 
(40 nM) enzyme and acts mainly intracellularly (Lloyd and Fredholm, 1995; 
Spychala, 2000; Spychala et al., 1996). AK is fully active during resting 
conditions but is inhibited when adenosine concentrations rise (Tabrizchi and 
Bedi, 2001). Under steady state conditions endogenous adenosine
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concentrations are in the nanomolar range and the dominant pathway for 
adenosine metabolism is phosphorylation back to AMP. The activity of ADA 
becomes more relevant at higher adenosine concentrations, such as that 
seen under ischaemic conditions (Lloyd and Fredholm, 1995).
1.4.2.2 Nucleoside transporters
Adenosine generated intracellularly is transported across cell membranes via 
bi-directional nucleoside transporters, which are important in regulation of 
extracellular adenosine concentrations (Noji et al., 2004). These transport 
proteins have been cloned and characterised according to their functional 
characteristics and molecular structure. Two main categories have been 
identified: equilibrative nucleoside transporters (ENTs; solute carrier (SLC) 
29A1-29A2) that balances the intra- and extracellular levels of adenosine 
through facilitated diffusion and concentrative nucleoside transporters (CNTs; 
SLC 28A1-28A3) that mediate the influx of nucleosides into the cell under the 
force of a transmembrane sodium gradient (Baldwin et al., 1999; Cabrita et 
al., 2002; Mangravite et al., 2003). The role of these transporters in regulation 
of adenosine concentration has been studied utilising various adenosine 
transport blockers (for example dipyridamole), which decrease and increase 
extracellular adenosine concentrations (Latini and Pedata, 2001).
1.4.3 Adenosine receptor classification
The original classification of adenosine receptors was based on the order of 
potency of ligands, differing responses to ligands, and antagonism by 
methylxanthines. Adenosine receptors were first divided into Ai and A2
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receptors in studies showing that activation of these receptors by adenosine 
and other adenosine receptor antagonists inhibited or stimulated adenylate 
cyclase activity in cultured mouse brain cells. The order of potency of 
adenosine analogues was different for the two receptors and the effects were 
antagonised by methylxanthines (van Calker et al., 1979). A2 receptors were 
later subdivided into types A2A and A2b- The proposal that A2 receptors could 
be divided into two classes was based on the discovery of high-affinity A2 
receptors in rat striatum and low-affinity A2 receptors throughout the brain, 
both of which were able to activate adenylate cyclase (Daly et al., 1983). This 
classification was confirmed by ligand-binding assays and differential affinity 
towards adenosine derivatives, and later by molecular biological evidence 
(Fredholm et al., 2001). The A3 adenosine receptor is the most recent subtype 
identified, as it had remained pharmacologically obscure until Meyerhof et al 
cloned its gene in 1991 (Zhou et al., 1992). Molecular cloning and expression 
studies have provided clear evidence for the existence of all four adenosine 
receptors.
1.4.4 Structure of adenosine receptors
1.4.4.1 Gene structure
The four adenosine receptors have been cloned and their gene sequences 
reveal that they all belong to the superfamily of GPCRs (Fredholm et al., 
2001). The A1 receptor gene has been cloned in man and animals (rat, 
mouse, dog, cow, rabbit, guinea pig, and chick) and show high sequence 
homology amongst the different species (Yaar, 2005). Although differences in 
the gene sequence between mammalian species for the A-i receptor is 10% at
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most, this is adequate to cause differences in ligand binding and 
desensitisation. For instance, the affinity of the non-selective agonist 5'-N- 
ethylcarboxamidoadenosine (NECA) for Ai is shown to be 9-fold higher in rat 
compared to human cortical membranes and inhibition of adenylate cyclase 
by the selective agonist N6 -cyclopentyladenosine (CPA) is significantly 
greater in guinea pig atria and ventricles when compared with rat (Kapicka et 
al., 2003; Maemoto et al., 1997).
The human Ai receptor gene has been mapped to chromosome 1q32.1. 
Similar to other adenosine receptors, the structure of the Ai receptor contains 
two exons interrupted by a single intron which is in the coding region 
corresponding to the second intracellular protein loop (Fredholm et al., 2000; 
Olah and Stiles, 2000). Genes of all adenosine receptors include part of the 
coding sequence and the entire 3’-untranslated region as the last exon.
There are, however, variations in the 5’-untranslated sequence of adenosine 
receptors. The Ai receptor contains two exons interrupted by an intron at this 
region. This creates two types of transcripts for the human Ai receptor 
containing either exons 1B, 2, and 3 (transcript a ) or 1A, 2, and 3 (transcript 
(3) (figure 1.3). Two separate promoters, which control the relative abundance 
of these transcripts, have been reported as promoter A and promoter B. 
Promoter B and exon 1B are part of intron 1A when promoter A is active (Ren 
and Stiles, 1994; Ren and Stiles, 1995).
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Figure 1.3 Schematic diagram illustrating the structure of the Ai receptor
gene. Adapted from Fredholm (2000).
The A 2a receptor has been cloned from a number of species including human, 
rat, mouse, dog and guinea pig with about 90% sequence homology. The 
human A2A receptor gene has been mapped to chromosome 22q11.23 
(Moreau and Huber, 1999). Two alternative transcripts exist for the A 2a 
receptor gene in rat, which are controlled by two independent promoters (Chu 
et al., 1996)
Adenosine A2B receptors have been cloned from human, mouse and rat and 
localised to either chromosome 11 or chromosome 17 (for the human gene). 
The human A2B receptor shows 8 6  to 87% homology with the rat and mouse 
sequences (Feoktistov and Biaggioni, 1997). A human A2B pseudogene with 
79% homology has also been identified and localised to chromosome 1q32. 
The pseudogene contains multiple deletions, point mutations, and frame shifts 
and is therefore unable to code for a functional receptor (Jacobson et al., 
1995).
Initially isolated as an orphan receptor, the A3 receptor has now been cloned 
in human, rat, dog, rabbit and sheep and localised to human chromosome
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1p21-p13 (Meyerhof et al., 1991). This receptor has the highest interspecies 
sequence variation with a 30% difference identified in the human and rabbit 
genes; this reflects the observed differences in potencies of agonist and 
antagonist compounds such as methylxanthines (Fredholm et al., 2001). The 
human A3 receptor has two transcripts of 2 and 5 kilobases, with the latter 
being less abundant (Atkinson et al., 1997).
1.4.4.2 Protein structure
In regard to protein structure, adenosine receptors are typical of GPCRs, with 
seven a-helical transmembrane spanning domains connected by three 
extracellular and three intracellular loops with the amino-terminus located in 
the extracellular space and the C-terminus on the cytoplasmic side (figure 
1.4). Each of the seven transmembrane domains is composed of 
approximately 21 - 28 hydrophobic amino acids. The extracellular loops, in 
particular loop 2  and the transmembrane domains are important for ligand 
binding (Olah et al., 1994; Rivkees et al., 1995). The histidine residues 
(His250 and His278) in transmembrane 6  and transmembrane 7 are, for 
example, particularly important for ligand binding to the A 2a receptor (Moreau 
and Huber, 1999). The 2nd extracellular loop contains N-linked glycosylation 
sites (Moreau and Huber, 1999); glycosylation does not appear to affect 
ligand binding but may be involved in the inhibition of receptor dimerisation 
and protection from proteolytic digestion (Linden, 2001). The 3rd intracellular 
loop and the C-terminus appear to be important for G-protein coupling (Olah, 
1997; Palmer and Stiles, 1995; Tucker et al., 2000). In the absence of
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glycosylation, adenosine receptors such as the A2A and A3 subtypes are 
susceptible to phosphorylation and desensitisation (Palmer and Stiles, 1997).
The molecular mass of A^ A2b, and A3 receptors are very similar: 36.7, 36.4 
and 36.6 kilodalton (kDa) respectively, whereas A 2a receptors, as a result of a 
longer C-terminus have a larger predicted size (45 kDa) (Palmer and Stiles, 
1995). There is considerable amino acid sequence homology between the 
same adenosine receptors in different species but sequences between 
different adenosine receptors are quite different. For example the Ai and A3 
receptors and the A ^  and A2B receptors display 49% and 45% sequence 
homology respectively (Olah and Stiles, 2000; Stefano Moro, 2006).
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Figure 1.4 Schematic diagram illustrating the structure of Ai receptor.
From Ralevic and Burnstock (1998).
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1.4.5 Adenosine receptor signalling pathways
Adenosine receptors are either associated with a stimulatory alpha subunit 
(Gas) or an inhibitory alpha subunit (Gai/o) (Palmer and Stiles, 1995). 
Classically, this leads to the stimulation or inhibition of adenylate cyclase and 
changes in cAMP production. Adenylate cyclase can exist as nine different 
isotypes (I-IX) and comprise a family of transmembrane proteins, that 
catalyse the cyclisation of AMP (Fimia and Sassone-Corsi, 2001). Adenosine 
receptors are also now known to activate other pathways including the 
phospholipase C (PLC), protein kinase C (PKC) pathway and mitogen- 
activated protein kinases (MAPKs) (Gao et al., 1999; Rogel et al., 2005; 
Schulte and Fredholm, 2003b). Adenosine receptors have also shown to 
regulate K+, KAt p , N, P and Q type Ca2+ channels (Fredholm et al., 2001; 
Ralevic and Burnstock, 1998) (figure 1.5).
The Ai receptor is coupled to pertussis toxin-sensitive Gi1,2,3 and Go 
proteins and the inhibition of adenylate cyclase (Londos et al., 1980; van 
Calker et al., 1979). Activation of Ai receptors via PLC leads to the production 
of inositol 1, 4, 5-triphosphate (IP3), diacylglycerol (DAG) and Ca2+ 
mobilisation and activation of K + channels (Rogel et al., 2005) and KAtp 
channels whilst inhibiting Q, P and N type Ca2+ channels (Fredholm et al.,
2001). These have been shown in cardiac muscle, neurons, ventricular 
myocytes and coronary arteries (Yaar, 2005).
The A ^  receptor is positively coupled to adenylate cyclase via activation of 
cholera toxin-sensitive Gs-proteins (Palmer and Stiles, 1995). Gs-coupling
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seems to be the main route in A2a signalling in the periphery but not in 
striatum, where A2a receptor concentrations are highest. The striatal A2a 
receptors act largely through activation of G-olfactory (Golf) which is abundant 
in the striatum, and is similar to Gs in its ability to activate adenylate cyclase 
(Kull et al., 2000). In COS-7 cells, A ^  receptors appears to mediate activation 
of Ga15 and Ga16 proteins and the induction of inositol phosphates to raise 
intracellular calcium and activate PKC (Offermanns and Simon, 1995).
The A2b receptor, like the A2A receptor, is also coupled to Gs proteins and 
stimulates adenylate cyclase. Some of the actions of the A2b receptor are 
mediated through the activation of PLC and Gq/11 proteins (Feoktistov and 
Biaggioni, 1997; Linden et al., 1999) and the stimulation of inositol phosphate 
formation has been observed in the human mast cell line, HMC-1. Activation 
of A2b receptors also appears to increase intracellular calcium, either from 
intracellular stores by PLC coupling or from the extracellular space by 
promoting calcium influx directly and activation of PKA (Feoktistov and 
Biaggioni, 1997; Gao et al., 1999). This effect can be antagonised by the A2B 
receptor selective antagonist, enprofylline (Feoktistov and Biaggioni, 1997).
Similar to the Ai receptor, the main transduction system that is associated 
with the A3 receptor is inhibition of adenylate cyclase via activation of 
pertussis toxin-sensitive Gi2,3-proteins (Palmer and Stiles, 1995). Activation 
of the A3 receptor has also been shown to stimulate phospholipases C and D 
via activation of Gq/11 (Abbracchio et al., 1995). In HL-60 promyeloid 
leukaemia cells A3 receptor activation results in the influx of calcium and its
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release from intracellular space. The A3 receptor mediates cardiac protection 
through activation of the K a tp  channel and RhoA-phospholipase D1 signalling 
and suppression of melanoma cell function via the Wnt signalling pathway 
(Tracey et al., 1998). In common with other adenosine receptors, the A3 
receptor also couples to MAPK, which is involved in cell growth, survival, 
death and differentiation (Mozzicato et al., 2003; Schulte and Fredholm, 2002; 
Schulte and Fredholm, 2003b).
PKB/AKT
CAMP-PKA -CREB -  [ ) «-CREB«- PKA -CAMP
y*PKC? 
L d ^  \
Figure 1.5 Possible signalling pathways via Ai, A2A, A2b and A3 receptor 
stimulation. Adapted from Feoktistov and Biaggioni (1998); Jacobson and 
Gao (2006); Schulte and Fredholm (2003b).
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1.4.6 Adenosine receptor agonists
Adenosine has a limited use for the investigation of adenosine receptor 
function due to its short half life. A large number of adenosine receptor 
agonists with greater stability than adenosine have been produced, mainly by 
modification of the adenosine molecule itself (figure 1.6). Several positions in 
adenosine molecular structure have been modified to increase affinity to 
specific receptor subtypes without disturbing the agonistic activity: the N and 
C2 positions of the adenine ring and the 3-, 4- or 5- position of the ribose 
moiety of adenosine (Jacobson and Gao, 2006). Table 1.1 shows some of 
common adenosine receptor agonist and their Kj value.
Modification of adenosine at both N6 and C2-positions led to the development 
of 2-chloro-A/6-cyclopentyladenosine (CCPA) as a potent and selective Ai 
receptor ligand (Klotz et al., 1997). Substitution with small alkyl amide groups 
at the 5-position of adenosine gave rise to a non-selective agonist NECA. 
Further modification of NECA at the 2-position led to the development of CGS 
21680 (2-[p-(2-carboxyethyl) phenethylamino]adenosine-5’-A/-ethyluronamide) 
a selective agonist for A2A receptor (Hutchison et al., 1989; Klotz, 2000).
Although agonists with an apparent high affinity and selectivity for A2B 
receptors have been recently developed i.e. LUF5835 (EC50 = 1 0  nM) and 
BAY 60-6583 (Beukers et al., 2004; Chen et al., 2009), these compounds are 
not well characterised or commercially available. Action at A 2b receptors is 
often investigated by comparing responses to NECA and CGS 21680; a 
strong response to NECA and a weak response to CGS 21680 are indicative
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of A2b receptor activation whereas a dominant response to CGS 21680 
indicates A2a receptor activity. NECA itself strongly binds the Ai, A2a and A3 
receptors (Ki approx 10 nM) but only weakly (Ki 2.4 pM) to the A2b receptor 
(Feoktistov and Biaggioni, 1998). Stimulation of adenylate cyclase activity has 
been used to demonstrate activation of both A2Aand A2B receptors; an agonist 
profile NECA>A/6-3-lodobenzyladenosine-5’-A/-methyluronamide (IB-MECA) 
> CGS 21680 is indicative of A2B receptors (Feoktistov and Biaggioni, 1997). 
Agonists that are selective for A3 receptors are compounds that contain an 
N6 -benzyl substitution as well as a 5’-modification (Muller, 2000). IB-MECA 
(or its chlorinated derivative) is one of these agonists that is widely used for 
studying the A3 receptor (Adachi et al., 2007).
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Figure 1.6 Structure of adenosine receptor agonists. From Jacobson and 
Gao (2006)
1.4.7 Adenosine receptor antagonists
The structural core for the development of adenosine receptor antagonists 
has been modification of naturally occurring xanthines, theophylline and
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caffeine (Moro et al., 2006). As is the case for agonists, potent and selective 
xanthine antagonists stem from multiple substitutions of the parent 
heterocycle. Table 1.1 shows some of the common adenosine receptor 
antagonists and their Kj value.
The main sites of the xanthine structure that allows for the variation of the 
pharmacological profile is the C8  residue (Klotz, 2000). Among Ai receptor 
antagonists, 8 -cycloalkyl xanthine derivatives are well known potent ligands. 
One such derivative is DPCPX (1,3-dipropyl-8 cyclopentylxanthine), with a 
1000 fold higher potency at the rat Ai receptor (Ki-value 0.3 nM) compared to 
the rat A2A receptor (Redman and Silinsky, 1993). Several A2A receptor 
xanthine antagonists (8 -styrylxanthines) have been synthesised, However 
they suffer from sensitivity to photoisomerisation (Moro et al., 2006; Yuzlenko 
and Kiec-Kononowicz, 2006) Non-xanthine antagonists such SCH 58261 and 
SCH 442416 with a high affinity (Ki 0.5 and 0.048 nM respectively) and 
selectivity for A2A receptors have therefore been developed and found useful 
in discriminating A2B and A2A receptor function (Feoktistov and Biaggioni, 
1998; Fredholm et al., 2003). Xanthines that have been developed as 
selective antagonists of the A2b receptor bear a C8 -substitution combined with 
N1- and N3- (and sometimes N7) substitutions. For example 8 -phenyl 
xanthine substitution such as the p-cyanoanilide derivative MRS 1754 (A/-(4- 
cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl) 
phenoxy]acetamide, with a Ki-value of 2 nM, is found to be 204-, 255-, and 
289 fold more selective when compared with human Ai, A2A and A3 receptors 
respectively (Giovanni Baraldi et al., 2006). Other A2b receptor highly selective
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antagonists, include MRS 1706, [3H] OSIP3991 and MRE2029-F20 (Giovanni 
Baraldi et al., 2006; Jacobson and Gao, 2006). In contrast to Ai and A2 
receptors the A3 receptor is insensitive to xanthine molecules (Muller, 2001) 
with binding affinities of around 100 pM. Therefore the majority of A3 
antagonists have a non-xanthine structure; MRE 3008F20 is the most 
selective antagonist (KD 0.8 nM) for the human A3 receptor (Jacobson and 
Gao, 2006; Muller, 2001).
Compound Ai A2a A2B a 3
Agonists
Adenosine 3-30 1-20 5000-20000 >1000
NECA 14 20 2400 6.2
CCPA 0.8 2300 18800 42
CGS 21680 289 27 888000 67
IB-MECA 3.7 2500 11000 1.2
Antagonists
PSB 36 0.12 552 187 2300
SCH 442416 1110 0.048 >10000 >10000
MRS 1706 157 112 1.39 230
MRS 1754 403 503 2 570
Table 1.1 Binding affinity for selective agonists and antagonists for 
adenosine receptors (Kj values in nM). Adapted from Jacobson and Gao 
(2006).
1.4.8 Adenosine receptor distribution and function
All four subtypes are widely distributed throughout the body and their spectra 
of physiological and pathological functions have been described in many 
tissues and organs, such as in the cardiovascular system, the central nervous 
system (CNS), immune system and the respiratory system. Adenosine Ai 
receptors are ubiquitously expressed within the CNS with particularly high 
expression in the cerebral cortex, hippocampus, cerebellum, thalamus, brain
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stem, and spinal cord. In this setting, Ai receptors have a neuroprotective role 
by blocking neurotransmitter release (Ribeiro et al., 2002). Additionally, Ai 
receptors have been reported to be potentially useful in the treatment of 
dementia and anxiety disorders, and mice lacking the receptor show 
increased anxiety-related behaviour and a loss of the analgesic effects of 
adenosine (Johansson et al., 2001). In support of these findings, Ai receptor 
agonists were shown to improve memory defects and reduced anxiety in rats 
(Maemoto et al., 2004).
The Ai receptors are also highly expressed in the cardiovascular system, 
where they have been shown to reduce heart rate and atrial contractility, and 
the attenuation of stimulatory actions of catecholamines (Fraser et al., 2003; 
Zablocki et al., 2004). In patients with paroxysmal supraventricular 
tachycardia (PSVT), normal heart rhythm is restored by intravenous infusion 
of adenosine and activation of Ai receptors (Jacobson and Gao, 2006). 
Overexpression or activation of Ai receptors produced a protective response 
in the cardiac tissues of mice subjected to ischemia/reperfusion, whilst mice 
lacking the receptor showed reduced heart recovery and systolic blood 
pressure after an ischemic event (Regan et al., 2003; Reichelt et al., 2005). Ai 
receptors are also abundant in testis, white adipose tissue, spleen, pituitary, 
liver, eye, and kidney (Fredholm et al., 2001).
Like the Ai receptor, the A2A receptor also plays important roles in CNS and 
the cardiovascular system. Studies of mice lacking the A2A receptor showed 
several disturbances in CNS activity including, decreased exploratory activity,
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increased aggressiveness and hypoalgesia, attenuated psychostimulant 
responses and reduced alcohol sensitivity (Chen et al., 2003; Ledent et al., 
1997; Naassila et al., 2002). Antagonising the A2A receptor is potentially a 
treatment for Parkinson’s (Xu et al., 2005). In the cardiovascular system, 
activation of A2a is involved in vasodilation in the aorta and coronary artery 
(Fredholm et al., 2001). A2A receptors also have anti-inflammatory effects and 
their activation in immune cells has been shown to inhibit T-cell activation, 
proliferation and production of inflammatory cytokines whilst enhancing the 
production of anti-inflammatory cytokines. A2a receptor knockout animals are 
more susceptible to inflammation and the production of proinflammatory 
cytokines (Hasko and Pacher, 2008; Sitkovsky et al., 2004).
A2b receptors are abundantly expressed in the cecum, colon, bladder, kidney, 
lung, and pituitary (Fredholm et al., 2001). The physiological role of the A2b 
receptor is less studied in comparison to other adenosine receptors, probably 
due to the lack of potent selective agonists and until recently, the A2b 
knockout mice had not been created (Jacobson and Gao, 2006). 
Nonetheless, the A2b receptor is shown to be involved in the control of 
cardiovascular tone, cardiac myocyte contractility, regulation of inflammation, 
modulation of neurosecretion and neurotransmission, regulation of intestinal 
tone and secretion and regulation of mast cell function (Dubey et al., 2002; 
Dubey et al., 2001; Eckle et al., 2007; Feoktistov and Biaggioni, 1997; 
Giovanni Baraldi et al., 2006; Hasko et al., 2009; Hua et al., 2007).
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The A3 receptor is highly expressed in lung and liver and has also been 
detected in the testis, lung, kidney, placenta, heart, brain, spleen, liver, uterus, 
bladder, aorta, proximal colon and eye (Fredholm et al., 2001). Expression of 
the A3 receptor appears to mainly involve pathological conditions such as 
ischemia, inflammation and cancer. The receptor also seems to have 
cardioprotective, proinflammatory, anti-inflammatory, neuroprotective and 
neurodegenerative effects in different pathophysiological situations (Gessi et 
al., 2008). The A3 receptor is also highly expressed in tumour cells such as 
melanoma, lymphoma, pineal gland, colon, and prostate carcinomas (Gessi et 
al., 2004; Madi et al., 2003; Madi et al., 2004). Within cancer cells A3 
receptors appear to have anti-tumour effects such as inducing apoptosis and 
inhibiting tumour cell growth both in vitro and in vivo (Fishman et al., 2002a; 
Fishman et al., 2002b).
1.4.9 Adenosine receptor signalling pathways in adipocytes and 
adipogenesis
Adenosine is known for many years to be involved in the regulation of several 
aspects of adipose tissue functions including lipolysis and lipogenesis. The 
first evidence was reported about 50 years ago by Dole showing that 
adenosine decreased the lipolytic effect of adrenaline in rat adipose tissue 
(Dole, 1961). Later, adenosine was shown to be released by adipocytes in 
vitro and in vivo and this was sufficient to inhibit cAMP accumulation and 
lipolysis (Lonnroth et al., 1989; Schwabe et al., 1973; Schwabe et al., 1974). 
Adenosine has been shown to be involved in both lipolysis (break down of fat) 
and lipogenesis (formation of fat) in various mammalian cell culture systems
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including human, rat, mouse and dog (Johansson et al., 2008; Lonnroth et al., 
1989; Sollevi and Fredholm, 1981; Szkudelski et al., 2008; Vannucci et al.,
1989).
The pharmacological evidence and molecular studies suggest that the action 
of adenosine on adipocytes is mainly through activation of Ai receptors 
(Fatholahi et al., 2006; Johansson et al., 2008; Schoelch et al., 2004; 
Vannucci et al., 1989). Many Ai adenosine receptor agonists have been 
shown to induce antilipolytic effects (Dhalla et al., 2007a; Dhalla et al., 2003; 
Fatholahi et al., 2006). Furthermore, overexpression of Ai receptors and 
subsequent inhibition of lipolysis in adipocytes have been suggested as a 
potential cause of a lower and slower rate of weight loss in obese African- 
American women (Barakat et al., 2006). The related observation of reduced 
adenosine sensitivity and decreased adenosine receptor number in 
adipocytes isolated from obese men also highlight the importance of 
adenosine in the activities of adipocytes (Kaartinen et al., 1991).
Adenosine, acting through the Ai receptor, regulates glucose and lipid 
metabolism and enhances the antilipolytic action of insulin (Schwabe et al., 
1974). Overexpression of the adenosine Ai receptor in adipose tissue is 
shown to be associated with reduced insulin resistance in mice and rats on a 
high fat diet (Dhalla et al., 2007a; Dong et al., 2001) by lowering free fatty 
acids and triglyceride concentrations (Dhalla et al., 2007b). Adenosine 
appears to regulate glucose transport and facilitate insulin regulation of 
glucose metabolism (Schwabe et al., 1974; Smith et al., 1984), whereas
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removal of adenosine or antagonism of adenosine receptors is found to 
reduce insulin-stimulated glucose transport (Steinfelder and Petho-Schramm,
1990). Adenosine also has similar stimulatory action on leptin secretion. 
Activation of the Ai receptor has been shown to increase circulating leptin 
levels, whilst, targeted disruption of adenosine action was associated with a 
reduction in secretion of leptin (Cheng et al., 2000; Rice et al., 2000).
As described above, there have been several studies on the role of adenosine 
receptors on adipocyte function; there is however little information on how 
expression of these receptors may change during adipogenic differentiation. 
There is some evidence to support this hypothesis; Vassuex and colleagues 
(1993) reported the presence of A2 receptors in preadipocytes and the Ai 
receptor in mature adipocytes in the stromal-vascular fraction of the 
epididymal fat pad. Similar findings were reported in human primary 
preadipocytes and in a mouse preadipocyte cell line, Ob1771 (Borglum et al 
1996). A2 receptors were markedly reduced during adipocyte differentiation of 
Ob1771 cells and the Ai receptor was only present in fully differentiated cells. 
Induced expression of the Ai receptors also appeared to induce adipogenesis 
(Tatsis-Kotsidis and Erlanger, 1999). In addition, universal adenosine receptor 
agonists were shown to enhance corticosterone-induced adipocyte 
differentiation by 47% (Borglum et al., 1996). Together these data suggest a 
role for adenosine and Ai receptors in adipocyte differentiation and function.
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1.4.10 Adenosine signalling pathways in osteoblasts and 
osteoblastogenesis
There is little information on the expression and function of adenosine 
receptors in osteoblasts or during their differentiation from precursor stem 
cells. Recent studies in our department described the expression of 
adenosine receptors, in particular the A2 subtypes in human primary 
osteoprogenitor cells and the immortalised human cell line HCC-1 (Evans et 
al., 2006). Subsequently adenosine receptor expression was demonstrated in 
mouse MSCs (Katebi et al., 2009) and in the human osteoblastic cell line MG- 
63 (Russell et al., 2007). These cells also have the capacity to produce 
adenosine as they express high levels of CD73 (Evans et al., 2006; Katebi et 
al., 2009). In these studies, adenosine acting via A2b receptors stimulated 
interleukin-6 (IL-6) secretion and inhibited osteoprotegerin but not the receptor 
activator of nuclear factor kB ligand (RANK-L) expression (Evans et al., 2006). 
Activation of A2a receptors in osteoblasts was shown to inhibit LPS-induced 
IL-6 release (Russell et al., 2007). These data suggest that adenosine 
receptors may play a role in the control of inflammation as well as in 
osteoclastogenesis and bone resorption.
In patients with rheumatoid arthritis (RA), adenosine has been shown to 
reduce the levels of proinflammatory cytokines such as tumor necrosis factor 
alpha (TNFa) and interleukin-1 P- (IL-13-) (Forrest et al., 2005). Additionally, 
methotrexate (MTX) which is one of the most widely used drugs for the 
treatment of RA is thought to exert its effects by increasing the level of 
adenosine and activation of A ^  and A3 receptors (Cronstein, 2005). Studies in
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A2A and A3 receptor knockout mice support this finding, as MTX treatment 
reduces leukocyte and TNFa accumulation in wild-type mice, but not in 
receptor null mice (Montesinos et al., 2003). Furthermore, adenosine receptor 
antagonists reversed the anti-rheumatic effects of MTX in adjuvant-induced 
arthritis in rats (Montesinos et al., 2000) and A3 receptor agonism has been 
shown to prevent bone resorption in adjuvant-induced arthritis (Rath-Wolfson 
et al., 2006).
A2A receptors have also been reported to play a role in promoting proliferation, 
development and protein expression in mouse bone marrow MSCs. Disruption 
of A2a receptor signalling using antagonists or in null animals was associated 
with a reduction in CFU-Fs and in procollagen type I expression (Katebi et al., 
2009). Adenosine was also shown to be mitogenic for MC3T3 osteoblasts 
(Shimegi, 1998) and activation of Ai and A2A receptors have been shown to 
prevent oxidative stress induced cell death in MC3T3 (Fatokun et al., 2006). 
In contrast to this, other researchers have reported a lack effect of adenosine 
on osteoblast function, i.e. mineralisation and production of intracellular Ca2+ 
(Hoebertz et al., 2002; Orriss et al., 2006). ATP, on the other hand, strongly 
inhibits mineralised bone nodule formation and stimulates Ca2+ production.
To date, data suggest that adenosine receptors have a role in adipocyte and 
osteoblast function but there is little information on how these receptors are 
modulated during adipocyte and osteoblast lineage specific differentiation. 
There is also little information on whether adenosine can induce the process 
of adipogenesis or osteoblastogenesis.
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1.5 Aims of the study
The preferential differentiation of MSCs into adipocytes rather than 
osteoblasts is thought to contribute to bone loss and diseases such as 
osteoporosis. Currently PTH (Blick et al., 2008; Cranney et al., 2006) is the 
only compound in clinical use, that induces bone formation. The 
understanding of the mechanisms involved in adipocyte and osteoblast 
differentiation could be considered as targets for therapeutic intervention. Our 
previous findings and those of others suggest that adenosine is likely to have 
a role in adipocyte and osteoblast function and differentiation.
I have, thus, explored how adenosine receptors are modulated as MSCs are 
induced to differentiate into osteoblasts and adipocytes and how these 
processes may be influenced by adenosine. I have also investigated whether 
adenosine is involved in the transdifferentiation of osteoblasts to adipocytes. 
Specific aims and objectives are described in the appropriate chapters.
Specifically the aims were:
• To investigate the expression and function of adenosine receptors in 
MSCs and during their differentiation to osteoblasts and adipocytes.
• To investigate the role of adenosine signalling pathways in the 
regulation of osteoblastic and adipogenic differentiation of MSCs.
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• To investigate the expression and function of adenosine receptors in 
7F2 and HOB cells and as they are induced to transdifferentiate to 
adipocytes.
• To investigate the role of exogenous adenosine in the regulation of 
adipocyte differentiation of 7F2 and HOB cells.
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2.1 Materials
2.1.1 Reagents
General laboratory chemicals and reagents were obtained from Sigma Aldrich 
(Poole, UK) and Fisher Scientific (Loughborough, UK) unless otherwise 
stated. All cell signalling reagents were obtained from TOCRIS Biosciences 
(Bristol, UK) (see table 2.1 for details).
Compound Dissolved in Description
Adenosine PBS Adenosine receptors natural ligand
NECA DMSO Adenosine receptors universal agonist
CCPA DMSO A i receptor agonist
CGS 21680 DMSO A2A receptor agonist
IB-MECA DMSO A3 receptor agonist
PSB 36 DMSO A1 receptor antagonist
SCH 442416 DMSO A2A receptor antagonist
MRS 1754 DMSO A 2b receptor antagonist
MRS 1706 DMSO A2B receptor antagonist
Forskolin DMSO Adenylate cyclase activator
PMA DMSO PKC activator
RO 20-1724 DMSO PDE inhibitor
RO-32-0432 DMSO PKC inhibitor
U-73122 DMSO PLC inhibitor
PD 98059 DMSO MAPK inhibitor
Wortmannin DMSO PI3K inhibitor
2',5'-dideoxyadenosine (DDA) DMSO Adenylate cyclase inhibitor
Table 2.1 Details of cell signalling reagents.
2.1.2 Cell culture consumables and reagents
Tissue culture plastic dishes and flasks were all purchased from Fisher 
Scientific (Loughborough, UK). Cell culture reagents and materials were 
purchased from Invitrogen (Paisley, Scotland), Sigma Aldrich (Poole, UK) and 
Lonza (Berkshire, UK) unless otherwise stated.
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2.2 Cell culture
2.2.1 Culture medium
Cells were cultured in minimal essential medium alpha (a-MEM) (without 
ribonucleosides or deoxyribonucleosides). A stock solution of a-MEM was 
prepared by dissolving 10.08 g of a-MEM and 2.2 g sodium hydrogen 
carbonate (NaHC03) in one litre distilled water (dH20). The medium was 
sterilised by passing through a 0.2 pM bottle top rac filter (VacuCap 90) and 
500 ml aliquots were transferred into sterile glass bottles. The medium was 
stored at 4°C and L-glutamine (2 mM), penicillin (50 U/ml), streptomycin (50 
pg/ml) and 10% fetal calf serum (FCS) were added prior to use. This medium 
will be referred in this thesis as normal growth medium. FCS was first tested 
for its ability to support cell growth and the same batch was used throughout 
the project.
2.2.2 Isolation and expansion of MSCs
8 - 1 0  week old male Wistar rats were sacrificed by carbon dioxide inhalation 
according to UK Home Office regulation. The femurs and tibias were 
dissected away from attached muscle, cleaned of all connective tissue and 
the proximal end of the femur and distal end of tibia were excised to expose 
the marrow. The bones were put into bottomless 0.5 ml centrifuge tubes and 
inserted into 1.5 ml centrifuge tubes; the marrow was collected after 
centrifugation for 1 minute at 6,500 x g. The pellet was resuspended in 1 ml of 
normal growth medium and dispersed by passage through a 16-gauge 
needle. From the cell suspension 4 pi was resuspended in 796 pi of medium 
(1:200), mixed well and 10 pi of this suspension was mixed with 10 pi of 2%
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acetic acid (to disrupt the red blood cells). Cells were counted using a 
haematocytometer and plated at a density of 2 * 106/cm2 in 75 cm2 tissue 
culture flasks. The flasks were incubated at 37°C in a humidified 5% CC>2:95% 
air atmosphere for three days. The medium was then changed to remove the 
non-adherent cells, and every 3 - 4 days thereafter. The cells were expanded 
and used at passage 0 - 3.
2.2.3 7F2 cell line
The 7F2 mouse osteoblast cell line was kindly provided by Dr Colin 
Farquharson (University of Edinburgh, UK) and used at passage 8 - 20. The 
cells are derived from the bone marrow of p53”/_ mice and represent mature 
osteoblasts as they express ALP, secrete type I collagen and mineralise 
extensively (Thompson et al., 1998). The cells were grown in normal growth 
medium in 25 cm2 tissue culture flasks and maintained at 37°C in a humidified 
5% C02:95% air atmosphere. The cells were passaged by trypsinisation on 
reaching confluency (split 1:5) as described in section 2.2.5 and the culture 
medium was routinely changed every 3 - 4  days.
2.2.4 Human osteoblast (HOB) cells
Primary human osteoblast cells were purchased from Lonza (Berkshire, UK). 
The cells were grown in normal growth medium in 25 cm2 tissue culture flasks 
and maintained at 37°C in a humidified 5% C02.‘95% air atmosphere. Upon 
reaching confluency cells were passaged by trypsinisation as described in 
section 2.2.5 and the culture medium was routinely changed every 3 - 4 days. 
The cells were expanded and used at passage 2 - 6.
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2.2.5 Cell culture maintenance
On reaching confluence cells were detached by trypsinisation. The medium 
was removed and the cells were washed with sterile phosphate buffered 
saline (PBS) and dislodged by incubation with 0.5 - 1 ml (per 25 cm2 and 75 
cm2 tissue culture flasks respectively) of 0.25% trypsin/ 0.25% EDTA 
(ethylenediaminetetraacetic acid) (Worthington Biochemical Corp. distributed 
by Lome Laboratories, Ltd. Reading, Berkshire UK) for 3 - 5 minutes at room 
temperature. Cell detachment was monitored by light microscopy and aided 
by gentle intermittent taping on the side of flask. The trypsin was inactivated 
by the addition of 3 ml of normal growth medium. The cells were then either 
reseeded in a number of new flasks or were set up for an experimental 
procedure. For the latter, the cell suspension was centrifuged for 3 minutes at 
500 x g at room temperature. The supernatant was discarded and the cells 
were resuspended in a known volume of normal growth medium, counted with 
a haemocytometer (section 2.2.6) and seeded at a known density into 6, 12, 
24 or 96 well plates.
2.2.6 Cell counting
Cell suspensions were diluted appropriately (to give 20 - 100 cells per square 
of haemocytometer chambers) in a known volume of normal growth medium 
and 7 pi was transferred to each chamber of a haemocytometer. Cells were 
counted using x100 magnification. Counts from 10 squares of both 
haemocytometer chambers were averaged and the number of cells was 
calculated as follows:
Cell number per ml = the average count x dilution factor x 104
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2.2.7 Cryopreservation of cells
For long-term storage in liquid nitrogen, 7F2 cells were grown in 75 cm2 tissue 
culture flasks until reaching 90% confluency. The cells were then detached by 
trypsinisation and suspended in 3 ml of freezing medium (50% a-MEM, 40% 
FCS, 10% dimethyl sulfoxide (DMSO)). A uniform cell suspension was 
prepared by repeated pipetting and 1 ml aliquots were dispensed into 
cryotubes (Nunc, Thermo Fisher Scientific, Loughborough, UK), transferred 
into cryocontainers which contained isopropanol at room temperature and 
placed in a -80°C freezer. On the following day, the vials were transferred to 
liquid nitrogen for storage. To resurrect cells from liquid nitrogen, they were 
thawed rapidly by plunging the vial into a 37°C water bath. The thawed cells 
were transferred to a 25 cm2 flask containing 10 ml of warm normal growth 
medium and incubated overnight at 37°C in a 5% C02:95% air atmosphere. 
The medium was then replaced to eliminate the remaining DMSO in the 
culture.
2.3 Analysis of mRNA expression
2.3.1 RNA extraction
Total cellular RNA was extracted using TRIzol® reagent (Invitrogen, Paisley, 
Scotland), a monophasic solution of phenol and guanidine isothiocyanate that 
solubilises cell components while maintaining the integrity of the RNA. Cells 
were directly lysed with appropriate amount of TRIzol® reagent based on the 
area of the culture dish, and transferred to an RNase/DNase free 1.5 ml tube. 
Cell lysates were homogenised by passing several times through a pipette tip 
and incubated for 5 minutes at room temperature for complete dissociation of
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nucleoprotein complexes. Following the incubation, 200 pi of chloroform was 
added and the mixture shaken vigorously by hand for 15 seconds and 
incubated at room temperature for 2 to 3 minutes. Samples were centrifuged 
at 12,000 x g  for 15 minutes at 4°C to separate the mixture into a lower red, 
phenol-chloroform phase (containing the DNA), an interphase, and a 
colourless upper aqueous phase (containing the RNA). The aqueous phase 
was transferred to a fresh RNase/DNase free 1.5 ml tube and RNA was 
precipitated by mixing with 500 pi of isopropanol. Samples were incubated at 
room temperature for 10 minutes and the precipitated RNA pelleted by 
centrifugation at 12,000 x g  for 10 minutes at 4°C. The supernatant was 
removed and the pellet was washed with 1 ml of 75% ethanol by vortexing 
and centrifugation at 7,500 x g  for 5 minutes at 4°C. The ethanol supernatant 
was removed and the RNA air-dried and re-suspended in RNase-free water 
by passing the solution a few times through a pipette tip and incubating for 10 
minutes at 55°C.
2.3.2 DNase treatment of RNA
Contaminating DNA was removed by DNase I treatment using the TURBO 
DNA-free kit (Ambion, Warrington, UK). 0.1 volume of 10x TURBO DNase 
Buffer and 1 pi of TURBO DNase were added to each RNA sample, mixed 
gently and incubated for 20 - 30 minutes at 37°C. The digestions were 
stopped by treatment with 5 pi DNase Inactivation reagent for 2 minutes at 
room temperature. Following centrifugation at 10,000 x gfor 1.5 minutes, the 
supernatant, which contained the RNA, was transferred into a fresh tube.
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2.3.3 RNA quantification
Total RNA was quantified using a GeneQuant spectrophotometer (GE 
Healthcare UK Ltd., Buckinghamshire, UK) by measuring optical density at 
260 nm wavelength and the purity was confirmed by checking the ratio at a 
wavelength of 260/280 nm (RNA is detected at 260 nm, whereas protein at 
280 nm). RNA with a ratio of 1.8 to 2 was considered to be sufficiently pure.
2.3.4 Reverse transcription (RT)
cDNA was synthesised from 1 pg of total RNA in a final volume of 20 pi 
reaction mixture containing Moloney Murine Leukemia Virus ( M-MLV) reverse 
transcriptase with its supplied buffer, Rnasin ribonucleotide inhibitor, oligo 
dTi5 primer and deoxyribonucleotide triphosphate (dNTP) mix (all from 
Promega, Southampton, UK) as described in table 2.2. Initially RNA samples 
were heated for 10 minutes at 65°C to denature the secondary structure and 
quickly cooled on ice to stop them reforming. The RNA was then added to the 
reaction mix and the RT reaction carried out for 60 minutes at 37°C. For any 
one sample there was a no-RT control to check for residual DNA. The cDNA 
was stored at -20 °C until required.
Reagents Concentration/reaction Volume/reaction
M-MLV RT 100 u 0.5 pi
M-MLV RT 
Buffer 5x 4 pi
dNTP mix 10 mM 1 pi
Oligo dT 
primer 0.1 Mg 1 pi
Rnasin Rl 8 U 0.2 pi
RNA 1 M9 -
H20 - to 20 pi
Table 2.2 Concentrations and volumes of reagents used for RT.
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2.3.5 Primer design
Sequences for the genes of interest (GOI) were retrieved from University of 
California Santa Cruz (UCSC) genome browser program 
(http://genome.ucsc.edu/). In order to distinguish amplification of mRNA from 
any possible contamination by genomic DNA; where possible forward and 
reverse primers were designed in different exons. Primers were designed with 
Primer3 (http://frodo.wi.mit.edu/) software and obtained from Invitrogen 
(Paisley, Scotland). The desired amplicon length was chosen to be less than 
250 base pairs (bp) to increase the efficiency of the polymerase chain 
reaction (PCR) reaction. The primers were designed to have a melting 
temperature (Tm) close to 65°C and minimal self-dimerisation. All primer 
sequences were tested via BLAST searches 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) to eliminate those with significant 
homologies to other eukaryotic sequences. Each primer set was tested to 
ensure a single PCR product of expected size and a single melting peak on 
quantitative-RTPCR (q-RTPCR). The identity of PCR products was then 
checked by sequencing. The amplification efficiency for the primers was 
calculated in q-RTPCR analysis by measuring the slope of a standard curve 
created from serially diluted templates using MX 3000 PRO software 
(Stratagene, La Jolla, CA). The primer sequences (all 5’ - 3’) and amplicon 
size are indicated in tables 2.3, 2.4 and 2.5.
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Primers Forward Reverse Size (bp)
Ai GT CCT CAT CCT CACCCAGAG CAGATT GTT CCAGCC AAACA 189
A 2a T CTT CAGT CT CCT GGCCAT C T CC AACCTAGCATGGG AGT C 156
> CD CTCCATCTTCAGCCTTCTGG GGAAT GG AGT CAAT CCGAT G 152
APRT* GCTGCGT GOT CAT CCGAAAG CCTT AAGCGAGGT CAGCT CC 247
ALP GGACATGCAGTACGAGCTGA CCACCAAAT GT GAAGACGT G 282
Osteocalcin GGCAGCGAGGTAGTGAAGAG CTGGAGAGGAGCAGAACTGG 230
PPARy CAGT GGGG AT GT CT CATAA CTTTT GGC AT ACT CT GT GAT 390
LPL G AG ATTT CT CT GT AT G G ACC CT GC AAAT G AG ACACTTT CT C 275
Table 2.3 Human primer sequences.
*APRT: adenine phosphoribosyltransferase
Primers Forward Reverse Size (bp)
Ai* ATT GCT GT GG AT CG AT AC C GAATCCAGCAGCCAGCTAT 100
A2A CTT CGCTAT CACC AT CAGC A AAATTGCAAT GAT GCCCTT C 200
A2b* T CCAT CTTT AGCCT CTT G TCCT CTT GCTCGT GTT C 100
a 3 TTCTTGTTTGCCTTGTGCTG AGGGTT CAT CATGG AGTT CG 129
CD73 GGACT GATT GAT CCCCT CCT TT GT CCCTGGATTT GAGAGG 192
ADA AAGGAGACCTCACCCCTGAT GT CT CAT CCCC AGCCAAGT 198
AK CT AT GCT GCCG AGAAC AACA T GCCT CTT CG AGTT C ACCTT 225
Cbfal GGCCCT GGT GTTTAAATGGT AGGCT GTTT GACGCCATAGT 178
Collagen type I AGCT GGT GCT AAGGGT GAAG GCAAT ACC AGGAGCACCATT 174
ALP CT GCAAGG ACAT CGCCTAT C CAT CAGTT CT GTT CTT GGGGTA 101
Osteocalcin CCTT CAT GT CCAAGC AGG AG GTCCGCT AGCT CGT CACAAT 152
PPARy TTCAGAAGTGCCTTGCTGTG CCAAC AGCTT CT CCTT CTCG 84
C/E B Pa GCC AAG AAGT CGGT GG AT AA AAC ACCTT CTGCTGCGTCTC 125
LPL CTTCAACCACAGCAGCAAAA GGCCCGAT ACAACCAGT CT A 148
(3-actin* TGTCACCAACTGGGACGATA GGGGT GTT G AAGGT CT CAAA 165
Table 2.4 Rat primer sequences.
* Ai and A2b adenosine receptor sequences were obtained from (Novak et al., 2008) and (3- 
actin was obtained from (Bonefeld et al., 2008).
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Primers Forward Reverse Size (bp)
A-i GAT CGGT ACCT CCGAGTC AA TT GGCT AT CC AGGCTT GTT C 160
A2A GGCT ATT GCC AT CGACAGAT ATGGGT ACCACGT CCT CAAA 228
COCM
<
TGCT CACACAG AGCT CCAT C AGTCAATCCAATGCCAAAGG 158
A3 TCCCT GATTACCACGG ACT C T CCTT CT GTT CCCC AC ATT C 151
CD73 CCTCT C AAT CC AG G G AC AA TTT GG AAGGTGG ATTT CCT G 220
ADA GGCGT GGT CT AT GT GG AAGT GACCTTGATGCCAAAT GCTT 165
AK CTATGCTGCCGAGAACAACA T GCCT CTT CG AGTT C ACCTT 225
C/EBPP CAAGCTGAGCGACGAGTACA CAGCT GCT CC ACCTT CTT CT 157
PPARy TTTT CAAGGGT GCCAGTTT C AATCCTT GGCCCT CT GAG AT 220
GPDH* AT GCT CGCCACAGAATCCACAC AACCGGC AGCCCTT G ACTT G 124
LPL GCGTAGO AGG AAGT CT GACC CATCAGGAGAAAGGCGACTG 108
Osteocalcin AG ACT CCGGCGCT ACCTT TAGGCGGTCTTCAAGCCATA 104
ARP* G AGG AAT C AG AT G AGG AT ATGGG A AAGCAGGCT GACTT GGTT GC 72
Table 2.5 Mouse primer sequences.
*ARP: acidic ribosomal protein
*GPDH: glycerol-3-phosphate dehydrogenase
2.3.6 PCR
i. Principle
PCR is a technique for amplification of linear fragments of DNA within two 
specific short DNA sequences (primers). The starting material for nucleic acid 
amplification by PCR are a DNA template, which contains the segment of 
nucleic acid that is to be amplified, a pair of DNA primers, a thermostable 
DNA polymerase (Tag DNA polymerase) and a set of nucleotides (dNTPs), 
dATP, dCTP, dGTP,and dTTP. The basic PCR procedure includes repeated 
cycles of amplifying target nucleic acid sequences. Each cycle consists of 
three steps: initially, a double strand of DNA is separated into two single
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strands by heat at 90 - 95°C (denaturation). The reaction is then cooled to 55 
- 65°C to allow the primers to bind to their target sequence on the single 
strand (annealing). Finally, the reaction is warmed to 72°C to allow Taq 
polymerase to create new DNA fragments complementary to the target DNA 
(extension).
ii. Method
For gene detection PCR was performed in a TC-512 thermocycler (Techne, 
Cambridge, UK) using 1 pi of the cDNA with reagents from Promega 
(Southampton, UK) in a 50 pi reaction as shown in table 2.6. The thermal 
profile for PCR was 95°C for 1 minute (denaturation), followed by 40 cycles, 
each of which is comprised of 30 seconds at 95°C, 1 minute at 60°C and 1 
minute at 72°C. The extension step was 10 minutes at 72°C. No template 
controls (negative controls) were included for each set of primers used in PCR 
amplification.
Reagent Concentration/reaction Volume/reaction
cDNA template 1 pi
dNTP mix 10 mM 1 pi
Taq polymerase 2 U 0.4 pi
10x Taq buffer 
MgCI2 1.5 mM 5 piKCI 50 mM
Tris-Hcl 10 mM
Primer mix 25 pM for each primer 1 pi
H20 to 50 pi
Table 2.6 Concentrations and volumes of reagents used for PCR.
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2.3.7 Agarose gel electrophoresis
The sizes of PCR products were obtained using 2% agarose gel containing 
ethidium bromide (final concentration 1:20,000). Briefly, gels were prepared 
by adding agarose (Melford Laboratories Ltd, Ipswich, UK) to tris-acetate- 
EDTA (TAE) buffer consisting of 40 mM tris base/ glacial acetic acid and 1 
mM EDTA and heating in a microwave oven until dissolved. The solution was 
allowed to cool for few minutes and then poured into a gel tray and allowed to 
set for 30 minutes at room temperature. PCR products, 100bp DNA ladder 
(Promega, Southampton, UK) and negative and positive controls were 
prepared for electrophoresis by mixing with an appropriate volume of gel 
loading buffer (Promega, Southampton, UK) and applied to the gel. The gel 
was run at 100 volts using the Mupid-21 mini gel migration system (Cosmo 
Bio Ltd, Japan) for approximately 30 minutes or until the tracking dye migrated 
two-thirds down the gel. The gel was visualised and photographed under UV 
transillumination using a Multi Image™ light cabinet and Alphalmager™ 
documentation and analysis system (Alpha Innotech Corporation, San 
Leandro, USA).
2.3.8 DNA Sequencing
The identity of PCR products were confirmed by direct sequencing. PCR 
products were gel extracted and purified using the Wizard® SV Gel and PCR 
Clean-Up System based on the ability of DNA to bind to silica membranes in 
the presence of chaotropic salts (Promega, Southampton, UK). The band of 
interest was excised with a minimal volume of agarose with a clean scalpel 
and weighed. The guanidine isothiocyanate (Membrane Binding Solution) was
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added to the sample at a ratio of 100 pi of solution per 10 mg of gel slice, 
mixed by vortexing and incubated at 65°C for 10 minutes or until the gel slice 
was completely dissolved. To isolate the DNA, the sample was applied to a 
SV mini-column (containing silica), incubated for 1 minute at room 
temperature and centrifuged at 16,000 x gfor 1 minute. The flow-through was 
discarded and the DNA fragment was washed twice in Membrane Wash 
Solution (700 pi and 500 pi respectively) and centrifuged at 16,000 * g. The 
flow-through was discarded and the SV column was centrifuged for an 
additional 1 minute with the microcentrifuge lid open to allow evaporation of 
any residual ethanol.
Extracted cDNA was collected into a clean 1.5 ml microcentrifuge tube by the 
addition of 50 pi of nuclease-free water directly to the centre of the column, 
incubation at room temperature for 1 minute and a final centrifugation for 1 
minute at 16,000 *  g. To quantify the amount of purified cDNA, 5 pi of 
samples were run on an agarose gel and compared to DNA fragments from a 
100bp ladder (Promega, Southampton, UK).
Extracted DNA was sequenced using the BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystem, Warrington, UK). The sequencing 
reactions were set up as described in table 2.7 and subjected to cycling 
conditions as described in table 2.8 using a TC-512 thermocycler. Following 
the reaction, the cDNA samples were precipitated by addition of 2 pi of 3 M 
sodium acetate (pH 4.6) and 50 pi of 95% ethanol and incubation at room 
temperature for 15 minutes. The precipitated DNA was then centrifuged for 20
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minutes at 16,000 *  g and the DNA pellets were washed by addition of 250 pi 
of 70% ethanol and centrifugation at 16,000 * g for 5 minutes. The pellets 
were dried by placing the tubes with the lids open in a heat block at 90°C for 1 
minute. The sequencing was preformed on an ABI 377 sequencer (Applied 
Biosystems) by Central Biotechnology Services, Cardiff University School of 
Medicine.
Reagents Concentration Amount
Ready Reaction Premix 2.5x 4 pi
BigDye Sequencing Buffer 5x 2 pi
Primer 3.2 pmol
Template 2 - 4 ng
H20 to 20 pi
Final Volume 1 X 20 pi
h 2o - to 20 pi
Table 2.7 Concentrations and volumes of reagents used for sequencing 
reaction.
25 cycles
Denaturation 96°C for 30 seconds
Annealing 50°C for 15 seconds
Extension 60°C for 4 minutes
Table 2.8 Cycling conditions used for sequencing reaction.
2.3.9 qPCR 
i. Principle
Real time or qPCR is the state of the art technique based on conventional 
PCR chemistry, to quantify nucleic acid expression in real time by the labelling 
of primers, oligonucleotide probes (oligoprobes) or amplicons with reporter
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molecules capable of fluorescing. The fluorescent reporter molecules fall into 
two groups: 1) DNA-binding dyes (e.g. SYBR green) and 2) Dye-labelled 
probes such as hydrolysis probes (e.g. TaqMan probes). The former of these 
has been used in this investigation i.e. SYBR Green.
A. SYBR Green
SYBR Green is the most commonly used double stranded DNA (dsDNA) 
binding dye. In solution (i.e. not bound to DNA), it displays relatively low 
fluorescence; however on binding to dsDNA, the level of fluorescence emitted 
by the molecule increases by 1000 fold (Wittwer et al., 1997). Therefore, as 
the amount of dsDNA in the PCR increases, the amount of fluorescence 
increases proportionally. One potential disadvantage of assays based on 
DNA-binding dye chemistry is the inherent non-specificity. SYBR Green will 
bind to all dsDNA molecules, including primer dimers or genomic DNA. 
However it is possible to achieve additional specificity and to verify the identity 
of the product in each amplified sample by plotting fluorescence as a function 
of temperature to generate a melting curve of the amplicon. Each dsDNA 
molecule has a specific Tm based on its nucleotide composition at which 50% 
of the DNA becomes single stranded. The presence of two or more peaks 
suggests that more than one amplified sequence was obtained, and the 
amplification was not specific for a single DNA target (Ririe et al., 1997).
B. Analysis
The amount of template in a sample can be described either relatively or 
absolutely. Both relative and absolute quantitation of gene expression utilises
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the cycle threshold (Ct) value to quantitate cDNA and thereby determine gene 
expression. The Ct is defined as the PCR cycle in which fluorescence intensity 
is greater than background fluorescence. The Ct value is directly correlated to 
the starting target concentration of the sample. The greater the amount of 
initial DNA template in the sample, the lower the Ct value for that sample. 
Relative quantification describes the change in expression of a target 
sequence in a test sample relative to the same sequence in an external 
standard or a reference sample, also known as a calibrator.
Typically the calibrator is an untreated sample or a zero-time point. The 
differences in Ct values between an unknown sample and calibrator are 
expressed as fold changes (i.e. upregulated or downregulated) relative to the 
calibrator sample. Using this approach, it is necessary to normalise the results 
with a normalising reference or housekeeping gene (e.g. cyclophilin, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), B-actin, 18S rRNA, 
etc.) that is not expected to change under the experimental conditions. This 
normalisation controls for possible differences in the amount of RNA used and 
in the efficiency of the reverse transcription reaction from sample to sample 
and experiment to experiment. This produces a corrected relative value for the 
target specific mRNA product, which can be compared between samples and 
allows an estimate of the relative expression of the GOI in those samples. In 
addition amplification efficiencies of the target and the reference must be 
determined and be incorporated into calculations because they directly affect 
the accuracy of any expression results (Livak and Schmittgen, 2001).
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ii. Method
Real-time PCR was performed using an MX3000p thermal cycler system 
(Stratagene, Cambridge, UK) and Platinum SYBR Green qPCR SuperMix- 
UDG (Invitrogen, Paisley, Scotland). All reactions were set up in a total 
volume of 25 pi containing 12.5 pi of SYBR green Master Mix, 1 pi of cDNA 
template, 1 pi of the forward and reverse primers, and 10.5 pi of nuclease free 
water. The mixtures were prepared in 96 well PCR plates, centrifuged for 1 
minute at 1000 x g and amplified using the following cycling parameters: 2 
minutes at 50°C (uracil-DNA glycosylase (UDG) incubation), 2 minutes at 
95°C (activation of Platinum DNA polymerase), followed by 45 cycles 
consisting of denaturation at 90°C for 15 seconds and annealing at 60°C for 
30 seconds (amplification of the specific target sequence).
Amplification was confirmed by monitoring the dissociation curve (at the end of 
the PCR, samples were subjected to a melting curve analysis: 60 seconds at 
95°C, 30 seconds at 55°C and 30 seconds at 95°C) (see an example of 
thermal profile in figure 2.1). All reactions were performed in at least duplicate. 
Template negative controls were also included in all amplification 
experiments.
The relative quantitative expression of GOI was analysed using the MxPro 
software (Stratagene). The relative quantitation value for each target gene 
compared with the calibrator for that target is first calculated separately for 
each assay, following normalisation of GOI assays to assigned normalisers.
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To do this, the following equation was used:
(1 +  EGO,)ACtGoi
Relative quantity to the calibrator = -----------------------
( 1 +  E n«m )-iCtno™
Where
Eqoi = efficiency of the target assay 
Enorm = efficiency of the normaliser assay
ACt = (Ctcaiibrator — Ctunknown)
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Figure 2.1 Example of q-RTPCR readout. (A) Thermal profile, (B) 
dissociation curve, (C) amplification curve and (D) efficiency curve of a 10 fold 
dilution series using rat ALP primers.
2.4 Analysis of protein expression
2.4.1 Cell lysis
Cells were washed twice with PBS and lysed (250 pi per well of 6 well plate) 
in radioimmunoprecipitation assay (RIPA) buffer (50 mM 
tris(hydroxymethyl)aminomethane (Tris)-hydrochloric acid (HCI), pH 7.5, 150
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mM sodium chloride (NaCI), 1% Nonidet P-40, 0.1% Sodium dodecyl sulfate 
(SDS), 0.5% sodium deoxycholate) containing a protease inhibitor cocktail 
(chymostatin, leupeptin, antipain and pepstatin all at 10 pg/ml), 1 mM sodium 
orthovanadate and 0.1 mg/ml phenylmethylsulfonyl fluoride (PMSF). Plates 
were stored overnight at -80°C and lysates were then transferred into 1.5 ml 
centrifuge tubes. Lysates were clarified by centrifugation (3 minutes at 6,500 x 
g), and protein levels determined with the use of the Bio-Rad protein assay 
(Bio-Rad Laboratories Ltd., Hertfordshire, UK) as described in section 2.6. 
Aliquots of cell lysates ( 1 5 - 3 0  pg of total cellular protein) and the pre-stained 
protein marker (Cell Signalling Technology, Hertfordshire, UK) were mixed 
with an equal volume of loading buffer (4% SDS, 2% p-mercaptoethanol, 20% 
glycerol, 100 mM Tris-HCI, pH 6.8, 0.004% pyronin Y), boiled for 5 minutes, 
centrifuged to remove the insoluble material, and then separated on SDS- 
polyacrylamide gel electrophoresis (PAGE) as described in section 2.4.3.
2.4.2 Phosphorylation assay
For detection of signal transduction molecules (extracellular signal-regulated 
kinases (ERK); CREB) cells were serum-starved for about 17 hours. Briefly, 
cells were washed twice with PBS and incubated in serum free medium 
overnight at 37°C in a 5% CC>2:95% air atmosphere. Medium was changed 
and cells were incubated for an additional two hours prior to stimulation with 
the test compounds as described in the results. The reaction was terminated 
by two quick washes in ice-cold PBS containing 1 mM sodium orthovanadate 
and lysed in ice-cold RIPA buffer with inhibitors as described above and 
subjected to Westsrn blot analysis (section 2.4.3).
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2.4.3 Western blotting
i. Principle
SDS-PAGE and Western blotting were used for identification and comparative 
quantification of proteins of interest. SDS-PAGE relies on the migration of 
charged molecules in a gel matrix and facilitates the separation and resolution 
of a mixture of proteins according to molecular weight. SDS is an anionic 
detergent that denatures proteins, providing them with the same 
conformational properties and also with a similar net negative charge. SDS 
coated proteins are therefore subjected to the same field strength and migrate 
in an electric field with equal charge toward the anode. SDS-PAGE also 
involves linearisation of proteins by dissociation of disulphide bonds with 
reducing agents such as 2-mercaptoethanol. SDS-PAGE separation is, 
therefore, determined not by intrinsic electrical charge of the polypeptide, but 
by their molecular weight through the sieving action of the acrylamide gel 
matrix. SDS-PAGE separated proteins are then blotted to a nitrocellulose or 
polyvinyldifluoride (PVDF) membrane for immuno-blotting analysis (Bolt and 
Mahoney, 1997; Towbin etal., 1979).
ii. Methods
A. SDS-PAGE
The separation of proteins was carried out using the discontinuous system 
and denaturing conditions originally described by Laemmli (Laemmli, 1970). 
The discontinuous system utilises different buffer ions and pH in the gel and in 
the electrode reservoirs. It is composed of a slightly acidic (pH 6.8), non- 
restrictive large pore stacking gel which overlays a smaller pore resolving gel.
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High resolution of protein separation is achieved, as proteins concentrate into 
narrow zones during migration through the large-pore stacking gel, before 
entering the separation gel, where higher pH (8.8) and acrylamide 
concentration causes proteins to be resolved according to size.
The percentage of acrylamide used in the separation gel is based on the size 
of the protein of interest; low molecular weight proteins are resolved on higher 
percentage gels while proteins with higher molecular weight are resolved on 
lower percentage gels. 10% gel was routinely used for separating proteins in 
the range of 30 - 80 kDa. Proteins of greater than 80 kDa should be run on an 
8% gel and those of less than 30 kDa on a 12% gel. The recipes for the 
stacking and resolving gels can be found in tables 2.9 and 2.10. Once 
prepared the resolving gel mixture was mixed by swirling and 7 ml of the 
mixture was immediately transferred into a 1.5 mm gel casting system (Bio- 
Rad, Hertfordshire, UK). The gel was overlaid with 500 pi of N-butanol and 
allowed to set for 45 minutes at room temperature. Once the resolving gel has 
polymerised, the gel surface was washed twice with 1 ml of dH20 . The 
stacking gel was poured on top of the resolving gel and a 10 well comb was 
placed between the glass plates. The stacking gel was allowed to set for 30 - 
45 minutes at room temperature and the comb was removed. Samples with 
known concentration of protein ( 1 5 - 3 0  pg protein) were loaded onto each 
well and subjected to SDS-PAGE using a mini protean II system (Bio-Rad, 
Hertfordshire, UK). Electrophoresis was then performed at a constant current 
of 200 volts for about 30 - 45 minutes in running buffer.
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Component 10% (w/v) Gel
30% Acrylamide* 3.3 ml
dH20 2.92 ml
1M Tris (pH 8.8) 3.75 ml
10% SDS 100 pi
10% APS** 100 pi
TEMED*** 5 pi
Table 2.9 Resolving gel components.
Component 4% (w/v) Gel
30% Acrylamide* 1.3 ml
dH20 6.1 ml
0.5M Tris (pH 6.8) 2.5 ml
10% SDS 100 pi
10% APS** 100 pi
TEMED*** 10 pi
Table 2.10 Stacking gel components.
* Made up with acrylamide:bis-acrylamide ratio of 29:1 
** APS: Ammonium Persulfate (Freshly prepared in H20)
*** TEMED: N.N.N'.N'-Tetramethylethylenediamine (Added immediately prior to pouring the 
gel)
B. Western blotting
Proteins from SDS-PAGE gels were transferred to a PVDF membrane 
(Hybond-P, GE Healthcare, Bucinghamshire, UK) using a mini protean II 
system (Bio-Rad, Hertfordshire, UK). Following electrophoresis the resolving 
gel was soaked in blotting buffer along with PVDF membrane and filter paper 
that were all cut to the same size as the gel. The Western blot transfer 
cassette was assembled according to manufacturer’s instructions. The 
membrane was carefully located on top of the gel and these were sandwiched 
between the filter papers. A Pasteur pipette was drawn across the surface of 
the assembled sandwich to remove air bubbles that might have formed
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between the layers as they can disrupt the transfer of proteins from gels to 
membrane. The assembled sandwich was placed between sponge pads 
within the cassette as shown in figure 2.2. The cassette was then loaded 
along with a freezing block into the blotting tank with the membrane located 
between the gel and the positive electrode. The proteins were transferred 
onto the membrane by electrophoresis in continuosly stirred chilled blotting 
buffer for 1 hour at 350 mA using a POWER PAC 1000 (Bio-Rad, 
Hertfordshire, UK).
1 Cassette
2 Gel
3 Membrane
4 Filter paper
Figure 2.2 Western blot transfer cassette.
C. Immunoprobing of Western blots
The PVDF membrane was removed from the tank and cassette and washed 
with Tris buffered saline (TBS) (0.137 M NaCI, 0.02 M Tris-HCI, pH 7.6) and
0.1% Tween 20 (TBS-T) for 5 minutes. All the washing and staining steps 
were performed with continuous mechanical agitation. To prevent non-specific 
antibody binding, the membrane was blocked for a minimum of 1 hour with 
5% milk powder in TBS-T at room temperature. After blocking, the membrane 
was probed with a primary antibody specific to the protein of interest in 
blocking buffer by overnight incubation at 4°C or at room temperature for one 
hour. Table 2.11 gives details of antibodies used in these studies, along with
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their corresponding dilutions. Following incubation with primary antibody the 
blot was washed with TBS-T ( 3 x 5  minutes) and probed with the appropriate 
horseradish proxidase (HRP) conjugated secondary antibody (at a dilution of 
1:5000) for 1 hour in blocking buffer at room temperature. The blot was 
extensively washed in TBS-T (2 x for 30 seconds; 1 x for 15 minutes; 3 x for 5 
minutes) before visualisation by chemiluminescence.
D. Detection of immuno-labelled protein
Specific antibody binding was visualised with enhanced chemiluminescence 
(ECL) plus Western blotting detection reagents (GE Healthcare, Amersham, 
UK). The ECL Plus contains lumigen PS-3 acridan substrate, which is 
catalysed by HRP to produce an acridinium ester intermediate that reacts with 
peroxide in alkaline conditions and emits light. This light is captured on 
autoradiography film. The ECL reagent consisted of two solutions (A and B) 
that were mixed in 40:1 ratio according to manufacturer’s instructions and the 
protein side of the blot was overlaid with a sufficient volume (~ 2.5 ml for a 5 x 
8 cm blot) for 5 minutes. The excess ECL solution was then removed and the 
blot covered with saran wrap. The blot was transferred to a photographic 
cassette with the protein side facing up and exposed to an autoradiography 
film (Hyperfilm™ ECL; GE Healthcare, Amersham, UK) for periods ranging 
from 30 seconds to 60 minutes depending on signal strength. The film was 
developed and the bands obtained were analysed using an Alphalmager™ 
documentation and analysis system (Alpha Innotech Corporation, San 
Leandro, USA).
75
Chapter 2 Materials and methods
Antibody Ab Host/type Species
Reactivity
Dilution MW
(kDa)
Supplier Catalog #
Anti-Ai Rabbit/polyclonal H, R 1:1000 36 Abeam® ab3460
Anti-A2A Rabbit/polyclonal H, D 1:2000 45 Abeam® ab3461
Anti-A2e Rabbit/polyclonal H, M, R 1:1000 36 Alpha diagnostics A2BR23-A
Anti-A3 Rabbit/polyclonal H 1:1000 36 Abeam® ab13160
Anti-CD73 Goat/polyclonal H, M, R 1:500 71 Santa Cruz 
Biotechnology
sc-14684
Anti-p-actin Goat/polyclonal H, M, R 1:1000 43 Santa Cruz 
Biotechnology
sc-1616
Anti-ERK1 Rabbit/polyclonal H, M, R 1:2000 44 Santa Cruz 
Biotechnology
sc-94
Anti-ERK2 Rabbit/polyclonal H, M, R 1:2000 42 Santa Cruz 
Biotechnology
sc-153
Anti-p-ERK1/2 Mouse/monoclonal H, M, R 1:2000 42, 44 Cell Signalling 
Technology
9106
Anti-CREB Rabbit/polyclonal H, M, R 1:1000 44 Santa Cruz 
Biotechnology
SC-186
Anti-P-CREB Rabbit/monoclonal H, M, R 1:1000 43 Cell Signalling 
Technology
9198
Anti-Phospho-
Threonine
Mouse/monoclonal H, M, R 1:1000 Cell Signalling 
Technology
9386
Anti-goat IgG- 
HRP
1:5000 Santa Cruz 
Biotechnology
SC-2354
Anti-rabbit
IgG-HRP
1:5000 - GE Healthcare NA934V
Anti-mouse
IgG-HRP
1:5000 GE Healthcare NA931V
Table 2.11 Summary ol antibodies. Reactivity Key: H=Human; M=Mouse;
R=Rat; D=Dog
2.4.4 Striping and re-probing PVDF blots
To check sample loading, the blot was stripped and re-probed with a 
housekeeping antibody (anti-p-actin). The blot was incubated with stripping 
buffer (6.25 ml, 0.5 M Tris (pH 6.8), 10 ml 10% SDS, 0.35 ml mercaptoethanol 
and 33.5 ml of dH20) in a hybridisation oven with gentle mixing for 30 minutes 
at 60°C. The blot was then washed (3 x for 10 minutes) with a large volume of 
TBS-T, blocked and re-probed with appropriate housekeeping antibody as 
described in section 2.4.3 Western blotting.
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2.4.5 Pro-Q Diamond
i. Principle
Pro-Q Diamond dye is a fluorescence based detection method for the 
selective and sensitive analysis of phosphorylated proteins. The dye binds 
noncovalently to phosphoproteins and allows direct detection of 
phosphoserine, phosphothreonine and phosphotyrosine containing proteins.
ii. Method
Proteins were separated by electrophoresis on a 10% SDS-polyacrylamide 
gel, and blotted to a PVDF membrane. After blotting, the membrane was 
allowed to dry completely. Dried PVDF membranes were re-wetted by dipping 
into 100% methanol for a few seconds and were stained for phosphoproteins 
using Pro-Q Diamond dye (Invitrogen, Paisley, Scotland). Briefly, the 
transblotted proteins were fixed to the membrane by immersing the 
membrane in 7% acetic acid/10% methanol solution (25 ml) for 10 minutes. 
The membrane was then washed four times in 25 ml of dH20  for 5 minutes 
per wash and incubated in 25 ml of Pro-Q Diamond stain for 15 minutes. The 
membrane was destained with 25 ml of a solution of 50 mM sodium acetate 
and 20% acetonitrile (pH 4.0) for 15 minutes. This wash was repeated twice 
for a total of three washes. The membrane was then air-dried, visualised and 
photographed under UV transillumination using the Multi Image™ light cabinet 
and Alphalmager™ documentation and analysis system (Alpha Innotech 
Corporation).
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2.5 Analysis of cAMP production
2.5.1 Sample preparation
Cells in 24 well plates were washed with serum free medium containing the 
experimental treatments used for that particular experiment. Cells were 
incubated with varying concentrations (10'8 to 10'4 M) of adenosine, NECA, or 
CGS 21680 in the presence of 1CT4 M RO 20-1724 (cAMP specific PDE 
inhibitor) for 15 minutes at 37°C. The reaction was stopped by rapid aspiration 
of medium and degradation of cyclic nucleotides was prevented by the 
addition of 200 pi of 0.1 M HCI. Acid extracts were dried by overnight vacuum 
centrifugation. The dried samples were dissolved in 1 ml of assay buffer (50 
mM sodium acetate with 0.25% bovine serum albumin (BSA), pH 5.2). This 
extract was stored at -20°C and used directly in the immunoassay system.
2.5.2 cAMP radioimmunoassay
i. Principle
Intracellular cAMP contents were measured by an in-house acetylation 
radioimmunoassay (RIA) (Brooker et al., 1979; Harper and Brooker, 1975). 
This is a sensitive and specific method, which allows measurement of pmolar 
concentrations of the nucleotide. RIAs are based upon competition of 
substrate with a radiolabelled substrate for binding sites on antibody 
molecules. With a constant and limiting amount of antibody, the amount of 
radioactive label bound by the antibody will be inversely proportional to the 
concentration of substrate in the sample. Free and antibody-bound antigens 
are separated by precipitation of the antibody-bound fraction with either a 
second antibody or polyethylene glycol. The radioactivity in the antigen-
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antibody complex is then counted and the concentration of substrate in 
samples is determined by interpolation from a standard curve of known 
substrate concentrations.
ii. Method
Standards were prepared in assay buffer from a cAMP stock (20 pmol) by 2 
fold serial dilution over the range of 4 - 0.039 pmole/tube. Samples were 
prepared by diluting in assay buffer in a final volume of 400 pi based on the 
results of the prior test assays. Also included were assay blanks i.e. for non­
specific binding (NSB) and for background subtraction (C0) which received 
assay buffer only. Standards, blanks and appropriately diluted samples were 
acetylated by adding 10 pi of triethylamine and immediate vortexing, followed 
by addition of 5 pi acetic anhydride. The mixture was again mixed by 
vortexing for few seconds and 100 pi of diluted [125l]-cAMP label (NEN Life 
Sciences Products, UK) (~ 10,000 cpm) was then added along with 100 pi of 
affinity purified rabbit antisuccinyl cAMP (in house) in a final dilution of 
1:10000. Non-specific binding was determined in the absence of antiserum 
(NSB tube). The tubes were incubated overnight at 4°C and the antibody- 
bound [125I]-cAMP was then separated from the free form by precipitation of 
the antibody-bound fraction by adding 100 pi of bovine gamma globulins (2% 
in PBS) and 750 pi of polyethylene glycol (20% in PBS). Table 2.12 shows the 
components added for NSB, total binding (C0) and samples and standards 
(C). Tubes were mixed to homonogeneity and centrifuged at 3000 x g at 4°C 
for 20 minutes. The supernatants were aspirated and the amount of [125l]-
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cAMP radioactivity in the pellets was determined by counting for 50 seconds 
in a mini-assay type 6-20 gamma counter (Thermo Scientific, Cheshire, UK).
NSB Co C
400 pi buffer 
10 pi triethylamine 
5 pi acetic anhydride 
100 pIcAMP label 
100 pldH20
400 pi buffer 
10 pi triethylamine 
5 pi acetic anhydride 
100 pi cAMP label 
100 pi antibody
400 pi standard or sample 
10 pi triethylamine 
5 pi acetic anhydride 
100 pIcAMP label 
100 pi antibody
Overnight at 4°C
100 pi gamma globulins 
750 pi polyethylene glycol
100 pi gamma globulins 
750 pi polyethylene glycol
100 pi gamma globulins 
750 pi polyethylene glycol
Table 2.12 Components for NSB, total binding (C0) and samples (C) for 
cAMP RIA.
The percentage (ratio of counts bound/total counts bound) of each standard 
and unknown sample was calculated according to the following formula 
(average of the counts was used for each standard duplicates):
C - NSB 
C0 -NSB x 100
A calibration curve was obtained by plotting this percentage verses log 
concentration (pmoles) of standards as an exponential curve using the scatter 
plot function of Microsoft Excel and the value of unknowns were calculated 
from the equation from each different set of experiments. An example of a 
calibration curve for cAMP measurement is shown in figure 2.3.
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Figure 2.3 Sample calibration curve obtained for cAMP RIA.
2.6 Cellular protein quantification
i. Principle
Total cellular protein was determined with the Bio-Rad Protein Assay kit (Bio- 
Rad Laboratories Ltd., Hertfordshire, UK), a colourimetric assay based on the 
Bradford method (Bradford, 1976). This assay relies on the binding of proteins 
to Coomassie Brilliant Blue G-250 dye which can exist in three ionic forms: 
cationic (red), neutral (green), and anionic (blue) (Bradford, 1976). Under 
strongly acid conditions, the dye is predominantly in the doubly protonated red 
cationic form. When the dye binds to protein, however it is most stable as an 
unprotonated blue form that has an absorbance maximum at 590 nm 
(Compton and Jones, 1985). The quantity of protein in the sample can be 
estimated by measuring the amount of the blue protein-dye at 595 nm in a 
spectrophotometer.
ii. Method
A. Collection of cellular protein
Cells were washed with 500 pi of PBS and fixed with 500 pi of 100% methanol 
for 1 minute. Subsequently, methanol was removed and the wells were
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allowed to dry at room temperature. An appropriate volume (depending on the 
area of the well and the cell number) of 0.5 M sodium hydroxide (NaOH) was 
then added to each well and left for 30 minutes. Plates were stored for 24 
hours at -20°C before collecting homogenates in 1.5 ml eppendorf tubes. 
Tubes were stored at -20°C for subsequent quantification of total cell protein.
B. Quantitation of Cellular Protein
A standard curve was constructed by using known concentrations (2.5 to 20 
pg/ml) of BSA in dH20  in a total volume of 800 pi in clean dry test tubes. 
Samples were also prepared by diluting in dH20  in a final volume of 800 pi 
based on the results of the test assay, whereas the blank contained 800 pi of 
dH20 . 200 pi of concentrated dye reagent was added to each tube (i.e. 
standards, test samples and blank) and mixed for a few seconds. Tubes were 
left for 10 minutes and the absorbance at 595 nm measured using a 
GENESYS 10UV spectrophotometer (Thermospectronic, Cambridge, UK). 
The total protein concentration in each unknown sample was determined by 
comparison with the standard curve.
2.7 Cell viability assay
i. Principle
A  commercially available kit (CellTiter 96 A Q ue0us solution cell proliferation 
assay; Promega, Southampton, UK) was used to measure cell number. This 
assay is referred to here as the MTS assay and comprises a metabolic 
colourimetric test, which utilises a tetrazolium compound (3-(4,5- 
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
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tetrazolium, inner salt— MTS) and an electron coupling reagent, phenazine 
methosulfate (PMS). The MTS tetrazolium compound is bio-reduced by cells 
into a coloured formazan product that is soluble in tissue culture medium. 
Cellular metabolism by dehydrogenase enzymes in metabolically active cells 
via formation of reducing equivalents such as beta-nicotinamide adenine 
dinucleotide/reduced (NADH) or beta-nicotinamide adenine dinucleotide 
phosphate/reduced (NADPH) is thought to be responsible for the conversion 
of the tetrazolium compounds to the coloured formazan products that has 
been shown to be directly proportional to the number of living cells (Dunigan 
et al., 1995; Goodwin et al., 1995).
ii. Method
Cells were seeded in 96 well tissue culture plates in 100 pi of normal growth 
medium, the outer wells were not used and contained only culture medium to 
prevent evaporation. After 24 hours the culture medium was replaced with 
fresh medium containing test compounds which was renewed every 3 days or 
as stated in the results. At the end of the experiment, cells were processed by 
addition of 20 pi of MTS directly to each well. The plate was then covered in 
aluminium foil (MTS is light sensitive) and incubated at 37°C in a humidified 
atmosphere of 5% CO2 for 2 hours. The absorbance of the formazan at 490 
nm was measured directly from 96 well assay plates on a SpectraCount™ 
microplate photometer (Canberra Packard Ltd, Berkshire, UK) after 1 and 2 
hours. The 1 hour reading was used in final data analysis, the 2 hour readings 
were used when the absorbance readings were particularly low.
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2.8 Analysis of osteoblastic differentiation
2.8.1 ALP enzyme activity
i. Principle
The enzyme ALP is involved in osteoblast maturation and mineralisation in 
the early phase of bone calcification and was used here as a marker of 
osteoblastic development (Balcerzak et al., 2003). The assay for measuring 
the activity of ALP utilizes p-nitrophenylphosphate (p-NPP) as a substrate. 
Hydrolysis of this phosphomonoester releases inorganic phosphate and p- 
nitrophenol. The rate of p-nitrophenol liberation, which is measured 
photometrically at 405 nm, is proportional to the activity of ALP in the 
samples.
ii. Method
ALP activity was determined in 24 or 96 well plates using the phosphatase 
substrate with its supplied alkaline buffer (Sigma Aldrich, Poole, UK). Briefly, 
cells were washed with PBS and then a solution of phosphate 
substrate/alkaline buffer pH 10.3 at an appropriate ratio (depending on the 
level of ALP activity) was added to each well. The plate was incubated for 20 
minutes at room temperature in the dark and absorbance was read at 405 nm 
on a SpectraCount™ microplate photometer (Canberra-Packard Ltd, 
Beaconsfield, Berks, UK). The ALP activity values were normalised to the 
relative number of viable cells in the same plate by prior determination using 
the MTS proliferation assay as described in section 2.7 or in a parallel set of 
experiments using total protein concentration if 24 well plates were used as 
described in section 2.6.
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2.8.2 Mineralisation (Alizarin Red S staining)
i. Principle
Alizarin Red S staining is a common histochemical technique for visualisation 
of calcium mineral deposition in the extracellular matrix of osteoblast cultures 
in vitro. Calcium forms a complex with Alizarin red S in a chelation process 
which can be visualised as dark red colour.
ii. Method
The mineralised matrix was stained for calcium with Alizarin Red S. A working 
solution of stain was prepared by dissolving Alizarin Red S (1:100) in dH20, 
adjusted to pH 4.2 and passed through a 150 mm filter paper (Whatman, 
Maidstone, UK) prior to use. Cells were washed with PBS and fixed in 4% 
formaldehyde in PBS (formal saline) for 15 minutes. The formal saline was 
removed, and the cells were washed with dH20. The cells were then stained 
by complete immersion in the working solution of Alizarin Red S for 10 
minutes at room temperature. The Alizarin Red S solution was removed and 
the cells were washed five times with 50% ethanol and then air-dried. The 
plates were scanned using an Epson Perfection 4990 photo flatbed scanner 
and the stained calcium deposits were assessed microscopically with a phase 
contrast ELWD 0.3 inverted microscope (Nikon) and images were captured by 
the Penguin 150 CL camera (Pixera Corporation, Surrey, UK) through 
Viewfinder 3.0.1 (Pixera Corporation). To quantify the level of mineralisation, 
cells were destained by an overnight incubation in 10% (w/v) cetylpyridinium 
chloride (CPC) at room temperature with continuous mechanical agitation and 
the obtained dye was transferred to a 96 well plate and the absorbance was
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read at 562 nm using a SpectraCount™ microplate photometer (Canberra 
Packard Ltd, Oxfordshire, UK).
2.9 Analysis of adipogenic differentiation
i. Principle
Adipogenesis was quantified by measuring intracellular lipid accumulation by 
Oil Red O and Nile red staining. These lipophilic stains have a tendency to 
accumulate in the lipid containing vacuoles of adipocytes and can be used to 
distinguish adipogenic cells during differentiation (Fowler and Greenspan, 
1985). Oil Red O is a common stain for neutral lipids and was used to 
determine relative amounts of lipid in treated and untreated adipocyte 
populations. Nile red (9-diethylamino-5H-benzo[alpha]phenoxazine-5-one), 
which is also a stain for lipids was used to identify the number of adipocytes in 
a given culture. The fluorescence of Nile red is quenched in an aqueous 
environment, whereas in a hydrophobic lipid environment Nile red fluoresces 
yellow to orange. After staining with Nile red, neutral lipids fluoresce yellow 
(peak fluorescence at 580 - 596, 590 nm), whereas polar lipids fluoresce 
orange (peak fluorescence at 597 - 620, 600 nm) (Greenspan et al., 1985).
ii. Methods
A. Oil Red O staining
Accumulation of intracellular lipid was assessed by staining with Oil Red O. A 
stock solution of Oil Red O was prepared by dissolving 5 g of Oil Red O in 100 
ml absolute isopropanol. This stock solution was stored at room temperature 
for up to 12 months. To achieve a working concentration, 3 parts of stock
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solution were mixed to 2 parts of dh^O, left for 15 minutes at room 
temperature, and filtered through a 150 mm Whatman filter paper prior to use. 
Cells were washed with PBS, fixed for 15 minutes with 4% formal saline, 
washed with dH20  and stained for 15 minutes by complete immersion in the 
Oil Red O working solution. The cells were washed once with 60%
isopropanol and twice with PBS. The lipid accumulation was assessed 
microscopically with a phase contrast ELWD 0.3 inverted microscope (Nikon) 
and images were captured by the Penguin 150 CL camera (Pixera 
Corporation, Surrey, UK) through Viewfinder 3.0.1 (Pixera Corporation). In 
order to determine the extent of adipogenesis, the dye retained by the cells 
was extracted by incubation with 200 pi of isopropanol, immediately
transferred to a 96 well plate by gentle pipetting and the absorbance was read 
at 490 nm using a SpectraCount™ microplate photometer (Canberra Packard 
Ltd, Oxfordshire, UK).
B. Nile red staining
To achieve a quantitative measure of adipocyte number, the Nile red staining 
method used was based on the method described by Sen (Sen et al., 2001). 
A stock solution was made by dissolving Nile red in DMSO (1 mg/ml) and 
stored at 4°C. A working solution was prepared immediately before use by 
diluting 1:100 in ice-cold PBS. Cells were detached carefully by trypsinisation 
and fixed for 30 minutes with 4% formal saline at 4°C. Cells were then
centrifuged for 5 minutes at 200 x g at 4°C and the cell pellet was
resuspended in 1 ml of Nile red working solution and stained for 30 minutes at 
4°C. The samples were then analysed with a FACSCalibur flow cytometer
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(Becton Dickinson Biosciences, Oxfordshire, UK) on the FL2 fluorescent 
emission channel at 585 nm. Firstly undifferentiated cells were used to set up 
the experiments. Using a forward scatter (FSC) versus side scatter (SSC) 
representation of events (based respectively on the size and granular content 
of the cell), a first R1 region (figure 2.4 Ai&Bi) was defined to exclude cellular 
debris from the analysis. The population within the R1 region was then used 
to plot the FL2 (emission channel at 585 nm that recognises the fluorescent 
emission by Nile red) versus FSC (size) (figure 2.4 Aii). The FL2 versus FSC 
plot was divided into quadrants using the undifferentiated cells (lower 
quadrants) as the base line of fluorescent emission. The lower quadrants 
therefore display events that are negative for Nile red fluorescent emission 
and represent undifferentiated cells (figure 2.4 Aii). The upper quadrants (R2) 
on the other hand contain events that are positive for Nile red fluorescent 
emission and therefore represent the adipocyte population (figure 2.4 Bii). 
Figures Aiii & Biii are histograms showing Nile red negative and positive 
populations respectively. For each sample 15,000 events were collected. The 
analysis and presentation of the data were done using the CellQuest™ 3.1 
software (Becton Dickinson Biosciences, Oxfordshire, UK).
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Figure 2.4 Sample of flow cytometery plots of Nile red analysis. (A)
undifferentiated 7F2 cells and (B) following differentiation to adipocytes.
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2.10 Stable transfection of Ai and A2b receptors into 7F2 cells
2.10.1 Plasmid constructs
Gene constructs for human Ai and A2b receptors were a kind gift from K-N 
Klotz (Institute for Pharmacology und Toxicology, University of Wurzburg, 
Germany). These were cloned or sub-cloned into the plasmid pcDNA3.1 by 
our group.
2.10.2 Isolation of plasmid constructs
E.coli (DH5a, Invitrogen, Paisley, Scotland) containing pcDNA3/Ai and 
pcDNA3/A2B constructs were incubated overnight on nutrient agar plates 
containing ampicillin (100 pg/ml) at 37°C. A single bacterial colony was 
inoculated in 10 ml of Luria Bertani broth containing ampicillin at 100 pg/ml 
and incubated overnight at 37°C in an orbital incubator with shaking. 600 pi 
bacterial broth was used to isolate pcDNA3/Ai and pcDNA3/A2B plasmid DNA 
using PureYield™ Plasmid Miniprep System (Promega, Southampton, UK). 
The culture was placed into a 1.5 ml microcentrifuge tube, 100 pi of cell lysis 
buffer (containing NaOH) was added, and the complex was mixed by inverting 
the tube 6 times. Then, 350 pi of cold (4°C) neutralisation solution was added, 
the complex was mixed as before and centrifuged at 16,000 x g for 3 minutes. 
The supernatant was transferred to a PureYield™ minicolumn, placed into a 
PureYield™ collection tube and centrifuged at 16,000 x g for 15 seconds. The 
flow-through was discarded and the column was washed with 200 pi of 
endotoxin removal wash and centrifuged at 16,000 x g for 15 seconds. The 
column was then washed with 400 pi of column wash solution and centrifuged 
at 16,000 x g for 30 second. Plasmid DNA was collected into a clean 1.5 ml
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microcentrifuge tube by the addition of 50 pi of elution buffer directly to the 
centre of the column, incubation at room temperature for 1 minute and a final 
centrifugation for 15 seconds at 16,000 *  g.
2.10.3 Transfection of 7F2 cells
Transfection was performed using TransFast™ Transfection Reagent 
(Promega, Southampton, UK) according to manufacturer’s instructions. 
Briefly, 7F2 cells were plated in a 6 well plate at a seeding density of 1.5 x 105 
cells per well in normal growth medium on the day before transfection. For 
each transfection, 5 pg of pcDNA3/Ai, pcDNA3/A2B or empty pcDNA3 vector 
(as the control) and 15 pi of TransFast™ Reagent (DNA:TransFast™ Reagent 
ratio of 1:3) were added to 1 ml of pre-warmed serum free medium, mixed by 
vortexing and incubated at room temperature for 15 minutes. The culture 
medium was aspirated and the DNA/TransFast™ Reagent mixture was added 
to the well and the plate was incubated for 1 hour at 37°C in a 5% CC>2:95% 
air atmosphere. At the end of the incubation period, 2 ml of normal growth 
medium was added to the well and the plate was incubated for further 48 
hours. Cells containing the vector or vector/DNA were selected with G418 
sulphate (0.4 mg/ml) and expanded prior to experimentation. Cells were 
maintained in media containing 0.2 mg/ml G418 sulphate.
2.11 Statistical Analysis
Data are presented as the mean ± standard error of the mean using Origin 7 
software unless otherwise stated. Statistical comparisons between means 
were made by one-way analysis of variance (ANOVA) using the Statistical
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Package for Social Sciences (SPSS) version 16. When ANOVA provided a P- 
value less than 0.05, post hoc analyses were preformed using the Tukey test 
to evaluate the differences among the mean values between groups. If 
comparisons were made only between two groups Student's t test (SPSS 
16, SPSS) was used. A P-value of less than 0.05 was considered statistically 
significant. In figure legends n refers to the number of experiments.
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3.1 Introduction
3.1.1 Bone biology
Bone is a specialised connective tissue that, together with cartilage, makes up 
the skeletal system. It is composed of an organic matrix that is strengthened 
by deposits of calcium salts in order to provide a high level of rigidity and 
strength to the skeleton while maintaining some degree of elasticity (Shea and 
Miller, 2005). This is important for both maintaining the structural integrity of 
the skeleton and calcium homeostasis (Gideon, 2003). To achieve its 
functions bone is continuously being resorbed and formed. This can either 
occur at different locations, in a process called modelling which alters the size, 
shape, or position of the bone or in a coupled process called remodelling in 
which bone resorption and formation are balanced. In remodelling, old bone is 
continuously replaced by new tissue. This ensures that the mechanical 
integrity of the bone is maintained without any changes in the morphology 
(Gideon, 2003; Hill, 1998; Pogoda et al., 2005). Imbalances of remodelling 
however can occur with ageing, metabolic bone diseases, states of increased 
or decreased mobility and certain therapeutic interventions. The long-term 
result of such imbalances in remodelling is a change in bone mass, strength, 
structure, and eventually a variety of skeletal disorders such as osteoporosis.
3.1.2 Bone cells
3.1.2.1 Osteoclast lineage
Osteoclasts are specialised cells responsible for bone resorption. They are 
tissue specific macrophage polykaryons formed from the differentiation of 
haematopoietic stem cells of monocyte/macrophage precursors in the
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circulation and bone marrow (Boyle et al., 2003). Early haematopoietic 
progenitor cells give rise to osteoclasts when stimulated by the macrophage 
colony stimulating factor (M-CSF) and RANK-L that are expressed by MSCs 
or their osteoblastic derivatives (Khosla, 2001). M-CSF which acts via the c- 
fms receptor on osteoclast progenitors promotes their differentiation and 
proliferation (Franzoso et al., 1997; Yoshida et al., 1990). RANK-L is 
necessary for fusion of the mononuclear cells into an immature osteoclast 
(Franzoso et al., 1997). This occurs at or near the site of resorption where the 
circulating precursors exit the peripheral circulation and fuse with one another 
to form a multinucleated immature osteoclast. Further differentiation of the 
immature osteoclast occurs under the continued presence of RANK-L and the 
polypeptide growth factor CSF-1 is required for the expression of several 
genes, including those encoding tartrate-resistant acid phosphatase (TRAP), 
cathepsin K (CATK), calcitonin receptor and the p3-integrin (Lacey et al., 
1998). Once the transition to mature osteoclast is reached, the bone- 
resorbing activity and survival of the mature osteoclast are regulated by 
RANK-L, hormones and cytokines (Boyle et al., 2003).
The mature osteoclasts initiate the bone resorption by peripheral attachment 
to the mineralised bone surface; a process that involves matrix derived 
signals, transmitted by the cell attachment receptor p3-integrin (McHugh et al., 
2000). After attaching to the bone, osteoclasts form a micro-compartment 
between the ruffled basal border of the cell and the bone surface. H+ ions are 
pumped into the compartment by the osteoclast to solubilise the mineral 
component by acidification of the extracellular environment, which causes a
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decrease in pH. Following this, CATK, a lysosomal protease, degrades the 
organic component (Downey and Siegel, 2006). This process produces 
irregular scalloped cavities on the bone surface, called Howship's lacunae. 
Osteoclasts will then detach from the site and osteoblasts will come into the 
area and replace the resorbed bone.
3.1.2.2 Osteoblast lineage
Osteoblasts are derived from MSCs that also give rise to chondrocytes, 
myoblasts and adipocytes as described in chapter 1. The process of 
osteoblast differentiation has been subdivided into three stages: 1) 
proliferation, 2) extracellular matrix development and maturation, and 3) 
mineralisation (figure 3.1.1). At the proliferation stage committed 
osteoprogenitors, i.e. progenitor cells restricted to osteoblast development 
and bone formation, divide rapidly to generate sufficient numbers of 
preosteoblasts for bone formation. During proliferation of preosteoblasts, 
mitotic activity is reflected by the expression of cell cycle regulated genes e.g., 
histones and proto-oncogenes. Several genes associated with formation of 
the extracellular matrix such as type I collagen and fibronectin are expressed 
at this stage (Aubin, 2001).
As preosteoblasts differentiate into more mature osteoblasts, they begin to 
secrete bone matrix proteins. Type I collagen is the major protein in bone 
matrix, comprising 90 - 95% of the organic matrix. The network of type I 
collagen fibres provides the structure on which bone mineral is deposited. 
During matrix mineralisation osteoblasts also secrete a number of non-
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collagenous proteins that are incorporated into the extracellular matrix 
(Downey and Siegel, 2006). The non-collagenous proteins include 
proteoglycans, sulfated glycoproteins and proteins modified to contain Gla 
amino acid residues (Gundberg, 2003). The main proteoglycans secreted by 
osteoblasts are decorin and biglycan that belong to the family of small 
leucine-rich proteoglycans (SLRPs). Biglycan binds to several growth factors, 
including TGF-p and mediate their action on osteoblast precursors. Decorin 
on the other hand appears to regulate collagen fibrillogenesis. Osteonectin, 
bone sialoprotein, osteopontin, tenascin-C and fibronectin are among the 
glycoproteins present in the bone matrix, all of which are important in bone 
cell adhesion, migration, proliferation and/or differentiation. Other osteoblast 
derived proteins include osteocalcin and matrix Gla protein that are 
regulators of bone formation and mineralisation (Gundberg, 2003).
As a result of changes during differentiation, bone matrix undergoes a series 
of modifications in composition and organisation that facilitate mineralisation 
via the formation of hydroxyapatite. This is thought to occur through two 
possible mechanisms; i) the formation of matrix vesicles, small vesicles that 
bud from the plasma membrane and accumulate high concentrations of Ca2+ 
and inorganic phosphate that create an optimal environment for the formation 
of hydroxyapatite (Anderson, 2003), and/or ii) the nucleation of collagen, 
regulated by noncollagenous proteins that are incorporated into the bone 
matrix such as bone sialoprotein, osteocalcin and osteonectin (Boskey, 1998). 
Osteoblasts also contribute to the process of mineralisation by expression of 
ALP, a membrane-bound marker of osteoblast differentiation that hydrolyses
96
Chapter 3 MSCs to osteoblasts
pyrophosphate, thereby generating the inorganic phosphate that is required 
for hydroxyapatite crystal formation (Balcerzak et al., 2003).
Once the osteoblasts have differentiated and accomplished their cycle of 
bone matrix formation, they can become trapped within the matrix as 
osteocytes (Knothe Tate et al., 2004). When incorporated in bone matrix, they 
begin to generate long cytoplasmic processes to remain in communication 
with surrounding cells and express E11, an early osteocyte marker 
(Wetterwald et al., 1996). As the matrix matures and mineralises, osteocytes 
become located deeper within the bone tissue, begin to mature and express a 
new set of genes, including matrix extracellular phosphoglycoprotein (MEPE) 
and sclerostin (Nampei et al., 2004; van Bezooijen et al., 2005). The mature 
osteocytes are thought to be important in cellular communication and nutrition 
within a mineralised matrix. They act as mechanosensory cells that 
communicate with other bone cells (osteoblasts and osteoclasts) to 
coordinate formation and resorption of the bone. Osteocytes are also involved 
in cell-mediated exchanges of minerals between the fluids in the bone and the 
vascular supply (Bonewald, 2007; Nakamura, 2007).
An alternative fate of some osteoblasts is differentiation into flat and inactive 
lining cells on the bone surface. Little is known about the function of these 
cells. It has been proposed that they secrete collagenase, which removes 
bone matrix and uncover a mineralised surface of the bone in preparation for 
osteoclastic resorption. Bone lining cells may also mediate the crystal growth
97
Chapter 3 MSCs to osteoblasts
in bone, or function as a barrier between extracellular fluid and bone (Downey 
and Siegel, 2006).
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Figure 3.1.1 Postulated steps in the osteoblast differentiation process.
Modified from Aubin (2001).
3.1.3 Osteoblastic induction
Osteoblastic differentiation of MSCs is well established in vitro. Differentiation 
is normally induced by addition of a combination of dexamethasone (Dex), 
ascorbic acid, and p-glycerophosphate (P-GP). Dex, a synthetic 
glucocorticoid, has been shown to induce osteoblastogenesis in both human 
and rat MSCs (Atmani et al., 2003; Cheng et al., 1996). Dex consistently 
induces ALP activity, expression of osteocalcin and bone sialoprotein, 
enhances PTH-induced cAMP production, and increases the rates of in vitro 
mineralisation in many in vitro models (Atmani et al., 2003; Jorgensen et al., 
2004). However, the effects are not lineage specific, and Dex has also been 
shown to induce differentiation and maturation of adipocytes (see section 
4.1.3). Ascorbic acid is thought to exert its effects on osteoblastogenesis by 
enhancing the production of the collagenous bone extracellular matrix. The
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effect is mainly attributed to the essential role of ascorbic acid as a cofactor in 
the hydroxylation of proline and lysine residues and subsequent increase in 
the proline hydroxylation pool, the secretion and processing of type I 
procollagen and procollagen synthesis and gene expression (Alcain and 
Buron, 1994; Franceschi et al., 1994). Ascorbic acid stimulated collagen 
synthesis is also shown to increase bone markers such as ALP and 
osteocalcin (Franceschi et al., 1994; Shiga et al., 2003; Takamizawa et al., 
2004). One major disadvantage of ascorbic acid for use in culture system is its 
instability in solution. Therefore, the more stable ascorbic acid 2-phosphate 
(AA) with similar cofactor activity for collagen biosynthesis has been used 
instead of ascorbic acid in cultures of osteoblastic cells (Takamizawa et al., 
2004). Although Dex and ascorbic acid are able to induce osteoblastic 
differentiation as evidenced by the expression of osteoblastic makers and 
extracellular matrix formation, in most cases p-GP is required for 
mineralisation of extracellular matrix. Mineralisation depends on a constant 
supply of phosphate ions, which is necessary for hydroxyapatite crystal 
formation (Balcerzak et al., 2003). p-GP is known to act as a substrate to 
produce high levels of local phosphate ions at sites of mineralisation when 
hydrolysed by ALP. p-GP has been also reported to induce osteogenesis and 
ALP activity (Coelho and Fernandes, 2000; Hamade et al., 2003).
3.1.4 Bone diseases
3.1.4.1 Osteoporosis
Osteoporosis is characterised by low bone mass and microarchitectural 
deterioration of bone tissue (figure 3.1.2) resulting in enhanced bone fragility
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and a consequent increase in fracture risk (Christiansen, 1991). It is a well- 
recognised cause of morbidity and mortality in older men and women 
(Reginster and Burlet, 2006). The prevalence is higher in women than men, 
with 1 in 3 women beyond the age of 50 years being affected (Downey and 
Siegel, 2006). The lower incidence of osteoporosis in men is mainly due to 
greater bone mass and size as well as the absence of an equivalent male 
menopause (Olszynski et al., 2004).
Figure 3.1.2 Normal (left) and osteoporotic (right) bones. From Poole and 
Compston (2006).
In both men and women, peak bone density occurs early in life, when there is 
a combination of anabolic effects due to sex hormone and environmental 
influences leading to linear increases in bone mass favouring bone formation 
(Heaney et al., 2000). At peak bone mass the amount of bone formation is 
exactly matched by the amount of resorption (figure 3.1.3). However, with age 
a process of bone loss begins as a consequence of increased and 
imbalanced bone remodelling such that bone resorption exceeds bone 
formation (Simon, 2007). This occurs either as result of increase in the 
number and/or activity of osteoclasts, reduction in number and/or the function
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of osteoblasts or a combination of the two, mainly due to changes in the 
production of local or systemic growth factors (Abdallah et al., 2006; 
Cheleuitte et al., 1998; Manolagas, 2000; Seek et al., 2001).
Gain Peak bone mass Loss
Men
Women
Age —►
Figure 3.1.3 Age related changes in bone mass throughout 
life, in women and men. From Poole and Compston (2006).
In women, these changes often take place at the same time as the onset of 
menopause, which is associated with the decrease in the female sex 
hormone, estrogen, an important regulator of osteoblast and osteoclast 
formation and activity. The loss of estrogen elevates the rate of bone 
remodelling, by promoting the formation of osteoclasts and osteoblasts form 
their progenitors. This is sufficient to increase the loss of bone, as resorption 
always precedes and is faster than bone formation and new bone is less 
dense than older bone. In addition, estrogen deficiency increases the lifespan 
of osteoclasts that consequently leads to excessively deep cavities, which 
cannot be filled by the action of the osteoblasts. On the other hand, the loss of 
estrogen leads to shorter lifespan of osteoblasts that is unable to efficiently fill 
in normal sized lacuna (Manolagas, 2000; Manolagas et al., 2002).
101
Chapter 3 MSCs to osteoblasts
The loss of bone in the elderly is also closely related to nutritional intake, 
especially vitamin D and calcium insufficiency, hormonal status such as 
decreased production of IGFs and also physical activity (Poole and 
Compston, 2006). Several genes that are involved in peak bone mass such 
as the vitamin D receptor gene and collagen type I have been also implicated 
in age related bone loss (McGuigan et al., 2002). Osteoporosis could also be 
caused secondary to a variety of chronic medical conditions such as 
Cushing’s syndrome, hypogonadism, hyperthyroidism, hyperparathyroidism, 
RA, multiple myeloma, as well as liver or renal disease. Osteoporosis could 
also occur as a result of heparin drug therapy (increased osteoclast activity) 
and most commonly oral glucocorticoid therapy (increase in osteoclast and 
decrease in osteoblast life span) (Mauck and Clarke, 2006; Simon, 2007).
Pharmacological interventions
Pharmacological therapies available for the treatment of osteoporosis are 
mostly drugs that target osteoclast induced bone resorption. Bisphosphonates 
(alendronate, risedronate and ibandronate) are the most potent agents 
available for treatment of osteoporosis that block bone resorption by inhibiting 
osteoclast activity (Mauck and Clarke, 2006; Simon, 2007). These compounds 
bind to hydroxyapatite crystals and coat the surface of the bone. However, as 
osteoclasts arrive at the site of resorption, the bisphosphonates detach from 
the bone and are taken up by osteoclasts, and subsequently inhibit their 
activity. It is also more difficult for osteoclasts to bind to and exert their action 
on the coated bone surface (Simon, 2007). Calcitonin is another anti- 
resorptive agent that inhibits the activity of osteoclasts, but not as effective as
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bisphosphonates. It apparently acts by blocking the formation of the ruffled 
border by osteoclasts and also decreasing the number of osteoclasts (Zaidi et 
al., 2 0 0 2 ).
Strontium ranelate that reduces osteoclastogenesis and promotes osteoblast 
replication, estrogen replacement and selective estrogen receptor modulators 
(Raloxifene) that act by reducing bone resorption, are among other anti- 
resorptive therapies available. Calcium and vitamin D are also often given as 
an adjunct to other therapies for osteoporosis (Compston, 2009; Meunier et 
al., 2004; Poole and Compston, 2006).
Recombinant human PTH i.e. teriparatide (1 - 34 PTH peptide) and Preotact 
(1 - 84 PTH peptide), both of which promote bone formation, are currently the 
only anabolic drug available (Compston, 2009). Low and intermittent doses of 
PTH have been shown to stimulate bone formation and increase bone mineral 
density (Blick et al., 2008; Cranney et al., 2006). PTH is thought to promote 
bone formation by increasing the life span of mature osteoblasts by reducing 
the rate of their apoptosis as well as inducing their differentiation from MSCs. 
These actions of PTH are mainly attributed to receptor coupling and the 
subsequent activation of adenylate cyclase, cAMP and PLC (Blick et al., 
2008).
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3.2 Aims
This chapter describes the expression and function of adenosine receptors in 
MSCs and during their differentiation to osteoblasts.
Specifically the aims are:
• To investigate the expression and function of adenosine receptors in 
MSCs.
• To induce differentiation of MSCs toward the osteoblast lineage and 
subsequently investigate the changes in expression and function of 
adenosine receptors at various stages of differentiation.
• To investigate the role of adenosine signalling pathways in the 
regulation of osteoblastic differentiation of MSCs.
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3.3 Methods
3.3.1 Analysis of mRNA expression
MSCs were cultured in 6  well multidishes at a seeding density of 5 x 104 cells 
per well in normal growth medium. After 24 hours, the medium was replaced 
with osteoblastic differentiation medium consisting of normal growth medium 
supplemented with 50 pg/ml AA and 10' 8 M Dex in the presence or absence 
of the indicated concentrations of adenosine or NECA as well as appropriate 
vehicle controls. The cells were treated for the indicated periods, with the 
media being changed every 2 - 3 days. At the end of the incubation periods, 
total RNA was isolated and DNase treated. The quality and quantity of RNA 
was determined spectrophotometrically by measuring absorbance at 260/280 
nm. cDNA was synthesised from 1 pg of total RNA and subjected to q-RTPCR 
amplification using specific primers for the target genes. Detailed methodology 
has been described in chapter 2 .
3.3.2 Analysis of protein expression
MSCs were cultured as described above and cell lysates were prepared at 
indicated time points during osteoblastic differentiation by treating cells with 
RIPA buffer and the protein content determined using the Bio-Rad protein 
assay. Proteins were separated on 10% SDS-PAGE, transferred to PVDF 
membranes and expression of adenosine receptors detected. Blots were 
stripped and re-probed with p-actin antibody for normalisation. The ratios of 
adenosine receptor expression during the differentiation to the housekeeping 
control p-actin were calculated from densitometry and compared to control 
(undifferentiated cells). Detailed methodology is described in chapter 2.
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3.3.3 Analysis of cAMP accumulation
MSCs were prepared as above. After differentiation for the indicated time 
points or following mineralisation, cells were stimulated for 15 minutes with 
various concentrations (10'8 M to 1CT4 M) of adenosine, NECA, or CGS 21680 
in the presence of 10 pM RO 20-1724 at 37°C. Reactions were stopped by 
rapid aspiration of media and the cyclic nucleotides extracted by the addition 
of 200 pi of 0.1 M HCI. cAMP in the acid extract was measured using a 
radioimmunoassay as described in section 2.5.2. For undifferentiated MSCs, 
cells were allowed to reach 80% confluence before assaying for cAMP. To 
assess the effects of Ai receptor on cAMP, cells were pre-incubated for 15 
minutes with the Ai receptor agonist CCPA at varying concentrations (10 ' 8 M 
to 10-4 M) in the presence of 10 pM RO 20-1724 at 37°C. The cells were then 
incubated in the same medium for further 5 minutes in the presence of 
forskolin (0.5 x 10’5 M) (to stimulate cAMP production).
3.3.4 Analysis of ALP activity
MSCs were cultured in 24 well multidishes at a seeding density of 4 *  103 
cells per well in normal growth medium. After 24 hours, cells were treated with 
adenosine receptor agonists and antagonists (as well as appropriate vehicle 
controls) during osteoblastic differentiation for the indicated periods, with the 
media being changed every 2 - 3  days. In some experiments MSCs were pre­
differentiated with osteoblastic medium for 5, 7 and 9 days before treating with 
various concentrations of agonists for a further 2  days in the presence of 
osteoblastic differentiation medium. ALP activity was assessed 
colourimetrically as the release of the yellow chromogen p-nitrophenyl from p-
106
Chapter 3 MSCs to osteoblasts
nitrophenyl phosphate substrate, as described in section 2.8.1. Protein 
content of cells was measured using the Bio-Rad protein assay in parallel 
experiments. The ALP results were corrected for protein content and 
expressed as percentage of control values.
3.3.5 Analysis of mineralisation
MSCs were cultured in 12 well multidishes at a seeding density of 2 x 104 
cells per well in normal growth medium. After 24 hours, cells were incubated 
with osteoblastic differentiation medium supplemented with 2 mM P-GP in the 
presence of the indicated concentrations of adenosine receptor agonists and 
antagonists as well as appropriate vehicle controls for 1 0  to 1 2  days. 
Treatments were replenished every weekday since adenosine has a very 
short half life. Mineralisation was determined by staining for calcium deposits 
using Alizarin Red S (described in section 2.8.2)
3.3.6 Analysis of cell number
MSCs were cultured in 96 well multidishes at a seeding density of 1.5*103 
cells per well in normal growth medium with reduced serum content (5% FCS) 
(optimum serum concentration for the proliferation assay was determined by 
plotting growth curves for several serum concentrations i.e. 1%, 5% and 10% 
FCS) (see figure 3.4.3 A). After 24 hours, the indicated concentrations of 
adenosine receptor agonists (as well as appropriate vehicle controls) were 
added for 2 and 5 days. Cell proliferation was measured by the MTS assay as 
in section 2.7.
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3.4 Results
3.4.1 Adenosine receptor expression and function in MSCs
3.4.1.1 mRNA expression
Initially the involvement of adenosine signalling in MSCs was studied by 
investigating the expression of mRNA for adenosine receptors and enzymes 
in the ATP - adenosine pathway by using standard RT-PCR. Amplification of 
mRNA gave rise to sharp bands of appropriate sizes (Ai: 100bp, A2A: 200bp, 
A2B: 100bp, A3: 129bp, CD73: 192bp, ADA: 198bp, AK: 225bp, p-actin: 165bp) 
when visualised on an agarose gel stained with ethidium bromide (figure 3.4.1 
A&B). Sequencing of amplicons confirmed gene expression, an example is 
shown in figure 3.4.1 C.
3.4.1.2 Protein expression
Although RT-PCR demonstrated that mRNA for Ai, A ^, A2B and A3 receptors 
are expressed in MSCs, it does not predict the presence of adenosine 
receptors at the protein level. The effective translation of mRNA into the 
corresponding protein was therefore investigated by Western blotting of whole 
cell lysates using affinity-purified rabbit polyclonal antibodies for each receptor 
(figure 3.4.1 D). The antibody against the adenosine Ai receptor recognised a 
single band with the expected molecular weight of around 38 kDa. The 
antibody against the A2a adenosine receptor recognised a specific band of 
around 46 kDa, corresponding to its expected molecular weight; in addition to 
two non-specific bands with higher molecular mass of about 60 and 130 kDa 
were also detected.
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Figure 3.4.1 Expression of adenosine receptors and enzymes on rat 
MSCs. RT-PCR analysis of rat MSC mRNA using primers (A) for A i, A 2A, A 2b , 
A3 receptors and (B) adenosine metabolic (CD73) and catabolic enzymes 
ADA and AK. Left margin indicates the sizes (bp) of DNA ladder. (C) Example 
of DNA sequencing fragment for a PCR product (A ^  receptor). (D) Western 
blot analysis of adenosine receptor protein expression. Positive control for the 
A3 receptor is shown. Left margin indicates the sizes (kDa) of protein marker.
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The antibody against the A2B adenosine receptor recognised a band of around 
52 kDa, consistent with the published data for the A 2b protein by other 
research groups (Peyot et al., 2000; Puffinbarger et al., 1995; Trincavelli et 
al., 2004). An extra band of low intensity at 65 kDa was also seen on the A2B 
immunoblots. There was no detectable band for the A3 receptor. To confirm 
the absence of the A3 receptor a cell line (GH3 pituitary cells) transfected with 
the A3 receptor was used as a positive control and this showed a faint band 
with the expected molecular weight of around 36 kDa, in addition to bands of 
around 17 and 55 kDa. These data show that MSCs express Ai, A2A and A2B 
but undetectable levels of the A3 receptor at the protein level.
3.4.1.3 Adenosine mediated cAMP responses in MSCs
Adenosine receptors can be functionally identified using selective adenosine 
receptor agonists and their coupling to cAMP. Adenosine produced a dose 
dependent accumulation of cAMP in MSCs, suggesting that the A2 rather than 
Ai or A3 receptors are functionally predominant (figure 3.4.2 A). This does not 
however rule out the presence of Ai and A3 receptors in MSCs. To find out 
whether the observed cAMP responses to adenosine were due to A2A or A2B 
receptor activation, cells were stimulated with CGS 21680, a high-affinity 
selective A2A receptor agonist, and NECA, a synthetic universal adenosine 
receptor agonist. No sufficiently selective A2B receptor agonist is currently 
commercially available. Therefore NECA when used in conjunction with CGS 
21680 can be used to demonstrate the presence of A2B receptors; a greater 
potency of NECA compared with CGS 21680 indicates the existence of A2b 
receptors.
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Treatment of MSCs with adenosine and NECA produced dose dependent 
accumulations of cAMP. NECA was the most efficacious agonist; at 100 pM, it 
stimulated endogenous cAMP levels by 24 fold (P < 0.001), whereas similar 
concentrations of adenosine showed a 9 fold (P < 0.001) increase. In contrast, 
CGS 21680 was ineffective and failed to elicit a cAMP response at 
concentrations up to 100 pM (figure 3.4.2 A). These findings indicate a rank 
order of potency of NECA > adenosine > CGS 21680. This potency order is 
consistent with the published pharmacology profile of A2B receptors 
(Feoktistov and Biaggioni, 1998).
Although these results suggest the predominance of the A2B receptor, it does 
not preclude the co-expression of functional Ai receptors as MSCs were 
shown to express this receptor at the mRNA and protein level. The functional 
presence of the Ai receptor was therefore investigated by measuring the 
changes in cAMP production in response to incubation with the Ai receptor 
agonist CCPA followed by stimulation with forskolin. Since the Ai receptor is 
negatively coupled to adenylate cyclase a reduction in forskolin stimulated 
cAMP could be expected. In MSCs CCPA at a concentration of 10'4 M 
resulted in an apparent increase in cAMP production (figure 3.4.2 B) whereas 
at lower concentrations there was little or no effect on forskolin stimulated 
cAMP. A possible explanation for this is that CCPA loses receptor selectivity 
at high concentrations and is able to bind to A2 receptors (Klotz et al., 1997). 
These data, together, indicate a dominance of functional A2B receptors when 
compared with Ai, A2A and A3 receptors in MSCs.
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Figure 3.4.2 Effects of adenosine receptor agonists on intracellular 
cAMP production in MSCs. MSCs were incubated (A) with the indicated 
concentrations of adenosine, NECA and CGS 21680 for 15 minutes in the 
presence of the cAMP PDEs inhibitor RO 20-1724 (lO^M) and cAMP was 
measured by an in-house RIA (n=3; total of 12 replicates). (B) To assess the 
presence of Ai receptors, cells were pre-incubated for 15 minutes with CCPA 
(10'8 M to 10-4 M) in the presence of 10 pM RO 20-1724 at 37°C and for a 
further 5 minutes with forskolin (0.5 x 10'5 M) (n=2; total of 8 replicates). **P < 
0.01, and ***P < 0.001 when compared with untreated control.
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3.4.1.4 Effects of adenosine receptor agonists on MSC cell number
Since the adenosine signalling pathway has been linked to cell death and 
proliferation in various tissues (Hofer et al., 2008; Lelievre et al., 1998; Merighi 
et al., 2002b; Olah et al., 2008; Rees et al., 2002; Shimegi, 1998), the effect of 
adenosine receptor agonists on the number of MSCs was investigated. Cells 
were treated with various concentration of adenosine, NECA, CGS 21680 and 
CCPA in a reduced serum condition (5% FCS was shown to support 
moderate growth of the cells as determined by growth curve studies (figure
3.4.3 A) for 2 and 5 days and cell number was assessed by the MTS assay. 
Except for the highest concentration of NECA i.e. 1CT4 M, which caused a 10% 
reduction in the number of MSCs after 5 days, there was no significant 
difference in cell number between control and agonist treated cells (figure
3.4.3 B). The observed effects of 10‘4 M NECA may be due to cell toxicity.
3.4.1.5 Effects of adenosine receptor agonists on ALP expression and 
activity in MSCs
As described previously, MSCs expressed functional A2B adenosine 
receptors. To examine whether activation of these receptors alone is sufficient 
for inducing differentiation to osteoblasts, MSCs were grown in normal growth 
medium in the presence of adenosine receptor agonists for 2, 5, 7, 9 and 12 
days and ALP mRNA expression determined.
Time course experiments using q-RTPCR showed that NECA at (10'5 M) 
significantly induced ALP mRNA expression by 6 fold at days 5 - 7  when 
compared with untreated MSCs (figure 3.4.4 A). NECA induction of ALP
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mRNA expression was accompanied with increased enzyme activity (figure
3.4.4 B). A dose dependent effect was observed when MSCs were treated 
with NECA for 2 and 5 days with a significant effect being detectable at 
concentrations as low as 10'6 M. Consistent with the ALP mRNA results the 
enzyme response was most evident following 5 days of treatment. Consistent 
with the lack of A2A receptors, CGS 21680 had no effect on ALP enzyme 
activity; a similar finding was seen when adenosine was used as the agonist 
(figure 3.4.5 A&B). The lack of effect of adenosine is unclear but may reflect 
its rapid metabolism.
3.4.2 Adenosine receptor expression during osteoblastogenesis
3.4.2.1 Differentiation of MSCs into osteoblasts
In order to study the expression and function of adenosine receptors during 
osteoblastic differentiation, it was necessary to first determine the osteoblastic 
differentiation potential of MSCs derived from rat bone marrow. MSCs have 
been shown to differentiate into osteoblasts by osteogenic medium 
(containing Dex and AA) and to undergo matrix mineralisation by addition of 
P-GP. Expression of mRNA of markers of various stages of osteoblast 
differentiation namely Cbfal, collagen type I, ALP and osteocalcin was 
investigated during a time course of 0, 2, 7 and 12 days of osteogenic 
induction. Under basal conditions (day 0), MSCs expressed some of these 
markers. Cbfal, type I collagen and ALP mRNAs were all easily detectable. In 
contrast, osteocalcin, the late marker of differentiation, was barely detectable. 
When treated with osteogenic medium mRNA expression of all the markers,
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Figure 3.4.3 Effects of adenosine receptor agonists on MSC cell number.
(A) Growth curves for MSCs using 1%, 5% and 10% FCS. (B) MSC cell 
number following 2 and 5 days of treatment with indicated concentrations of 
adenosine, NECA, CCPA and CGS 21680 (n=2; total of 24 replicates). Data 
are expressed as mean ± standard deviation of the mean (SDM).
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Figure 3.4.4 Effects of NECA on the induction of ALP mRNA expression 
and enzyme activity in MSCs. MSCs were treated with the indicated 
concentrations of NECA or DMSO (vehicle control) for the indicated period. 
Total cellular RNA was isolated and (A) mRNA expression of ALP was 
quantified with q-RTPCR. Expression was normalised to P-actin and 
presented as the relative mRNA expression level to untreated MSCs (n=2; 
total of 4 replicates). (B) ALP activity was measured and normalised to protein 
content (n=2; total of 8 replicates). Data are expressed as mean ± SDM.
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Figure 3.4.5 Effects of adenosine and CGS 21680 on ALP activity in 
MSCs. MSCs were treated with indicated concentrations of (A) adenosine, (B) 
CGS 21680 or DMSO (vehicle control) for the indicated times. ALP activity 
was measured and normalised to protein content (n=2; total of 8 replicates).
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as expected, increased strongly with time when compared with day 0 time 
point after normalisation to p-actin (figure 3.4.6 A). C bfal, type I collagen and 
ALP mRNA expression were significantly increased at day 7 and reached 7 - 
20 fold by day 12. Osteocalcin mRNA expression was barely detectable at 
day 2, but was massively induced (>104 fold) at day 7 and 0.5 x 105 fold after 
day 12 of osteoblastogenesis.
Parallel to osteoblastic marker expression, terminal differentiation of 
osteoblasts derived from MSCs was examined by their ability to undergo 
mineralisation, when cultured in the presence of osteogenic medium 
supplemented with p-GP. The first signs of mineralisation become apparent 
under microscopic visualisation after about 7 - 8 days and increased rapidly 
thereafter. Alizarin Red S positive calcium deposits were detectable in treated 
cultures, but not in those with basal medium (figure 3.4.6 B).
3.4.2.2 Adenosine receptor and adenosine metabolic enzyme mRNA 
expression during osteoblastogenesis
Having demonstrated the presence of functional adenosine receptors in 
undifferentiated MSCs, possible alterations in adenosine receptor expression 
associated with varying stages of differentiation was investigated. The relative 
mRNA expression of the four adenosine receptors during osteoblastogenesis 
is shown in figure 3.4.7. Expression of Ai receptor mRNA was upregulated by 
up to 8 fold between days 5 and 12 whereas the A2a and A2b receptors 
showed small increases (2 fold). Interestingly A2b receptor expression also 
appeared to decrease beyond day 7. There was no significant difference in
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expression of A3 receptor mRNA at any time point during osteoblastic 
differentiation.
Since CD73 and ADA are vital for metabolism and catabolism of extracellular 
adenosine, the changes in mRNA expression of these enzymes were also 
investigated during the process of differentiation. CD73 mRNA decreased 
(50% P < 0.05) by day 2 of osteoblastic differentiation and then progressively 
returned back to levels seen in undifferentiated cells (figure 3.4.7 E). No 
significant change in the expression of ADA was observed during osteoblast 
differentiation (figure 3.4.7 F).
3.4.2.3 Adenosine receptor protein expression during 
osteoblastogenesis
Representative blots for Western analysis of Ai, A2a and A2b receptors in 
MSCs during osteoblast differentiation for 0, 1, 2,  5, 7, 9 and 12 days are 
shown in figures 3.4.8 - 10. To facilitate comparisons between samples, 
receptor band densities were corrected for background and normalised to (3- 
actin. The day 0 time point was used as the reference to which other band 
densities were compared. In contrast to changes in Ai receptor mRNA 
expression during osteoblastogenesis the Ai receptor protein remained 
relatively unchanged or increased slightly during differentiation (figure 3.4.7). 
The reason for this difference may be related to the already high expression 
of the protein in undifferentiated MSCs which could limit further translation of 
mRNA.
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Figure 3.4.6 Osteoblastic differentiation of MSCs. Cells were incubated 
with osteoblastic differentiation medium containing AA (50 pg/ml) and Dex 
(10'8 M) for 2, 7 and 12 days. (A) mRNA expression of osteoblast specific 
markers i.e. Cbfal, Col type 1, ALP and osteocalcin was determined by q- 
RTPCR and presented as the relative expression to untreated MSCs after 
normalisation to P-actin (n=3; total of 6 replicates). **P < 0.01, and ***P < 
0.001 when compared with undifferentiated control. (B) Mineralisation was 
induced by addition of 2 mM P-GP and calcified extracellular matrix was 
visualised after 12 days by Alizarin Red S staining.
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Figure 3.4.7 Adenosine receptor and adenosine metabolic enzyme 
mRNA expression during the differentiation of MSCs into osteoblasts.
MSCs were cultured for indicated times in osteoblastic medium. mRNA 
expression of (A) Ai, (B) A 2a , (C) A 2Bi (D) A3 receptors, (E) CD73 and (F) ADA 
were quantified with q-RTPCR. Expression of each receptor was normalised 
to p-actin and values compared to untreated MSCs (i.e. day 0), which was 
assigned a value of 1 (n=3; total of 6  replicates). *P < 0.05, **P < 0.01, and 
***P < 0.001 when compared with day 0.
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Changes in A2A receptor protein expression paralleled changes in mRNA 
expression (figure 3.4.7 B) and there was direct correlation between protein 
and mRNA expression during differentiation. A relatively faint band for protein 
was detected in undifferentiated MSCs which increased gradually in intensity 
during osteoblast differentiation and was maximal at days 7 - 1 2  (figure 3.4.9). 
The A2B protein expression (figure 3.4.10) remained unchanged at day 1, but 
was strongly upregulated at day 2 and 7, by day 12 expression had fallen 
back to basal levels. A similar pattern of expression was seen for A2b receptor 
mRNA during osteoblastogenesis but the increase in protein level persists 
beyond that of the mRNA; this is probably because the protein signal is 
sustained after the mRNA has been degraded.
3.4.2.4 Adenosine mediated cAMP responses during osteoblastogenesis
Examination of adenosine receptor expression both at the mRNA and protein 
level by q-RTPCR and Western blotting identified differential expression of 
adenosine receptors during osteoblastogenesis. To check that these 
receptors were functional, cAMP responses to adenosine receptor agonists 
were investigated.
Treatment with adenosine and NECA increased cAMP accumulation in a dose 
related manner at all time points, indicating the predominance of A2 receptors 
at all stages of osteoblastogenesis (figure 3.4.11 A&B). When compared to 
undifferentiated MSCs (day 0), the efficiency of adenosine and NECA to 
stimulate cAMP production increased during the time of osteoblastic 
induction.
122
Chapter 3 MSCs to osteoblasts
1.5^ 
£  1.2 -
o
0  0 . 6 -CtJ1
PQ
^  0 .3 -
0 1 2 5 7 9 12
Days of differentiation
38
(kDa)
43
0 1 2 5 7 9 12
4 W M N M N * * —  —  — A1
(3-actin
Figure 3.4.8 Ai receptor protein expression during the differentiation of 
MSCs into osteoblasts. MSCs were cultured for 1, 2, 5, 7, 9 and 12 days in 
osteoblastic medium. Cells were lysed in RIPA buffer and equal amount of 
protein lysates were separated on 10% SDS-PAGE. Blots were probed for the 
Ai receptor, stripped and re-probed for P-actin for normalisation. The ratio of 
Ai receptor to p-actin was calculated from densitometry of Western blots and 
compared to control. Representative blots and combined densitometric values 
from at least 3 separate experiments are shown above.
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Figure 3.4.9 A2a receptor protein expression during the differentiation of 
MSCs into osteoblasts. MSCs were cultured for 1, 2, 5, 7, 9 and 12 days in 
osteoblastic medium. Cells were lysed in RIPA buffer and equal amount of 
protein lysates were separated on 10% SDS-PAGE. Blots were probed for the 
A 2a receptor, stripped and re-probed for (B-actin for normalisation. The ratio of 
A 2a receptor to p-actin was calculated from densitometry of Western blots and 
compared to control. Representative blots and combined densitometric values 
from at least 3 separate experiments are shown above. *P < 0.05, **P < 0.01 
when compared with day 0.
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Figure 3.4.10 A2b receptor protein expression during the differentiation 
of MSCs into osteoblasts. MSCs were cultured for 1, 2, 5, 7, 9 and 12 days 
in osteoblastic medium. Cells were lysed in RIPA buffer and equal amount of 
protein lysates were separated on 10% SDS-PAGE. Blots were probed for the 
A 2b receptor, stripped and re-probed for (3-actin for normalisation. The ratio of 
A 2b receptor to (3-actin was calculated from densitometry of Western blots and 
compared to control. Representative blots and combined densitometric values 
from at least 3 separate experiments are shown above. **P < 0.01 when 
compared with day 0.
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At day 0 10*4 M adenosine stimulated cAMP levels by 9 fold, this was 
increased to 22, 31, 153 and 25 fold respectively after 5, 7, 9 and 12 days of 
differentiation. The efficacy of NECA to increase cAMP was also increased 
significantly from 25 in MSCs to 42, 75, 275 and 125 fold at 5, 7, 9 and 12 
days of osteoblastogenesis respectively.
As shown previously, there was no evidence of functional coupling of A2A 
receptors to adenylate cyclase in undifferentiated MSCs (day 0). The selective 
A2A receptor agonist, CGS 21680, failed to elicit a cAMP response. However, 
upon osteoblastic induction CGS 21680 significantly stimulated cAMP 
production in a dose dependent manner (figure 3.4.11 C). The efficacy of 
CGS 21680 to increase cAMP accumulation was increased further during the 
differentiation process with the maximum response at day 9. However the 
maximal stimulation of cAMP accumulation by NECA was about 20 fold more 
than CGS 21680 at all stages of osteoblastogenesis. Together, these data 
indicate that A2A and A2B receptor expression increases during 
osteoblastogenesis of MSCs and concur with the previous data showing 
increased mRNA and protein expression. Nevertheless the A2b receptor still 
remains to be the dominant receptor in MSC derived osteoblasts.
3.4.2.5 Adenosine receptor agonist mediated cAMP responses in 
mineralised osteoblasts derived from MSCs
The stimulatory effects of adenosine and adenosine receptor agonists on 
cAMP accumulation were also investigated following mineralisation of MSC 
derived osteoblasts. As with MSC derived osteoblasts, mineralised
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osteoblasts also responded (in terms of cAMP changes) to CGS 21680, this 
was however not observed in unmodified MSCs. Adenosine, NECA and CGS 
21680 (10-4 M) increased cAMP concentrations from 9, 25 and 0 fold in MSCs 
to 16, 30 and 3 fold following 12 days of mineralisation respectively (figure 
3.4.12). The difference was most noticeable when CGS 21680 was used as 
the agonist confirming an increase in A2A receptor expression on 
osteoblastogenesis.
3.4.3 Effects of adenosine and NECA on markers of osteoblastogenesis 
during the differentiation of MSCs.
3.4.3.1 Cbfal, ALP, collagen type I and osteocalcin mRNA expression
Previous data showed that expression of the A 2A and A2b receptors in 
particular increased on osteoblastogenesis of MSCs. All four of the osteoblast 
markers, cbfal, ALP, collagen type I and osteocalcin increased within 2 - 5 
days of induced osteoblastogenesis (figure 3.4.13 to 3.4.16). The late 
osteoblast marker, osteocalcin showed a particularly large change with > 
10,000 fold increase in mRNA after 7 days of induced osteoblastogenesis 
(figure 3.3.16). Cbfal mRNA was increased 4 fold at day 7 in osteoblast 
medium and further enhanced by NECA to 7 fold (figure 3.4.13 B), no effect 
however was seen when adenosine was used in place of NECA (figure 3.4.13 
A). NECA and adenosine also stimulated ALP mRNA expression above that 
seen with osteoblastic medium alone (figure 3.4.14 A - C) but appeared to 
have little effect on the expression of collagen type I (figure 3.4.15 A&B) or 
osteocalcin mRNA (figure 3.4.16 A&B).
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Figure 3.4.11 Adenosine receptor agonist induced cAMP production in 
MSCs and at various time points during their differentiation into 
osteoblasts. MSCs were cultured in osteoblastic medium for 0, 5, 7, 9 and 12 
days. cAMP accumulation was measured after exposure to (A) adenosine (B) 
NECA and (C) CGS 21680 for 15 minutes in the presence of RO 20-1724 (10' 
4 M) (n=2; total of 8  replicates). Data are expressed as mean ± SDM.
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Figure 3.4.12 Comparison of the effects of adenosine receptor agonists 
on cAMP production in MSCs and mineralised osteoblasts. Mineralised 
osteoblasts were prepared from MSCs cultured for 12 days in osteoblastic 
differentiation medium supplemented with 2 mM P-GP. cAMP accumulation 
was measured in MSCs and mineralised osteoblasts. (A) MSCs treated with 
adenosine receptor agonists for 15 minutes in the presence of RO 20-1724 
(lO^M). <B) Adenosine, (C) NECA and (D) CGS 21680 induced cAMP 
accumulation in mineralised osteoblasts compared with MSCs (n=2; total of 8  
replicates). Data are expressed as mean ± SDM.
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3.4.3.2 Effects of adenosine receptor agonists on ALP enzyme activity
ALP mRNA expression was increased in a time related manner when MSCs 
were treated with adenosine or NECA during their differentiation to 
osteoblasts. In this set of experiments adenosine receptor agonists were used 
to investigate their effects on ALP enzyme activity. Adenosine and NECA both 
induced a dose dependent increase in ALP activity over 5 - 7  days of 
exposure (figure 3.4.17 A - B). The effects of NECA seemed to occur earlier 
(day 2) and appeared more potent than adenosine and this is likely to reflect 
the stability of NECA in comparison with adenosine. Beyond day 7 of agonist 
exposure, adenosine and NECA had little effect on ALP enzyme activity. 
Similar stimulatory effects on ALP enzyme activity were seen with the A2A 
receptor agonist CGS 21680, interestingly this increase in enzyme activity 
seemed to persist up to at least 12 days (figure 3.4.18 A). The selective A1 
receptor agonist, CCPA, also had an apparent stimulatory effect on ALP 
enzyme activity (figure 3.4.18 B) but this occurred only at 10'5 M and is 
probably due to activation of other adenosine receptors.
In addition to investigating the effects of adenosine receptor agonists during 
osteoblast differentiation of MSCs the effects of these compounds on ALP 
enzyme activity in pre-differentiated (osteoblasts) cells were also carried out. 
In these experiments the pre-differentiated cells were only exposed to 
adenosine receptor agonists for 2 days; it is possible that in the differentiation 
experiments desensitisation to long term exposure (up to 12 days) to 
adenosine receptor agonists could occur. In the pre-differentiated experiments 
adenosine, NECA and CGS 21680 stimulated ALP enzyme activity at 7, 9 and
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12 days (figure 3.4.19 A - C) and the effects were more potent than when 
adenosine receptor agonists were included for the whole duration of 
differentiation. This might suggest that prolonged exposure to agonists can 
lead to desensitisation of adenosine receptors.
3.4.3.3 Effects of adenosine receptor antagonists on NECA induced ALP 
mRNA expression and enzyme activity
Previous experiments showed that A2A and A2B receptors are increased during 
osteoblastic differentiation of MSCs and activation of such receptors also 
stimulate expression of osteoblast marker genes. To further confirm the 
identities of the receptors involved, antagonist compounds (A2a receptor, SCH 
442416; A2b receptor, MRS 1706) were used to inhibit the effects of NECA on 
ALP mRNA expression and enzyme activity. Initial experiments were carried 
out to see if these antagonists alone inhibited cell growth and using the MTS 
assay it was clear that concentrations up to 10'6 M were without effect (data 
not shown). These concentrations were subsequently used and exposure to 
antagonists alone for 2 or 5 days induced only a negligible change in the ALP 
expression or activity as MSCs differentiated into osteoblasts when compared 
to untreated control (figures 3.4.20 - 21). In the presence of SCH 442416, 
NECA induced ALP expression and activity during osteoblastogenesis was 
partially but significantly reversed by approximately 75% (P < 0.001) (figures 
3.4.20 - 21). In addition the A2B receptor antagonist, MRS 1706, abolished the 
increase in ALP expression and activity induced by NECA at day 2 and 5 of 
differentiation (figures 3.4 .20-21).
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Figure 3.4.13 NECA and adenosine mediated Cbfal mRNA expression 
during differentiation of MSCs into osteoblasts. MSCs were incubated 
with osteoblastic differentiation medium in presence or absence of (A) 
adenosine (10"4 M) and (B) NECA (10'6 M) for 2, 7 and 12 days. Cbfal mRNA 
was quantified with q-RTPCR and normalised to (3-actin and presented as 
mRNA expression relative to undifferentiated MSCs (day 0) (n=2; total of 4 
replicates). Data are expressed as mean ± SDM.
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Figure 3.4.14 NECA and adenosine mediated ALP mRNA expression 
during differentiation of MSCs into osteoblasts. MSCs were incubated 
with osteoblastic differentiation medium in presence or absence of (A) 
adenosine (10'4M), (B) NECA (10'6M) and (C) NECA (10'5 M) for 2, 7 and 12 
days. ALP mRNA was quantified with q-RTPCR and normalised to (3-actin and 
presented as mRNA expression relative to undifferentiated MSCs (day 0) 
(n=3; total of 6 replicates). *P < 0.05 and ***P < 0.001 when compared with 
day 0. #P < 0.05 and ##P < 0.01 when compared with vehicle at the same 
time point.
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Figure 3.4.15 NECA and adenosine mediated collagen type I mRNA 
expression during differentiation of MSCs into osteoblasts. MSCs were 
incubated with osteoblastic differentiation medium in presence or absence of 
(A) adenosine (lO^M) and (B) NECA (10*6 M) for 2, 7 and 12 days. Collagen 
type I mRNA was quantified with q-RTPCR and normalised to P-actin and 
presented as mRNA expression relative to undifferentiated MSCs (day 0) 
(n=2; total of 4 replicates). Data are expressed as mean ± SDM.
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Figure 3.4.16 NECA and adenosine mediated osteocalcin mRNA 
expression during differentiation of MSCs into osteoblasts. MSCs were 
incubated with osteoblastic differentiation medium in presence or absence of 
(A) adenosine (10'4M) and (B) NECA (10‘6 M) for 2, 7 and 12 days. 
Osteocalcin mRNA was quantified with q-RTPCR and normalised to p-actin 
and presented as mRNA expression relative to undifferentiated MSCs (day 0) 
(n=2; total of 4 replicates). Data are expressed as mean ± SDM.
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Figure 3.4.17 Effects of adenosine and NECA on ALP enzyme activity at 
various stages of osteoblastic differentiation. MSCs were treated with the 
indicated concentrations of (A) adenosine and (B) NECA or vehicle in 
osteoblastic differentiation medium for 2, 5, 7, 9 and 12 days. ALP activity was 
measured and normalised to protein content (n=2; total of 8  replicates). Data 
are expressed as mean ± SDM.
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Figure 3.4.18 Effects of CGS 21680 and CCPA on ALP enzyme activity at 
various stages of osteoblastic differentiation. MSCs were treated with the 
indicated concentrations of (A) CGS 21680 and (B) CCPA or vehicle in 
osteoblastic differentiation medium for 2, 5, 7, 9 and 12 days. ALP activity was 
measured and normalised to protein content (n=2; total of 8  replicates). Data 
are expressed as mean ± SDM.
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Figure 3.4.19 Dose dependent effects of adenosine receptor agonists on 
ALP enzyme activity on pre-differentiated osteoblasts. MSCs were pre­
differentiated with osteoblastic medium for 5, 7 and 9 days before treating with 
various concentrations of (A) adenosine, (B) NECA, and (C) CGS 21680 for a 
further 2 days in osteoblastic differentiation medium. ALP activity was 
measured and normalised to protein content (n=3; total of 12 replicates). *P < 
0  0 5  **p < o.01, and ***P < 0.001 when compared with vehicle at the same 
time point.
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Figure 3.4.20 Effects of A2A and A2b receptor antagonists SCH 442416 
and MRS 1706 on NECA induced expression of ALP mRNA during 
differentiation of MSCs into osteoblasts. MSCs were treated with 10'6 M 
SCH 442416 and MRS 1706 alone or in the presence of NECA (10-® M) in 
osteoblastic differentiation medium for 2 and 5 days. ALP mRNA expression 
was quantified with q-RTPCR and normalised to p-actin and compared to 
untreated cells at the same time point (n=3; total of 6 replicates). ***P < 0.001 
when compared with untreated cells. ##P < 0.01 when compared with NECA 
alone stimulated cells at the same time point.
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Figure 3.4.21 Effects of A2A and A2b receptor antagonists SCH 442416 
and MRS 1706 on NECA induced ALP enzyme activity during 
differentiation of MSCs into osteoblasts. MSCs were treated with 10'6 M 
SCH 442416 (A) or MRS 1706 (B) alone or in combination with NECA (1C)'6 M) 
in osteoblastic differentiation medium for 2 and 5 days. ALP activity was 
measured and normalised to protein content (n=3; total of 12 replicates). ***P 
< 0.001 when compared with untreated cells. ###P < 0.001 when compared 
with NECA alone stimulated cells at the same time point.
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These data combined with previous observations indicate that both A2a and 
A2b receptors are responsible for the induction of osteoblast markers in MSCs 
and during the differentiation into osteoblasts.
3.4.3.4 Effects of adenosine receptor agonists and antagonists on 
mineralisation of MSC derived osteoblasts
Current findings show that the A ^  and A2B receptors play an important role in 
osteoblastogenesis of MSCs and in these experiments I have investigated 
whether activation of the same receptors also stimulates matrix mineralisation. 
Moderate Alizarin Red S staining was observed in untreated MSCs in the 
presence of 2 mM p-GP after 10 to 12 days and this was further enhanced (P 
< 0.001) respectively by 109%, 50% and 37% when adenosine (10"4 M), 
adenosine (10'5 M) or NECA (10‘5 M) (figure 3.4.22 A&B) was included in the 
culture medium. Mineralisation was however unaffected by treatment with 
lower concentrations of NECA or adenosine. Surprisingly, CGS 21680 
(previously shown to induce ALP activity) had no effect on mineralisation 
(figure 3.4.23 A) and as expected, mineralisation was also unaffected by 
treatment with the Ai receptor agonist, CCPA (figure 3.4.23 B). The A2B 
receptor antagonist, MRS 1706, inhibited the increase in mineralisation 
induced by adenosine by up to 95% (P < 0.001) (figure 3.4.24 B), whereas the 
A ^  receptor antagonist, SCH 442416 had no significant effect (figure 3.4.24 
A). The lack of effect by CGS 21680 (A2A receptor selective agonist) and the 
lack of inhibition of adenosine induced mineralisation by SCH 442416 
suggests that the A2B receptor is responsible for the induction of 
mineralisation.
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Figure 3.4.22 Effects of adenosine and NECA on mineralisation of MSCs.
Cells were treated for 10 - 12 days with the indicated concentrations of (A) 
adenosine or (B) NECA or appropriate vehicle control in mineralisation 
medium and calcium deposition was determined by Alizarin Red S staining. 
(n=5; total of 15 replicates). **P <0.01, and ***P < 0.001 when compared with 
vehicle control.
142
N 10* M
Chapter 3 MSCs to osteoblasts
120
100
C  80
3  60«o
2 40a>
20
m u
0 10 107 10*  10*  
CCPA concentration (M)
140 
120 
Co 100
1  80
f0
£  60
2
g 40 
i  20
u n i
0 10 107 10* 10* 
CGS 21680 concentration (M)
Figure 3.4.23 Effects of CCPA and CGS 21680 on mineralisation of 
MSCs. Cells were treated for 10 -12  days with the indicated concentrations of 
(A) CCPA or (B) CGS 21680 or appropriate vehicle control in mineralisation 
medium and calcium deposition was determined by Alizarin Red S staining 
(n=3; total of 9 replicates).
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Figure 3.4.24 Effects of A2a and A2b receptor antagonists SCH 442416 
and MRS 1706 on adenosine induced mineralisation. MSCs were treated 
with adenosine (10*4 M) in mineralisation medium alone or in combination with 
10‘6 M to 10'7 M (A) SCH 442416 or (B) MRS 1706 and calcium deposition 
was determined by Alizarin Red S staining (n=3; total of 9 replicates). ***P < 
0.001 when compared with vehicle control. ##P < 0.001 and ###P < 0.001 
when compared with adenosine stimulated. (For pictures; 1= control, 2= 
adenosine (10'4 M), 3= adenosine (10'4 M) + SCH 442416 (10'7 M), 4= 
adenosine (10‘4 M) + SCH 442416 (10'6 M), 5= adenosine (10‘4 M) + MRS 
1706 (10'7M) and 6= adenosine (10’4M) + MRS 1706 (10'6M)).
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3.4.3.5 Effects of forskolin on osteoblastogenesis
The primary signalling molecule for A2 receptors is the activation of cAMP and 
figure 3.4.25 A shows that forskolin, an activator of adenylate cyclase is able 
to stimulate ALP enzyme activity in MSCs. Forskolin also stimulated ALP 
activity during early stages of osteoblastogenesis, whereas prolonged 
treatment had little effect or even reduced ALP activity (figure 3.4.25 B). 
Prolonged exposure to forskolin also inhibited mineralisation. These data 
could suggest that osteoblastogenesis is mediated via a transient rise in 
cAMP but prolonged cAMP is inhibitory. Prolonged forskolin treatment had a 
negative effect on ALP activity and on mineralisation, the mechanisms behind 
these observations are however unclear. These inhibitory effects of prolonged 
exposure to cAMP may be due to the induction of PDEs as seen in other cells 
(Conti et al., 2003; Hu et al., 2008).
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Figure 3.4.25 Effects of forskolin on ALP enzyme activity and 
mineralisation. MSCs were treated with (A) 10‘5 M forskolin in normal growth 
medium and (B) varying concentrations of forskolin in osteoblastic 
differentiation medium. ALP activity was measured and normalised to protein 
content (n=2; total of 8 replicates). Data are expressed as mean ± SDM. (C) 
Mineralisation following staining with Alizarin Red S in cells treated with 
forskolin (F) or DMSO (C).
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3.5 Discussion
Adenosine receptors are ubiquitously expressed throughout the body in many 
cells and tissues. Previously the presence of these receptors was 
demonstrated by our group in human osteoprogenitor cells (Evans et al., 
2006) and recently by Katebi and colleagues in mouse bone marrow derived 
MSCs (Katebi et al., 2009). In line with these results, we found here that 
MSCs derived from rat bone marrow also express mRNA for all four receptors 
and for enzymes involved in adenosine synthesis and metabolism. In addition 
to gene expression, Western blot analysis confirmed the presence of Ai, A2a 
and A2b receptor protein, whereas the A3 receptor protein was not detected.
It is important to note that based on protein sequences, the wild type A2B 
receptor is predicted to have a molecular mass of 36 kDa. However, in rat 
MSCs, A2b receptors appeared as a band with apparent molecular mass of 
about 52 kDa which is similar to the 50 - 55 kDa reported by others in various 
tissues and cells in human, mouse and rat (Peyot et al., 2000; Puffinbarger et 
al., 1995; Trincavelli et al., 2004). This greater molecular mass may be due to 
the formation of complexes or alternate splicing (Feoktistov et al., 2003).
Although the protein for the A3 receptor was undetectable in MSCs, the 
presence of A3 receptor protein cannot be completely excluded as Western 
blotting analyses are entirely dependent on the quality of the antibody used. 
Nonetheless it is likely that the expression of A3 receptor protein in MSCs is 
either not or lowly expressed. This is compatible with studies that reported a 
lack or low level of A3 receptor expression in various cell types (Gessi et al.,
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2004; Madi et al., 2004; Phelps et al., 2006; Rivkees et al., 2000). For 
example, in the MG-63 osteoblastic cell line, mRNA and protein for the A3 
receptor is absent (Russell et al., 2007). In contrast to normal cells, A3 
receptors are prominently expressed in tumour cell lines such as melanoma, 
lymphoma, pineal gland, colon, and prostate carcinoma (Gessi et al., 2004; 
Madi et al., 2003; Madi et al., 2004).
Although RT-PCR and Western blotting confirm the presence of A1, A2a and 
A2b receptor mRNA and protein, these results do not necessarily correlate 
with the presence of functional adenosine receptors on the cell surface. The 
functional relevance of adenosine receptors in MSCs was determined by 
measuring changes in cAMP expression. NECA, in the pM range, stimulated 
cAMP production, similar to that previously reported for cells expressing 
functional A2B receptors (Feoktistov and Biaggioni, 1998; Lynge et al., 2003; 
Phelps et al., 2006; Zeng et al., 2003) and for cells transfected with the 
human A2B receptor (Klotz et al., 1997; Schulte and Fredholm, 2000). The 
potency order for cAMP production was NECA > adenosine > CGS 21680 
and is in agreement with that reported previously for the A2B receptor 
(Feoktistov and Biaggioni, 1998; Klotz et al., 1997). The A2B receptor is a low 
affinity receptor that is inactive under physiological concentrations of 
adenosine and activated by high levels of adenosine such as that seen during 
high metabolism or in disease states such as ischemia. The inability of CGS 
21680 to induce a cAMP response in MSCs indicates that the A2A receptor is 
either not or weakly present or it is not coupled to adenylate cyclase. The lack 
of a cAMP response to CGS 21680 also indicates that the A2B receptor is
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dominant. The Ai receptor is also weakly expressed in MSCs as inhibition of 
forskolin stimulated cAMP could not be demonstrated although mRNA and 
protein studies show that the receptor is indeed expressed. The small 
stimulation of cAMP at high CCPA concentrations is probably due to non­
specific activation of A2b receptors (Klotz et al., 1997).
The apparent discord between the expression of the Ai and A2A receptors and 
their functional activity has been previously reported by other groups e.g. the 
Ai receptor in folliculostellate cells, the Ai and A ^  receptors in the 
glioblastoma cell line U87MG and in skeletal muscle cells and the A2A 
receptor in HMEC-1 cells. In these examples, although receptors were 
present, they failed to couple to the cAMP transduction pathway (Feoktistov et 
al., 2002; Lynge et al., 2003; Rees et al., 2002; Zeng et al., 2003). One 
plausible explanation for this phenomenon is the occurrence of post- 
translational modifications that result in alterations in the level of functional 
protein. On the other hand there could be alterations in sub-cellular 
localisation of the receptors that result in diminished signal transduction of the 
expressed receptor proteins (Zeng et al., 2003).
The A2b receptor is dominantly expressed in MSCs and is also important in 
their differentiation to osteoblasts as NECA alone but not adenosine or CGS 
21680 can stimulate ALP mRNA expression and enzyme activity in 
undifferentiated MSCs. The lack of effect of adenosine however could be 
attributed to the short half-life of adenosine (shown by our group to be <1 h in 
culture). Receptor expression is not static and may change as undifferentiated
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cells undergo lineage differentiation and this has been reported for P2 
receptors where there is a loss of P2X and an increase in P2Y, specifically the 
P2Y2 receptor in mature osteoblasts (Orriss et al., 2006). I therefore 
investigated the changes in expression of adenosine receptors during 
osteoblastogenesis.
MSCs expressed both osteoblast (Cbfal, collagen type I and ALP) and 
adipocyte (PPARy and C/EBPa) markers indicating their progenitor status and 
multilineage differentiation capacity (Rickard et al., 1996). In line with studies 
in rodent and human bone marrow derived progenitor cells, osteogenic 
induction in MSCs was accompanied by significant increases in osteoblast 
genes as well as mineralised matrix formation (Aubin, 1998).
Osteoblastogenesis of MSCs were also accompanied by increases in A2a and 
A2b receptor expression. The A2B receptor mRNA fell back to basal levels by 
day 5 of induced differentiation. The protein expression for A2B receptors 
followed a similar pattern but it persisted beyond that of the mRNA, possibly 
because the protein signal is sustained after the mRNA has been degraded. 
On the other hand Ai receptor mRNA also increased significantly during 
osteoblastogenesis, this however did not appear to translate to protein which 
showed little change. Increased expression of A2A and A2B receptors on 
osteoblastogenesis were also demonstrated by increased cAMP responses to 
NECA and CGS 21680; the response to NECA remained dominant showing 
that the A2B receptor is still the major subtype. However, it should be noted
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that MSC cultures undergoing differentiation contain both undifferentiated 
cells as well as cells at various stages of osteoblastic differentiation.
The differential expression of adenosine receptors suggests that they might 
be important at various stages of differentiation of MSCs or in regulating the 
activities of osteoblasts. The rapid induction of A2B receptor mRNA (day 2) 
prior to changes in the mRNA for osteoblast markers (day 7) could suggest 
that its expression is mainly involved in the early commitment stage of 
osteoblastogenesis, but is less important in later stages of differentiation 
where there is a tailing off of expression. Similar observations have been 
reported for the PTH/PTHrP receptor in which the expression was associated 
with early osteoblastic differentiation while cAMP production in response to 
PTH was elevated at the late stage of differentiation (Kondo et al., 1997). This 
contrasts with the A2A receptor which is upregulated at later stages of 
differentiation suggesting that this receptor may be related to differentiation or 
functional activities of osteoblasts.
Differentiation to osteoblasts was also associated with an early transient 
reduction in expression of the message for CD73 and no change for ADA. 
The association between CD73 and A2 receptors has been previously 
described; for example CD73 and the A2A receptor can regulate expression of 
each other (Katebi et al., 2009; Napieralski et al., 2003) and a coordinated 
increase in expression of A2B receptor and CD73 was observed under hypoxic 
conditions (Eltzschig et al., 2003). Coordinate regulation of CD73 and A2 
receptors has been suggested to be a mechanism for balancing receptor
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expression and extracellular adenosine levels. In osteoblastogenesis of 
MSCs, CD73 and A2b receptor expression were inversely proportional and in 
this case one could speculate that activity at the A2b receptor can be limited by 
reducing the production of adenosine. However the downregulation of CD73 
mRNA should be treated with caution as parallel changes in protein have not 
been determined. Furthermore the levels of adenosine have not been 
measured thus the ultimate end point of CD73 downregulation cannot be 
determined.
The importance of A2 receptors in osteoblastogenesis was also demonstrated 
as NECA and adenosine both increased expression of ALP and Cbfal mRNA. 
NECA, adenosine and CGS 21680 were also strong activators of ALP 
enzyme activity in MSCs that had been pre-differentiated to osteoblasts. 
These findings were clearly mediated by A2a and A2B receptors, as disruption 
of signalling through these receptors by co-incubation with specific 
antagonists significantly reduced NECA induced ALP mRNA expression. In 
contrast to ALP and Cbfal, collagen type I and osteocalcin were not 
significantly affected by treatment with adenosine or NECA during 
differentiation into osteoblasts.
Although Cbfal is a key transcription factor in the regulation of osteoblast 
differentiation, Cbfal independent pathways have also been demonstrated. 
Both in vivo and in vitro studies suggest that Wnt signalling through the LRP5 
receptor controls osteoblast differentiation and function by increasing ALP 
expression in a Cbfal independent manner (Kato et al., 2002; Rawadi et al.,
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2003). Thus it is possible that adenosine could activate multiple signalling 
pathways that are dependent or independent of Cbfal to regulate osteoblast 
differentiation. Further investigations are needed to establish the precise 
mechanisms involved in adenosine stimulated osteoblast differentiation.
The rapid induction of ALP enzyme activity by NECA is compatible with early 
upregulation of A2B receptor expression and function shown by increases in 
mRNA, protein and cAMP accumulation. The reversibility of NECA induced 
ALP activity by MRS 1706 confirms that osteo-inducing activity can be 
mediated mainly through activation of A2B receptors. The action of CGS 21680 
on ALP activity during osteoblastogenesis seemed to occur at later time 
points than NECA and is consistent with the later time frame for A2A receptor 
up regulation. One could perhaps speculate that A2B receptors are important 
for commitment to osteoblast differentiation and activation of the higher affinity 
A2a receptors maintains the differentiation process. Both receptors appear to 
be involved in osteoblastogenesis as NECA induced ALP activity is reduced 
by A2A and A2B receptor antagonists.
Preliminary experiments were also carried out to investigate if cAMP is a 
prime stimulator of osteoblastogenesis as cAMP is the primary signalling 
molecule for A2 receptors. Forskolin, an activator of adenylate cyclase, clearly 
induced ALP enzyme activity in MSCs and during osteoblast differentiation. 
Prolonged exposure to forskolin however inhibited ALP enzyme activity; the 
reason for this is unknown but may be related to downregulation of adenylate 
cyclase and upregulation of PDEs. It should be noted that adenosine
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receptors can also act through other signal transduction pathways, such as 
the MAPK pathway; both cAMP and ERK signalling have been reported to be 
involved in osteoblast differentiation and activity (Lai et al., 2001; San Miguel 
et al., 2005; Siddappa et al., 2008; Yang et al., 2008).
The data presented here shows that the A2A and A2b receptors are strongly 
implicated in osteoblastogenesis of MSCs; whether these receptors are also 
involved in calcium deposition was also investigated. Adenosine and NECA 
but perhaps surprisingly not CGS 21680 stimulated mineralisation. 
Adenosine/NECA induced mineralisation is unlikely to be due to changes in 
cell number because we were unable to observe any significant effects of 
these compounds on cell numbers or on protein content. The lack of A2a effect 
is surprising because it appears to be involved in the regulation of ALP activity 
during the later stages of differentiation.
In summary the data presented in this chapter show that the A2B receptor is 
the dominant subtype in MSCs and during their osteoblastogenesis. 
Osteoblast differentiation is associated with increases in the A ^  and A2B 
receptor expression and that these receptors stimulate osteoblastogenesis. 
The A2B receptor in particular is the major subtype in the differentiation 
process as it enhances the three stages of initiation, maturation and 
mineralisation in osteoblastogenesis of MSCs.
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Chapter 4
Adenosine receptor expression and 
function during the differentiation of 
MSCs to adipocytes
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4.1 Introduction
4.1.1 Adipose tissue
Adipose tissue was traditionally regarded as an inactive energy store and a 
source of insulation. In most mammals there are two forms, brown adipose 
tissue, which generates heat in newborns through mitochondrial uncoupling of 
lipid oxidation and white adipose tissue which form the majority of adipose 
tissue in adult humans and is responsible for storing energy, providing 
insulation and mechanical protection (Cinti, 2005). In addition, white adipose 
tissue is now known to secrete a variety of factors (e.g. leptin, adiponectin and 
IL-6 ) and express many receptors (e.g. leptin, adenosine Ai, PPARy) that 
suggests they have important autocrine, paracrine and endocrine actions 
(Ronti et al., 2006; Waki and Tontonoz, 2007). An excess of white adipocytes 
is found to be associated with a number of adverse metabolic consequences 
such as insulin resistance, hyperglycemia, dyslipidemia, hypertension and 
proinflammatory states (Eckel et al., 2005). In addition there is considerable 
evidence of links between increased adipocyte number in the bone marrow 
and decreased bone mineral density. Conditions associated with bone loss, 
including ageing, glucocorticoid treatment, increased cortisol production and 
osteoporosis also coincide with increased marrow adiposity. This may be due 
to preferential differentiation of MSCs into adipocytes at the expense of 
osteoblasts (see section 1.2.2). On the other hand factors secreted from 
adipocytes could affect the differentiation and function of stem cell precursors 
as well as other mature cell types such as osteoblasts and osteoclasts (Zhao 
et al., 2008). Therefore, understanding the cellular and molecular
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mechanisms behind the differentiation process and function of adipocytes 
could provide a basis for therapies aimed at improving bone formation.
4.1.2 The process of adipogenesis
The development of adipocytes from MSCs is a complex process, which 
involves changes in gene expression, hormone sensitivity and cell 
morphology. Adipogenesis is a multistage process (figure 4.1.1) and is 
regulated by transcription factors such as PPARy and C/EBPs. The first stage 
is determination, in which cells become committed to the adipocyte lineage 
and lose their ability to differentiate into other lineages. Committed cells 
undergo an initial period of growth arrest at the G0/G1 cell cycle boundary 
which is followed by mitotic clonal expansion in response to mitogenic and 
adipogenic signals and the formation of mature adipocytes (Gregoire et al., 
1998; Otto and Lane, 2005). These early events are accompanied by changes 
in gene expression and cell morphology which are initiated by transient 
expression of C/EBPp and C/EBP5 and followed by an accumulation of 
PPARy and C/EBPa. These latter two molecules remain high for the rest of 
the differentiation process and throughout the life of the mature adipocyte 
(Farmer, 2006; Gregoire et al., 1998; Lefterova and Lazar, 2009; Wu et al., 
1996). Several other genes are expressed during the early stages of 
adipocyte differentiation and these include preadipocyte factor-1 (Pref-1), 
sterol regulatory element binding protein-1 c (SREBP-1c) and LPL (Gregoire et 
al., 1998). Upregulation of LPL, in the early stages of differentiation, is thought 
to be associated with growth-arrest (Amri et al., 1986) whereas its expression 
in mature adipocytes is related to fatty acid and glycerol formation. In addition
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to these molecular events, remarkable changes also occur in cell morphology, 
cytoskeletal components and the amount and type of extracellular matrix 
(ECM). Reorganisation of ECM and cytoskeletal proteins causes cells to 
change their shape from fibroblast-like to a more spherical appearance 
(Gregoire et al., 1998). These changes are followed by terminal differentiation, 
in which preadipocytes become mature and gain all the machinery necessary 
for adipocyte function. Mature adipocytes accumulate, in addition to PPARy 
and C/EBPa (Gregoire et al., 1998), proteins that are involved in triglyceride 
metabolism, such as GPDH, LPL and fatty acid translocase (FAT). 
Morphologically, cells become spherical and accumulate small lipid droplets 
that subsequently fuse together to give a rounded appearance (figure 4.1.2 
shows the accumulation of fat droplets in mature adipocytes in vitro).
Adipocyte genes (e.g. GPDH) 
Secreted factors (e.g. leptin) 
Presence of lipid droplets
LPL *
• ----------------------------------------------------
Changes in ECM and cytoskeletal remodelling
Determination
,Pref1
Differentiation S U J J Il2 le «  Maturation
r
o
V  Y  >
O  - * ■  O  - ► °
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Extra-cellular signals PPARv and C/EBP a
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Figure 4.1.1 Postulated steps in adipocyte differentiation process.
Modified from Gregoire et al (1998) and Frith and Genever (2008).
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B
Figure 4.1.2 Mature adipocytes derived from rat MSCs. (A) in culture 
(phase contrast microscopy) and (B) stained with Oil Red O.
4.1.3 In  v itro  adipogenesis
Several cell culture models, including committed preadipocyte cell lines (3T3- 
L1 and Ob17), multipotent stem cell lines (C3H10T1/2) and primary cultures of 
MSCs, have been used to study the molecular and cellular events that occur 
during the process of adipocyte differentiation. Adipogenesis of such cells is 
induced by the addition of a cocktail of compounds that include insulin, Dex, 
IBMX and indomethacin. Insulin appears to increase the number of cells that 
differentiate into adipocytes as well as the amount of lipid accumulated; this 
effect of insulin, which only occurs at supraphysiological concentrations has 
been shown to be mediated through cross-activation of the IGF-1 receptor 
(Girard et al., 1994; Smith et al., 1988). Dex (a synthetic glucocorticoid 
agonist) has been shown to increase adipocyte differentiation, lipid 
accumulation and expression of C/EBPa and PPARy by activation of the 
glucocorticoid receptor (Wu et al., 1996). IBMX, a PDEs inhibitor, is known to 
induce adipogenesis by increasing the levels of cAMP (described in section 
1.3.6). Indomethacin, which has cyclooxygenase inhibitory activity, appears to
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stimulate the activation of adipose differentiation related protein (ADRP) and 
PPARy (Lehmann et al., 1997; Ye and Serrero, 1998). In other studies, 
PPARy agonists (such as troglitazone, pioglitazone, thiazolidinedione and 
rosiglitazone) have been added to the adipogenic cocktail (Abdallah et al., 
2006; Zhang et al., 2006). The above mentioned adipogenic inducing agents 
are most effective when used in combination and are unlikely to induce a 
significant effect on adipogenesis when used alone.
4.2 Aims
This chapter describes the expression and function of adenosine receptors 
during the differentiation of MSCs to adipocytes.
Specifically the aims are:
• To induce differentiation of MSCs toward the adipocyte lineage and 
subsequently investigate the changes in expression and function of 
adenosine receptors at various stages of differentiation.
• To investigate the role of adenosine signalling pathways in the 
regulation of differentiation of MSCs to adipocytes.
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4.3 Methods
4.3.1 Analysis of adenosine receptors expression and function
MSCs were seeded in multiwell plates at a density of 5.5 x 103 cells per cm2 
and cultured in normal growth medium until 50% confluent. This medium was 
then changed to adipogenic differentiation medium consisting of fresh growth 
medium supplemented with 10' 8 M Dex, 60 pM indomethacin and 10 pg/ml 
insulin. Adenosine receptor agonists and antagonists were sometimes 
included. Cultures were maintained in differentiation media for up to 12 days 
and fresh media were added every 2 - 3 days. mRNA and protein expression 
were assessed by q-RTPCR and Western blotting, and cAMP accumulation 
determined by radioimmunoassay as described in chapters 2 and 3.
4.3.2 Oil Red O analysis of lipid accumulation
For Oil Red O analysis, MSCs were plated into 12 well multidishes at a 
density of 5.5 x 103 cells per cm2 and cultured and treated as above. Lipids 
were visualised with Oil Red O and quantified spectrophotometrically 
(absorbance at 490nm) following dye extraction with 100% isopropanol as 
described in section 2.9.
4.3.3 Nile red analysis of adipogenesis
For Nile red analysis MSCs were seeded in 6  well multidishes at a density of 
5.5 x 103 cells per cm2 and cultured and treated as above. Labelled cells were 
identified by flow cytometry analysis as described in section 2.9.
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4.4 Results
4.4.1 Adenosine receptor expression during the differentiation of MSCs 
to adipocytes
4.4.1.1 Differentiation of MSCs to adipocytes
Adipogenic inducing mixes usually contain IBMX. IBMX is however a 
methylated xanthine derivative and is a non-selective adenosine receptor 
antagonist and could therefore potentially interfere with adenosine signalling 
pathways. Three adipogenic cocktail mixes were therefore tested in the 
presence or absence of IBMX for their ability to induce the differentiation of rat 
MSCs to adipocytes; these were 1: Dex (10"8 M), indomethacin (60 pM), 
insulin (10 pg/ml) and IBMX (10"4 M), 2: same as 1 but without IBMX and 3: 
biotin (33 pM), panthothenate (17 pM), tri-iodothyronine (1 nM), Dex (100 nM), 
thiazolidinedione (1 pM), (a P P A R y  agonist) and insulin (500 nM). MSCs were 
treated with normal culture medium and cocktail media, 1, 2 or 3 for 10 days; 
lipid content was assessed by Oil Red O staining of cultures.
As shown in figure 4.4.1, lipid accumulation was increased when all three 
adipogenic media were used, with media 1 and 3 possibly inducing slightly 
higher adipogenesis than media 2. However, media 2 was chosen for all of 
my MSC studies; as this does not contain IBMX which potentially could 
interfere with adenosine signalling.
In the presence of adipogenic differentiation, intracellular lipid droplets were 
microscopically detectable after about 4 days. The number of adipocytes and 
the size of the lipid vesicles increased progressively throughout the
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differentiation process as assessed by Oil Red O staining and by flow
cytometry of Nile red stained cells (figures 4.4.2 A&B). Differentiation to
adipocytes was further demonstrated by q-RTPCR analysis of the mRNAs for 
P P A R y, C /E B P a  and LPL. The mRNAs for these genes were all easily 
detectable in undifferentiated MSCs maintained under basal conditions, and 
on adipogenesis there was a progressive increase in their expression. As 
shown in (figure 4.4.2 C) P P A R y  was increased significantly by 3, 6  and 10 
fold; C E B /P a  by 4, 9 and 11 fold and LPL by 3, 23 and 29 fold after
respectively 2, 7 and 12 days of adipogenesis.
4.4.1.2 Adenosine receptor mRNA expression during adipogenesis
RNA was extracted from undifferentiated MSCs (day 0) and at different time 
points (1, 2, 5, 7, 9 and 12 days) after the initiation of adipogenesis. 
Expression of adenosine receptor mRNA was analysed using q-RTPCR, 
normalised to P-actin and compared with day 0 (undifferentiated MSCs) that 
was assigned a value of 1 .
The relative mRNA expression of the four adenosine receptors during 
adipogenesis is shown in (figure 4.4.3). Ai receptor mRNA expression was 
strongly up regulated during adipogenesis with an 800 fold increase at day 1 2  
(P < 0.001). Changes in A2A mRNA paralleled that of A1 receptor but only 
showed a 15 - 20 fold increase at 12 days (P < 0.001). There was no 
significant difference in expression of A2B and A3 receptor mRNA during the 
differentiation process. Both CD73 and ADA remained unchanged during 
adipogenesis (figure 4.4.3).
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Figure 4.4.1 Examination of Oil Red O stained MSCs under various 
adipogenic culture conditions. MSCs were cultured for 10 days in normal 
growth medium, adipogenic media 1 containing Dex (1 O'8 M), indomethacin 
(60 pM), insulin (10 pg/ml) and IBMX (10'4 M), adipogenic media 2 containing 
Dex (10"8 M), indomethacin (60 pM) and insulin (10 pg/ml), adipogenic media 
3 containing thiazolidinedione (1 pM), biotin (33 pM), panthothenate (17 pM), 
tri-iodothyronine (1 nM), Dex (100 nM) and insulin (500 nM) and stained for 
lipid with Oil Red O (x 100). (E) The retained dye was measured 
spectrometrically (490 nm) and compared with cells in normal growth medium 
(n=2; total of 6 replicates). Data are expressed as mean ± SDM.
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Figure 4.4.2 Adipogenic differentiation of MSCs. Cells were cultured with 
adipogenic medium. (A) Oil Red O labelling, measured at 490nm. (B) Flow 
cytometry analysis of Nile red stained cells after 7 days. (C) q-RTPCR of 
PPAR y, C /E B P a  and LP L  mRNA, normalised to p-actin mRNA and compared 
with day 0 that was assigned a value of 1 (n=3; total of 6 replicates). *P < 
0.05, **P < 0.01 and ***P < 0.001 when compared with undifferentiated 
MSCs.
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Figure 4.4.3 Changes in adenosine receptor and adenosine metabolic 
enzyme mRNA expression during the differentiation of MSCs to 
adipocytes. MSCs were cultured in adipogenic medium for the times shown 
and mRNA expression for (A) Ai, (B) A2a, (C) A2b and (D) A3 receptors 
determined. (E) and (F) show the expression of CD73 and ADA mRNA 
respectively (n=3; total of 6 replicates). *P < 0.05, **P < 0.01, and ***P < 
0.001 when compared with day 0.
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4.4.1.3 Adenosine receptor protein expression during adipogenesis
Western blot analyses were performed to investigate adenosine receptor 
protein expression during adipogenesis (up to 12 days) of MSCs. 
Representative Western blots for Ai, A2A and A2b receptors together with 
densitometric histograms for combined experiments are shown in figures 4.4.4 
- 6  respectively. For the densitometric histograms, band densities for each 
adenosine receptor were corrected for background and normalised to (3-actin 
and compared with day 0  (assigned a value of 1 ).
In parallel with changes in mRNA expression the proteins for the A1 and A2A 
receptors also increased on MSC differentiation to adipocytes as judged by 
individual Western blotting analyses and by densitometric profiles. There were 
no changes in A2b receptor protein expression during adipogenesis, 
consistent with a lack of change in its mRNA. The A3 receptor protein was not 
detectable.
4.4.1.4 Adenosine mediated cAMP responses during adipogenesis
Putative changes in adenosine receptor expression during adipogenesis of 
MSCs were also determined functionally by investigating cAMP responses to 
adenosine, NECA, CGS 21680 and CCPA. Figure 4.4.7 shows the changes in 
cAMP in MSCs and adipocytes, cultured respectively in normal growth 
medium and adipocyte differentiation medium for 9 days. At a concentration of 
10*4 M the fold increases in cAMP for MSCs and adipocytes were respectively
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Figure 4.4.4 A1 receptor protein expression during the differentiation of 
MSCs into adipocytes. MSCs were cultured in adipogenic medium. Protein 
lysates were separated by SDS-PAGE, probed for Ai receptor and then 
stripped and re-probed for (3-actin. Representative blots and combined 
densitometric values from at least 3 separate experiments are shown above 
*P < 0.05 and **P < 0.01, when compared with day 0 (assigned a value of 1).
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Figure 4.4.5 A2a receptor protein expression during the differentiation of 
MSCs into adipocytes. MSCs were cultured in adipogenic medium. Protein 
lysates were separated by SDS-PAGE, probed for A 2a  receptor and then 
stripped and re-probed for (B-actin. Representative blots and combined 
densitometric values from at least 3 separate experiments are shown above. 
*P < 0.05 when compared with day 0 (assigned a value of 1).
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Figure 4.4.6 A 2b receptor protein expression during the differentiation of 
MSCs into adipocytes. MSCs were cultured in adipogenic medium. Protein 
lysates were separated by SDS-PAGE, probed for A 2b receptor and then 
stripped and re-probed for (3-actin. Representative blots and combined 
densitometric values from at least 3 separate experiments are shown above.
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10 and 37 fold (adenosine (P < 0.001)), 25 and 55 fold (NECA (P < 0.001)) 
and 0 and 8 fold (CGS 21680 (P < 0.001)). These data indicate an overall 
increase in A2 receptor function in adipocyte differentiated MSCs compared 
with undifferentiated MSCs. This increase in cAMP responses indicates that 
the balance between A1 and A2 receptor expression is enhanced in favour of 
the latter and is consistent with increases in A2a mRNA and protein 
expression during MSC differentiation to adipocytes.
Although there was a large increase in A 1 mRNA during MSC differentiation to 
adipocytes this did not appear to be translated into protein where only a small 
increase was observed. The A1 receptor agonist, CCPA failed to have an 
inhibitory action on forskolin stimulated cAMP levels in either MSCs or 
adipocyte differentiated MSCs; this also suggests low expression of the A1 
receptor particularly in context of increased A2a receptor expression. At a 
concentration of 10-4 M, CCPA did have an apparent stimulatory effect on 
cAMP in both cell types; this was probably due to a lack of specificity and high 
concentrations of CCPA binding to A2 receptors.
4.4.2 Role of adenosine signal pathways on adipogenesis
4.4.2.1 Effects of adenosine and NECA on lipid accumulation
Changes in adenosine receptor expression as MSCs are induced to 
differentiate to adipocytes suggest that adenosine itself may have a role in the 
differentiation process. The effects of adenosine and NECA on lipid 
accumulation were thus investigated. As shown in Figure 4.4.8, treatment with 
NECA (10-6 M to 10'4 M) increases the number of cells that contain lipid when
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Figure 4.4.7 Effects of adenosine receptor agonists on intracellular 
cAMP production in adipocytes derived from MSCs. Cells were cultured 
for 9 days in adipogenic differentiation medium. At the end of incubation 
period cells were treated with the indicated concentrations of (A) adenosine, 
(B) NECA, (C) CGS 21680 and (D) CCPA for 15 minutes in the presence of 
RO 20-1724 (10'4M) and cAMP was measured using RIA (n=3; total of 12 
replicates). *P < 0.05, **P < 0.01, and ***P < 0.001 when compared with 
untreated cells; ###P< 0.001 when compared with MSCs stimulated with the 
same concentration of agonist.
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compared with vehicle control. The size and number of adipocytes also 
increased with time of exposure to the agonist and figures 4.4.9 and 10 
showed that the observed effects were dose dependent. The effect was 
statistically significant at all time points during the differentiation process and 
10"6 M was the lowest concentration that caused a significant (P < 0.01) 
response. At lO’4 M NECA there was over 50% increase (P < 0.001) in lipid 
accumulation when compared with cells incubated in media containing vehicle 
alone. Adenosine itself had less of an effect in comparison with NECA and 
probably reflects its short half-life. Treatment with 10'4 M adenosine 
significantly (P < 0.01) increased adipogenesis from day 7 with the maximum 
effect at day 12 (figure 4.4.10).
4.4.2.2 Effects of NECA on adipocyte cell number
Although Oil Red O staining analysis was used to demonstrate the induction 
of adipogenesis in NECA treated and untreated cells, this method only 
distinguishes the differences in total lipid content of the cells and could not 
identify the number of adipocytes in the population. Therefore, to achieve a 
quantitative measure of adipocyte number, Nile red staining with flow 
cytometry analysis was performed; this showed the number of adipocytes 
increased by up to 100% (P < 0.001) in the presence of 10-4 M NECA (figure 
4.4.11). In addition, mean Nile red fluorescence per unit cell was also 
upregulated suggesting that the adipocytes also contained, on average, more 
intracellular lipid. These results are consistent with the data obtained when Oil 
Red O was used.
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Figure 4.4.8 Light microscope examination of the effects of NECA on 
adipogenic differentiation of MSCs. MSCs were incubated with adipogenic 
differentiation medium in the presence of NECA (1 O' 4 M) or DMSO (vehicle) 
for 5, 7, 9 and 12 days. Accumulation of lipids in treated and untreated 
populations was visualised by staining with Oil Red O (x 200).
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Figure 4.4.9 Dose and time dependent effects of NECA on adipogenesis 
of MSCs as measured by Oil Red O staining. MSCs were incubated with 
adipogenic differentiation medium in the presence of NECA or DMSO for 5, 7, 
9 and 12 days. Lipid accumulation was (A) visualised by staining with Oil Red 
O (x 200) and (B) quantified by measuring the absorbance at 490 nm (n=3; 
total of 9 replicates). *P < 0.05, **P < 0.01, and ***P < 0.001 when compared 
with the control at the same time point.
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Figure 4.4.10 Dose and time dependent effects of adenosine on 
adipogenesis of MSCs as measured by Oil Red O staining. MSCs were 
incubated with adipogenic differentiation medium in the presence of 
adenosine or PBS for 5, 7, 9 and 12 days. Lipid accumulation was (A) 
visualised by staining with Oil Red O (x 200) and (B) quantified by measuring 
the absorbance at 490 nm (n=3; total of 9 replicates). **P < 0.01 and ***P < 
0 . 0 0 1  when compared with the control at the same time point.
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Figure 4.4.11 Dose and time dependent effects of NECA on MSC 
differentiated adipocyte cell number, as determined by Nile red staining.
MSCs were incubated with adipogenic differentiation medium in the presence 
of NECA (10-4 to 10’6 M) or DMSO for 5, 7 and 9 days. Cells were stained with 
Nile red and the % of positive cells was quantified with flow cytometry analysis 
(n=4; total of 8 replicates). *P < 0.05, **P < 0.01, and ***P < 0.001 when 
compared with control at the same time point.
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4.4.2.3 Effect of NECA on the expression of mRNA for adipocytic genes.
The previous results showed that adenosine and NECA, in the presence of 
adipogenic differentiation media, can further enhance adipogenesis as 
determined by lipid accumulation. Adipogenesis was also demonstrated by 
comparing the expression of adipogenic markers after NECA treatment. 
mRNA levels were normalised to p-actin and compared at different time 
points. Adipogenic differentiation caused a gradual increase in the expression 
of PPARy, C/EBPa and LPL mRNA, which was further enhanced by the 
addition of NECA (figures 4.4.12 -14). PPARy mRNA expression was induced 
significantly from 3, 7 and 10 fold in untreated MSCs to 6 (P < 0.05), 21 (P < 
0.001) and 31 (P < 0.01) fold in the presence of 10"4 M NECA for 2, 7 and 12 
days respectively. Treatment with 10'5 M NECA also tended to have a similar 
stimulatory effect, although statistical significant was not reached. NECA also 
induced similar, but more pronounced, changes in C/EBPa and LPL mRNA 
expression.
4.4.2.4 Effect of selective adenosine receptor agonists and antagonists 
on lipid accumulation
The mRNA, protein analysis and cAMP data suggests that the differentiation 
of MSCs to adipocytes is associated with changes in expression and 
activation of A2A and A1 receptors. The effects of CCPA and CGS 21680, in 
the presence of adipogenic differentiation medium, on Oil Red O staining 
were thus investigated. Both compounds stimulated adipogenesis in a time 
and dose related fashion (figures 4.4.15 and 16). There were also increases 
in adipogenesis in the presence of CCPA at 5, 7 and 9 days but only at the
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higher concentrations of 10'5 M and 10'6 M. Similar concentrations of CGS 
21680 had a much more pronounced effect on adipogenesis. The effects of 
CGS 21680 were comparable to that observed when NECA was used (figure 
4.4.9). These results indicate an involvement of Ai and A2A receptors in the 
adipogenic differentiation of MSCs.
To confirm the involvement of the A1 and A2A receptors as MSCs differentiate 
to adipocytes, the selective antagonists PSB 36 (A1) and SCH 442416 (A2a) 
were incubated together with NECA (figure 4.4.17). The concentrations of 
antagonist used were <10'6 M, as higher concentrations caused a reduction in 
cell number. Addition of PSB 36 or SCH 442416 alone at 10‘6 M and 10'7 M 
had no effect on lipid accumulation. PSB 36, however had no significant effect 
on the stimulation of adipogenesis by NECA suggesting that A1 receptors 
may not have an important role in adenosine mediated adipogenesis. On the 
other hand, SCH 442416 at 10'6 M and 10'7 M inhibited NECA stimulation of 
lipid accumulation by 80% (P < 0.001) and 75% (P < 0.01) respectively after 
12 days of treatment. This inhibitory action of SCH 442416 was however not 
seen at 7 days.
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Figure 4.4.12 Effect of NECA on PPARy mRNA expression during MSC 
differentiation to adipocytes. MSCs were treated with NECA (10*5 and 10'4 
M) for the indicated times during differentiation; PPARy mRNA, normalised for 
P-actin, was quantified by q-RTPCR (n=3; total of 6 replicates). *P < 0.05, **P 
< 0.01, and ***P < 0.001 when compared with day 0 (assigned a value of 1). 
#P < 0.05 and ###P < 0.001 when compared with vehicle at the same time 
point.
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Figure 4.4.13 Effect of NECA on C/EBPa mRNA expression during MSC 
differentiation to adipocytes. MSCs were treated with NECA (10'5 and 10"4 
M) for the indicated times during differentiation; C/EBPa mRNA, normalised 
for (3-actin, was quantified by q-RTPCR (n=3; total of 6 replicates). ***P < 
0.001 when compared with day 0 (assigned a value of 1). ##P < 0.01 and 
###P < 0.001 when compared with vehicle at the same time point.
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Figure 4.4.14 Effect of NECA on LPL mRNA expression during MSC 
differentiation to adipocytes. MSCs were treated with NECA (10‘5 and 10'4 
M) for the indicated times during differentiation; LPL mRNA, normalised for P- 
actin, was quantified by q-RTPCR (n=3; total of 6 replicates). *P < 0.05, **P < 
0.01, and ***P < 0.001 when compared with day 0 (assigned a value of 1). #P 
< 0.05 and ###P < 0.001 when compared with vehicle at the same time point.
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Figure 4.4.15 Dose and time dependent effects of CCPA on adipogenesis 
of MSCs. MSCs were incubated with adipogenic differentiation medium in the 
presence of CCPA or vehicle for 5, 7, 9 and 12 days. Lipid accumulation was 
(A) visualised by light microscopy of Oil Red O staining (x 200) and (B) 
quantified by measuring the absorbance at 490 nm (n=2; total of 6  replicates). 
Data are expressed as mean ± SDM.
183
Chapter 4 MSCs to adipocytes
Control CGS 21680 10-5 M
3.0
Control 
CGS 21680 10'7M 
CGS 2168010'6M 
CGS 2168010'5M
5 7 9 12
Days of adipogenic differentiation
Figure 4.4.16 Dose and time dependent effects of CGS 21680 on 
adipogenesis of MSCs. MSCs were incubated with adipogenic differentiation 
medium in the presence of CGS 21680 or vehicle for 5, 7, 9 and 12 days. 
Lipid accumulation was (A) visualised by light microscopy of Oil Red O 
staining (x 200) and (B) quantified by measuring the absorbance at 490 nm 
(n=2; total of 6 replicates). Data are expressed as mean ± SDM.
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4.5 Discussion
Induction of adipogenesis in vitro using Dex, indomethacin and insulin is well 
documented (Novakofski, 2004; Ookura et al., 2007; Pittenger et at., 1999; 
Yang et al., 2008). In my experiments, about 15% of the cells contained lipid 
droplets as determined by flow cytometry analysis of Nile red stained cells. 
Such cells also showed a change in morphology, from a fibroblast-like spindle 
shape for MSCs to a more spherical shape for adipocytes. The process of 
adipogenesis was supported by marked increases in expression of PPARy, 
C/EBPa and LPL.
Differentiation of preadipocytes to mature adipocytes has been previously 
shown to be associated with alterations in adenosine receptor expression. Ai 
receptor mRNA expression was reported to increase as the preadipocyte cell 
line Ob1771 underwent adipogenesis (Borglum et al., 1996). This was 
supported by decreased cAMP levels in differentiated Ob1771 preadipocytes 
and in mature adipocytes derived from mouse, rat and human in response to 
Ai receptor agonists (Borglum et al., 1996; Fatholahi et al., 2006; Johansson 
et al., 2008; Vassaux et al., 1993). These data are in agreement with the 
dramatic up regulation of Ai receptor mRNA expression seen in the 
experiments described here during the differentiation of MSCs into 
adipocytes. Changes in Ai receptor protein expression was however less 
marked possibly due to a low level of translation of mRNA into protein. In 
addition, as with undifferentiated MSCs, inhibition of forskolin induced cAMP 
levels using the selective Ai receptor agonist CCPA could not be 
demonstrated in MSC adipocytes. In fact, CCPA at 10'4 M resulted in an
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increase, rather than a decrease in cAMP accumulation, which could be due 
to activation of A2B receptors as previously described in chapter 3 and by 
other groups (Klotz et al., 1997; Lynge et al., 2003; Rees et al., 2002). These 
findings were perhaps not unexpected as only a small proportion (15%) of the 
cells could be designated as adipocytes after differentiation and A2 receptors 
are dominant in MSCs and preadipocytes as shown in chapter 3 and by 
Borglum et al (1996).
Furthermore the increase in Ai receptor expression during adipogenesis was 
unexpectedly accompanied by increases in A2A receptor expression at both 
the mRNA and protein level. It is likely that in these cultures A2 receptors are 
dominant (increase in cAMP accumulation) and thus Ai receptor inhibition of 
cAMP is masked by a greater stimulation of cAMP through activation of A2 
receptors. Dominance of A2 over Ai receptors has also been previously 
reported in anterior pituitary cells where the the inhibitory effect of CCPA on 
cAMP was also masked (Rees et al., 2002). An alternative explanation could 
be alterations in sub-cellular localisation of the receptors that result in 
diminished signal transduction of the expressed receptor proteins. For 
instance, Ai receptor is reported to be present at high density throughout the 
somatodendritic cytoplasm of the cortical neurons and caveolin membrane of 
rat ventricular myocytes. This may prevent the expressed receptor proteins 
from interacting with functional G-proteins or agonists (Lasley and Smart, 
2001; Ochiishi et al., 1999; Zeng et al., 2003).
The lack of an inhibitory effect on cAMP may not necessarily mean the lack of 
functional Ai receptors. Ai receptors could act via other signal transduction
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pathways including PKC, PI3K and MAPK as well as activation of K+ channels 
and inhibition of Q-, P- and N-type Ca2+ channels (Jacobson and Gao, 2006). 
In fact, cAMP independent action of Ai receptors has been demonstrated in 
isolated white adipocytes, where adenosine acting through the PLC-PKC 
pathway is able to regulate the insulin stimulated release of leptin (Cheng et 
al., 2000). Nevertheless the data in the experiments presented here shows 
that the increases in Ai and A2A receptor expression correlate in time with 
increases in lipid accumulation and expression of adipocyte marker genes. 
These finding suggest a potential role for both receptors in the adipocyte 
differentiation process or in the functional activities of adipocytes.
The increased expression of A2 receptors in my experiments is particularly 
surprising as Borglum and colleagues reported a loss of A2 receptor 
expression and function during adipogenesis of Ob1771 (Borglum et al., 
1996). Other researchers failed to detect A2 receptor expression in primary 
mature adipocytes (Vassaux et al., 1993). Increases in A2 receptor mRNA and 
protein expression on induced adipogenesis was supported by increases in 
cAMP stimulation in response to adenosine NECA and the A2A receptor 
agonist CGS 21680. CGS 21680 was ineffective on cAMP stimulation in 
MSCs. Although, adenosine and NECA induced cAMP accumulation was also 
increased in adipocyte differentiated MSCs, both of these compounds are 
universal agonists and thus can stimulate all adenosine receptors. However 
these changes in cAMP responses are likely due to activation of A2A receptors 
as there was no demonstrable change in A2B receptor expression. The 
potency of CGS 21680 to induce cAMP was almost equivalent to that of
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NECA, but NECA was more efficacious than CGS 21680. This 
pharmacological profile is in agreement with the functional expression of A2a 
receptors.
The increased expression of Ai and A2a receptors as MSCs were induced to 
differentiate to adipocytes suggest that activation of these receptors will also 
regulate adipogenesis. In this context, adenosine has been shown to regulate 
various adipocyte functions including lipolysis, lipogenesis, insulin activity, 
glucose transport and leptin secretion (Cheng et al., 2000; Dhalla et al., 
2007b; Johansson et al., 2008; Rice et al., 2000; Sollevi and Fredholm, 1981; 
Vannucci et al., 1989). The results presented herein clearly show that 
adenosine is also involved in the differentiation of MSCs to adipocytes. The 
degree and rate of adipogenic differentiation was increased in the presence of 
both adenosine and NECA, which elicited profound stimulatory effects on the 
accumulation of lipid and the number of adipocytes. NECA also stimulated the 
expression of mRNAs for P P A R y  and C /E B P a  throughout the duration of 
treatment, and L P L  expression at the later stages of the differentiation 
process. These findings are consistent with those of Borglum and co-workers, 
who reported that NECA enhanced corticosterone-induced adipogenic 
differentiation of a human preadipocyte cell line (Borglum et al., 1996).
The action of adenosine on adipocyte function has been mainly attributed to 
signalling via Ai receptors and negative regulation of cAMP production 
(Fatholahi et al., 2006; Johansson et al., 2008; Sollevi and Fredholm, 1981; 
Vannucci et al., 1989). Although Ai receptor coupling to an inhibition of
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forskolin induced cAMP was not demonstrated in my experiments the Ai 
receptor agonist CCPA did stimulate adipogenesis as shown by increased 
lipid accumulation. On the other hand the selective Ai receptor antagonist 
PSB 36 failed to have a significant effect on NECA induced adipogenesis. 
These results suggest that other adenosine receptors/mechanisms are also 
involved in adipogenesis. Increased expression of A2A receptors and a 
stimulation of Oil Red O staining by CGS 21680 clearly indicate an 
involvement of A2A receptor signalling in adipogenesis. Furthermore the 
adipogenic stimulatory effect of NECA was also inhibited by the A2A receptor 
antagonist SCH 442416. These results are in agreement with the hypothesis 
by Vassuex and colleagues who suggested a bimodal role for adenosine in 
adipose tissue; the A2 receptor is expressed in preadipocytes and involved in 
adipocyte cell differentiation whereas the Ai receptor is expressed in mature 
adipocytes and involved in cell function (Vassaux et al., 1993). The observed 
induced adipogenesis by CCPA could be attributed to increased lipogenic 
activity of adipocytes as well as a stimulation of differentiation.
The comparable potencies of CGS 21680 and NECA on adipogenesis 
suggest that cAMP may be an important signalling molecule for regulating 
adipogenesis. The cAMP pathway has been previously reported, in murine 
preadipocytes 3T3-L1 and in human MSCs, to stimulate adipogenesis and 
expression of adipocytic genes (Petersen et al., 2008; Reusch et al., 2000; 
Watanabe et al., 2003; Yang et al., 2008). In addition, activation of cAMP in 
preadipocytes has been associated with suppression of Wnt10b and Sp1, 
both of which are negative regulators of adipogenesis (Bennett et al., 2002;
190
Chapter 4 MSCs to adipocytes
Tang et al., 1999). Furthermore in vitro studies show that IBMX and forskolin, 
molecules that upregulate cAMP levels, are important for inducing 
adipogenesis (Farmer, 2006).
In the context of adipocyte differentiation, two mechanisms have been 
described for the action of cAMP. The most important and well documented is 
through activation of PKA, phosphorylation of CREB on serine 133 and 
subsequent activation of transcription factors. cAMP has also recently been 
reported to induce adipogenesis via activation of an Epac1/Rap1-dependent 
pathway, which induces ERK1/2-dependent phosphorylation and activation of 
CREB. The Epac1/Rap1-dependent pathway that also induces changes in 
cytoskeletal organisation and extracellular matrix has been implicated in IBMX 
induced adipogenesis (Petersen et al., 2008). It is not known whether NECA 
can activate the Epac1/Rap1-dependent pathway and my experiments appear 
to suggest that NECA has little effect on ERK1/2 activation in adipocytic 
differentiated MSCs.
In, summary, I have shown that adenosine receptor expression and function 
triggers a cascade of transcriptional events (C /E B P a , P P A R y  and LPL) that 
leads to the expression of factors associated with a mature adipocyte 
phenotype. The adenosine receptors involved in adipogenesis of MSCs are 
primarily the A2A and Ai receptors. The signal molecules involved in this 
process are likely to be cAMP/PKA/CREB. However other pathways such as 
MAPK, PLC, or PKC that are known to be activated by adenosine receptors 
might also be important. Experiments using additional specific receptor or
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pathway inhibitors or gene inhibition using siRNA are needed to confirm the 
current findings. These procedures have been used for analysing the effects 
of cAMP/PKA/CREB on adipogenesis (Pekkinen et al., 2008; Reusch et al., 
2000; Yang and Gerstenfeld, 1996).
Adenosine has also been shown to be involved in the release of hormones, 
growth factors and cytokines, such as leptin and IL-6, from MSCs and 
adipocytes and such molecules are known to be involved in differentiation and 
function (Cheng et al., 2000; Hamrick et al., 2005; Hasko et al., 2008; Rice et 
al., 2000). Adenosine induced adipogenesis could thus also be regulated 
through the secretion of autocrine and paracrine factors and this hypothesis 
needs to be explored.
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5.1 Introduction
5.1.1 Transdifferentiation
Transdifferentiation is a process whereby one type of differentiated cell is 
converted to another (Eguchi, 1995; Tosh and Slack, 2002). It belongs to a 
larger class of cell-type conversions known as metaplasias, which include 
transformation of stem cells of one lineage to another e.g. haematopoietic 
progenitor cells to astrocytes or to hepatocytes (Alison et al., 2000; Eglitis and 
Mezey, 1997; Slack, 2007; Tosh and Slack, 2002). Transdifferentiation is 
thought to occur as a result of changes in the expression of key transcription 
factors, either due to somatic mutation or by changes in the cellular 
environment (Thowfeequ et al., 2007). Whatever the underlying mechanism, it 
eventually results in a change in gene expression with a loss of some genes 
and a gain in other genes. Transdifferentiation may be accompanied by a 
dedifferentiation step, whereby a differentiated cell type is first reversed to an 
immature stem or progenitor cell stage (dedifferentiation) and then 
differentiated to another distinct cell type. In this case, cells lose their lineage 
specific genotypic and phenotypic properties before gaining others. However 
if transdifferentiation happens rapidly then the dedifferentiation stage may not 
occur and genotypic properties of both cell types may coexist (Liu and Rao, 
2003; Slack and Tosh, 2001). Transdifferentiation can only be considered to 
have taken place when a cellular phenotype with new characteristics is stably 
established (Slack and Tosh, 2001). Numerous examples of 
transdifferentiation exist within the literature including that of pancreatic cells 
to hepatocytes and myoblasts to adipocytes (Hu et al., 1995; Shen et al., 
2003).
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5.1.2 Transdifferentiation of osteoblasts to adipocytes and vice versa
In recent years several research groups have demonstrated possible 
phenotype switches between committed or differentiated osteoblast and 
adipocyte lineages in vitro. An early study by Nuttall and co-workers 
demonstrated that fully differentiated osteoblasts, as shown by ALP activity 
and osteocalcin synthesis, were able to undergo adipogenic differentiation 
after treatment with adipogenic inducing medium containing Dex and IBMX 
(Nuttall et al., 1998). Cells derived from collagenase-treated adult human 
trabecular bone fragments, when treated with Dex, indomethacin, IBMX and 
insulin transdifferentiated into adipocytes (Noth et al., 2002).
Overexpression of PPARy alone or in combination with C/EBPa in the mouse 
osteoblastic MC3T3-E1 cells in the presence of appropriate stimuli resulted in 
marked transdifferentiation to mature adipocytes expressing molecular 
markers of adipogenesis (Kim et al., 2005). In addition, osteoblasts were 
shown to undergo transdifferentiation towards an adipogenic phenotype after 
3 days of 18-a-glycyrrhetinic acid (AGRA) or oleamide-mediated inhibition of 
Gap-junctional communication (GJC) (Schiller et al., 2001). Moreover, single 
cell MSC derived clones were able to differentiate into osteoblasts and 
adipocytes and then transdifferentiate into other mesenchymal lineages by 
dedifferentiating back to the primitive stem cell stage, and subsequently 
differentiating into mesenchymal lineages (Song and Tuan, 2004; Song et al., 
2006). Adipocytes cloned from human bone marrow were shown to 
dedifferentiate into fibroblast-like cells, and subsequently to differentiate into 
osteoblasts and adipocytes under appropriate culture conditions (Park et al.,
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1999). Human subcutaneous extramedullary adipocytes were also shown to 
dedifferentiate prior to differentiation to either osteoblasts or adipocytes 
(Justesen et al., 2004). Evidence for dedifferentiation and/or 
transdifferentiation between osteoblasts and adipocytes has also been 
reported by other groups (Schilling et al., 2008; Schilling et al., 2007; Wang et 
al., 2007). Figure 5.1.1 shows possible mechanism of switching between 
osteoblasts and adipocytes.
Mesenchymal 
Stem cell
pre-adipocytepre-osteoblast
Transd iffe rentia tion
AdipocyteOsteoblast
Transd iffe rentia tion
Figure 5.1.1 Postulated mechanisms in mesenchymal lineage switching.
Although there is little information available, switching between osteoblasts 
and adipocytes might also occur in vivo and could partly account for bone loss 
seen in osteoporosis or osteopenia which are accompanied by increased
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adipocytes and a decreased osteoblasts in the bone marrow. Therefore, 
understanding the signalling molecules and the mechanisms behind the 
transdifferentiation process between osteoblasts and adipocytes could be 
important for the development of therapeutic strategies for the retention of 
osteoblasts or to prevent their transdifferentiation to adipocytes.
5.2 Aims
This chapter describes the expression and function of adenosine receptors in 
a murine osteoblast cell line (7F2) and in primary human osteoblasts (HOBS) 
and as they are induced to transdifferentiate to adipocytes.
Specifically the aims are:
• To investigate the expression and function of adenosine receptors in 
7F2 and HOB cells.
• To induce differentiation of 7F2 and HOB cells towards an adipocyte 
lineage and to investigate related changes in the expression and 
function of adenosine receptors.
• To investigate the role of exogenous adenosine in the regulation of 
adipocyte differentiation of 7F2 and HOB cells.
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5.3 Methods
5.3.1 Analysis of expression and function of adenosine receptors in 7F2 
cells and as they transdifferentiate into adipocytes
7F2 cells were seeded in to multiwell plates, as appropriate, at a density of 4 x 
103 cells per cm2 in normal growth medium for 24 hours. Transdifferentiation 
into adipocytes was induced by addition of 50 pg/ml AA, 10‘7 M Dex and 50 
pM indomethacin. The cells were either left untreated in differentiation 
medium or were treated with vehicle or the indicated concentrations of 
adenosine receptor agonist and antagonists for the indicated times with the 
medium being changed every 2 - 3 days. Changes in adenosine receptor, 
adipocyte and osteoblast marker mRNA and protein expression were 
assessed by q-RTPCR and Western blotting, as appropriate and cAMP 
accumulation determined by RIA as described in chapters 2 and 3. 
Adipogenesis in treated and untreated adipocyte populations was visualised 
by staining with Oil Red O and accumulation of lipids was quantified 
spectrophotometrically following extraction of the dye retained by the cells. 
The number of adipocytes in the sample was also determined by flow 
cytometry analysis of Nile red stained cells as described in chapter 2.
In some experiments ALP activity was assessed in 96 well plates following 
treatment with adenosine receptor agonists and antagonists or vehicle for 2 
and 5 days. The results were corrected for changes in cell number, 
determined on the same plate by the MTS assay and expressed as 
percentage of control.
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5.3.2 Analysis of expression and function of adenosine receptors in HOB 
cells and as they transdifferentiate into adipocytes
HOB cells were seeded in to multiwell plates at a density of 1.05 x 104 cells 
per cm2 and cultured in normal growth medium supplemented with 50 pg/ml 
AA for 24 hours. Transdifferentiation of HOB cells into adipocytes was 
induced using adipogenic differentiation medium consisting of the normal 
growth medium supplemented with 10'8 M Dex, 60 pM indomethacin and 10 
pg/ml insulin. The cells were either left untreated in differentiation medium or 
were treated with vehicle or NECA at 10'5 and 10'4 M for 2, 7, 12 and 17 days 
with the medium being changed every 2 - 3 days. Adipogenesis was 
visualised by staining with Oil Red O. Changes in adenosine receptor, 
adipocyte and osteoblast marker mRNA and protein expression, as 
appropriate, was assessed by q-RTPCR and Western blotting as described in 
chapter 2. ALP activity was also assessed as above.
In some experiments the effect of adenosine receptor agonists on 
mineralisation of 7F2 and HOB cells was also carried out. Mineralisation of 
7F2 cells was induced by addition of 50 pg/ml AA, 10'7 M Dex and 6 mM (3-GP 
for 10 - 12 days and HOBs by addition of 2 mM (3-GP for 20 days. 
Mineralisation was assessed by Alizarin Red S staining.
5.3.2 Analysis of ERK and CREB phosphorylation
Cells were cultured in either normal growth medium until 80% confluent or in 
differentiation medium for the indicated times in 6 well multidishes. After 17 
hours serum starvation, cells were exposed to adenosine receptor agonists in
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the presence or absence of adenosine receptor antagonists. Antagonists were 
given 30 minutes prior to stimulation. Time course responses to 0 - 60 
minutes exposure to NECA 10"6 M and dose response (NECA at 10'8 M to 10'5 
M) experiments were performed. Cell lysates were prepared and equal 
amounts of protein were separated on 10% SDS-PAGE; total and 
phosphorylated ERK1/2 and CREB were detected by probing with specific 
antibodies. Blots were then stripped and re-probed with unphosphorylated 
ERK1/2 or CREB antibodies. The ratio of phospho protein (ERK or CREB) to 
total protein (ERK or CREB) was calculated from densitometry of Western 
blots and compared to the unstimulated control. The detailed methodology for 
protein extraction and Western blotting is described in chapter 2.
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5.4 Results
5.4.1 Adenosine receptor expression and function in 7F2 and HOB cells
5.4.1.1 mRNA and protein expression
The expression of adenosine receptors was investigated in the 7F2 cell line 
and in primary HOB cells. PCR amplification of mRNA to adenosine receptors 
and adenosine metabolic enzymes gave rise to sharp bands of the 
appropriate size in mouse (Ai: 160bp, A^: 228bp, A2B: 158bp, A3: 151 bp, 
CD73: 220bp, ADA: 165bp, AK: 225bp, ARP: 72bp) and human (Ai: 186bp, 
A2a: 156bp, A2b: 152bp, A3: 360bp, APRT: 247bp) osteoblasts when 
visualised on an agarose gel stained with ethidium bromide (figure 5.4.1).
The presence of adenosine receptors was also checked at the protein level 
using Western blotting analysis. For 7F2 cells, antibodies against adenosine 
Ai, A2A and A2B receptors recognised bands with the expected molecular 
weights of around 38, 46 and 36 kDa respectively (figure 5.4.1 B). With the 
A ^  antibody, bands of apparent molecular masses, 58 and >100 kDa were 
also seen, the identity of which are unknown but are likely to be non-specific. 
There was no detectable band for the A3 receptor although the gene was 
detectable by PCR. For HOB cells, Western blotting showed a strong band for 
the Ai receptor and the A2b receptor antibody recognised a faint band of the 
expected size (36 KDa) but two strong bands of a much higher molecular 
weight (figure 5.4.1 D). The A2A antibody also picked up bands of unexpected 
sizes (25, 58 and 70 kDa) in HOB cells, the 46 kDa band, as found in 7F2 
cells was however not detectable. The presence of adenosine receptors in 
7F2 cells were further investigated using cAMP measurements.
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Figure 5.4.1 Expression of adenosine receptors and enzymes on 7F2 and 
HOB cells. RT-PCR analysis of 7F2 (A) and HOB cells (C) for A1t A2a, A2B, A3 
receptors and for (A) the enzymes CD73, ADA and AK. PCR products were 
separated on a 2% agarose gel and detected by ethidium bromide staining. 
Figures on the left show sizes (bp) of DNA ladder. (B and D) Western blot 
analysis of adenosine receptor protein expression in 7F2 (B) and in HOB cells 
(D). Equal amount of protein lysates were separated on 10% SDS-PAGE and 
the expression of adenosine receptors were detected by probing with specific 
primary polyclonal antibodies. Figures on the left show the sizes (kDa) of 
protein markers.
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5.4.1.2 Effect of adenosine on cAMP accumulation in 7F2 cells
The functional dominance of the A2B receptor during osteoblastogenesis of 
MSCs suggests that this receptor might also be dominant in 7F2 osteoblastic 
cells; the action of adenosine receptor agonists on cAMP activation was thus 
investigated. Adenosine and NECA produced a dose dependent accumulation 
of cAMP, suggesting the dominance of A2 receptors. At 10'4 M adenosine and 
NECA the cAMP levels were respectively 4 and 16 fold of basal (P < 0.001). 
In contrast, CGS 21680 did not produce a dose dependent response and only 
increased cAMP levels by 1 - 2 fold at 1CT4 M (figure 5.4.2 A).
These findings indicate a rank order of potency, NECA > adenosine > CGS 
21680, which is consistent with the presence of functional A2b receptors 
(Feoktistov and Biaggioni, 1998). Although an overall stimulation of cAMP, 
rather than an inhibition, by NECA and adenosine indicates the predominance 
of A2 receptors on 7F2 cells, co-expression of functional A1 receptors is also 
possible particularly as the mRNA and protein were detectable. CCPA (10'8 M 
to 10-4 M) however failed to inhibit forskolin induced cAMP accumulation, 
suggesting a lack of significant A1 receptor coupling to adenylate cyclase and 
the cAMP pathway (figure 5.4.2 B).
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Figure 5.4.2 Effect of adenosine receptor agonists on intracellular cAMP 
production in 7F2 cells. (A) Cells were incubated with the indicated 
concentrations of adenosine, NECA and CGS 21680 for 15 minutes in the 
presence of RO 20-1724 (10'4M) and cAMP was measured by an in-house 
RIA (n=3; total of 12 replicates). *P < 0.05, **P < 0.01, and ***P < 0.001 when 
compared with zero (basal values). (B) To assess the presence of A-i 
receptors, cells were pre-incubated for 15 minutes with CCPA (10'8 M to 10'4 
M) in the presence of 10 pM RO 20-1724 at 37°C. The cells were then 
incubated in the same medium for a further 5 minutes with forskolin (0.5 x 10'5 
M) (to stimulate cAMP production) and cAMP was measured (n=2; total of 8 
replicates). Data are expressed as mean ± SDM.
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5.4.1.3 Effect of NECA on ERK activation in 7F2 cells and 7F2 
differentiated adipocytes
Adenosine receptors have been shown to induce ERK activation in a wide 
range of tissues and culture cells (Schulte and Fredholm, 2003b). However, 
no information is available regarding the regulation of ERK signalling by 
adenosine receptors in osteoblasts. Therefore, to determine if adenosine 
receptors couple to ERK signalling in osteoblasts, serum starved 7F2 cells 
were incubated for 5 to 60 minutes with NECA at 10‘6 M and ERK activation 
was determined by Western blotting analysis using phospho specific ERK 
antibodies recognising the phosphorylated (Thr202/Tyr204) forms of p42/p44 
MAPK. Phorbol 12-myristate 13-acetate (PMA) at 10'6 M was used as positive 
control. As shown in figure 5.4.3 A, NECA and PMA induced phosphorylation 
of ERK; the effect of NECA was transient, peaking at 5 minutes and returning 
to near basal levels by 60 minutes. Total non-phosphorylated forms of 
p42/p44 remain unchanged. Comparing band intensities and after normalising 
for total ERK there was a 4 fold increase in phosphorylation at 5 minutes. 
NECA had little or no effect on ERK phosphorylation in 7F2 differentiated 
adipocytes (figure 5.4.3 B).
The dose response effect of NECA on ERK phosphorylation is shown in figure
5.4.4 A. At 10'7, 10'6 and 10'5 M the increases in ERK phosphorylation were 2, 
4 and 7 fold when compared with 10'8 M NECA. The loss of NECA stimulated 
ERK phosphorylation in 7F2 adipocytes occurred within 10 hours of inducing 
differentiation (figure 5.4.4 B).
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Figure 5.4.3 Time course of NECA-stimulated ERK1/2 activation in 7F2 
cells and after their differentiation into adipocytes. Serum starved (16 
hours) 7F2 osteoblasts (A) or adipocytes (B) were treated with NECA (10'6 M) 
for 0, 5, 10, 15, 30 and 60 minutes. Cells were lysed in RIPA buffer and 
analysed for phospho-ERK1/2 by Western blotting. Data were normalised to 
total ERK and compared with unstimulated controls. Representative blots and 
densitometric values from at least three separate experiments are shown 
above. *P < 0.05 and ***P < 0.001 when compared with zero (basal values).
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Figure 5.4.4 Dose response of NECA-stimulated ERK1/2 activation in 7F2 
cells and after their differentiation into adipocytes. (A) Dose dependent 
ERK1/2 activation in response to NECA. Serum starved (16 hours) 7F2 
osteoblasts or adipocytes were treated for 5 minutes with various 
concentrations of NECA (10' 5 to 10' 8 M) and the ERK1/2 phosphorylation was 
analysed by Western blotting. (B) ERK1/2 activation in response to NECA 
during adipogenesis. 7F2 cells were differentiated to adipocytes for the 
indicated times, serum starved and treated for 5 minutes with NECA (10' 6 M) 
(NS = not stimulated). Blots were stripped and re-probed for 
unphosphorylated ERK1/2. Representative blots from at least two separate 
experiments are shown above.
Hours of adipogenic differentiation
NS 10 20 0 0 40 60 110 160
m m * mm m ,w&mm
IM M IM IIII' mm*m*
7F2________ Adipocytes
10'8 10'7 10‘6 10-5 10-8 10'7 10-6 10-5
-
Chapter 5 Osteoblasts to adipocytes
5.4.1.4 Effect of adenosine receptor agonists and antagonists on ERK 
activation
Previous data suggests that A2b receptors are predominant in 7F2 cells. To 
determine if the A2b receptor was also responsible for stimulation of ERK 
phosphorylation, various adenosine receptor agonists and antagonists were 
also used. As shown in figure 5.4.5, adenosine and NECA induced 
phosphorylation of ERK, whereas CCPA and CGS 21680 were ineffective and 
IB-MECA was only weakly effective. These findings and complete antagonism 
by MRS 1706 but only weakly by PSB 36 and SCH 442416 (figure 5.4.5) 
indicate that the A2B receptor is primarily the mediator of ERK phosphorylation.
5.4.1.5 Transduction signals upstream of NECA stimulated ERK 
activation
Adenosine receptor activation of ERK is shown to be coupled to major 
signalling pathways such as PKC, PKA and PI3K in a number of cell types 
(Schulte and Fredholm, 2003b); various pathway inhibitors were used to 
investigate which occurred in 7F2 cells. Serum starved 7F2 cells were pre­
treated with inhibitors for 30 minutes prior to stimulation with NECA for 5 
minutes and ERK activation analysed. As shown in figure 5.4.6, NECA 
induced ERK activation was completely abolished by pre-treatment with PD 
98059, an inhibitor of MAPK/ERK kinase (MEK) 1 and 2. MEKs are part of the 
MAPK cascade that leads from the Raf kinases and directly causes 
phosphorylation of ERK1/2 on Thr and Tyr residues (Alessi et al., 1995). 
Upstream regulators of MEK1/2 were also investigated. Pre-treatment with 
Wortmannin, a specific inhibitor of PI3K or the PKC inhibitor, RO-32-0432,
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had little effect on NECA stimulated ERK phosphorylation. As shown in figure 
5.4.6, 20 pM RO-32-0432 did however cause a dramatic reduction in PMA 
(PKC activator) induced ERK phosphorylation. These data suggest that PKC 
is not involved in NECA induced ERK activation. In contrast, pre-treatment 
with the specific PLC inhibitor, U-73122, completely abolished the NECA 
induced effects on ERK phosphorylation whereas it had no effect on the 
activity of PMA. To investigate if cAMP levels were responsible for ERK 
phosphorylation, an inhibitor of adenylate cyclase (DDA) was used. Pre­
treatment with 50 pM DDA partially blocked NECA stimulated ERK activation. 
These results suggest that cAMP accumulation is only partly responsible for 
NECA stimulated ERK activation.
5.4.1.6 Effect of NECA on CREB activation in 7F2 cells
The effect of signalling pathways involving cAMP and MAPK on CREB 
activation have been studied intensively. Since A2B receptors are positively 
coupled to both cAMP and ERK signalling, experiments were set out to 
determine if A2B receptors were also involved in CREB phosphorylation. 
Serum starved 7F2 cells were incubated for 5 to 60 minutes with NECA (10'6 
M) and CREB phosphorylation was analysed using a CREB phospho specific 
antibody. Forskolin was used as a positive control. As shown in figure 5.4.7 A 
NECA induced CREB phosphorylation in a time dependent manner; the effect 
was evident after 5 minutes, peaked at 10 minutes (with a 2 - 3 fold increase) 
and a return to basal levels by 30 minutes. As expected NECA failed to 
induce CREB phosphorylation in 7F2 differentiated adipocytes (figure 5.4.7 B)
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Figure 5.4.5 Effect of adenosine receptor agonists and antagonists on 
ERK1/2 phosphorylation in 7F2 cells. Serum-starved 7F2 cells were 
stimulated for 5 minutes with 10' 4 M adenosine or 10' 6 M NECA, CCPA, CGS 
21680 and IB-MECA and in some experiments were pre-treated with selective 
adenosine receptor antagonists 10' 6 M PSB 36, SCH 442416 or MRS 1706 for 
30 minutes prior to stimulation for 5 minutes with 10' 6 M NECA. ERK 
phosphorylation was then assessed by Western blotting. Blots were stripped 
and re-probed for unphosphorylated ERK1/2. Representative blots from at 
least two separate experiments are shown.
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Figure 5.4.6 Involvement of signal pathways upstream of ERK1/2 
phosphorylation in 7F2 cells. Serum-starved 7F2 cells were pre-treated at 
37°C for 30 minutes with 20 pM RO-32-0432, 4 pM U-73122, 10 pM PD 
98059, 0.2 pM Wortmannin or 50 pM 2',5'-dideoxyadenosine (DDA) and 
compared with NS. Subsequently, the cells were stimulated with NECA (10' 6 
M) for 5 minutes, forskolin (10"5 M) or PMA (10' 6 M) for 10 minutes and 
ERK1/2 phosphorylation measured. Representative blots and densitometric 
values from at least two separate experiments are shown above.
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again suggesting a loss of A2 receptors whereas CREB phosphorylation to 
forskolin was retained in both types of cells (figure 5.4.7 A&B).
5.4.1.7 Mechanisms of CREB activation by A2b receptor
To investigate the mechanisms of CREB phosphorylation via the A2b receptor, 
serum starved 7F2 cells were pre-treated with inhibitors of upstream 
components of signal pathways that may be involved in the phosphorylation of 
CREB. As shown in figure 5.4.8, NECA induced CREB activation was partly 
reversed by pre-treatment with DDA, suggesting that cAMP accumulation was 
involved. Pre-treatment with PD 98059 resulted in complete loss of NECA 
induced CREB phosphorylation, suggesting that ERK activation was an 
intermediate. Similar results were obtained with U-73122. This was expected 
as PLC was found to be responsible for ERK phosphorylation in 7F2 cells. 
Since ERK was responsible for CREB phosphorylation, loss of ERK activation 
by U-73122 subsequently led to loss of CREB activation.
Surprisingly, pre-treatment with RO-32-0432 also completely abolished the 
NECA-induced CREB activity, suggesting that PKC may be an intermediate 
step downstream of ERK and upstream of CREB signalling. Pre-treatment 
with Wortmannin had no effect on NECA stimulated CREB phosphorylation, 
suggesting that PI3K was not involved in CREB activation by NECA. Table
5.4.1 shows a summary illustrating the sites of action and the effects of the 
different inhibitors on NECA induced ERK activation.
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Figure 5.4.7 Time course of NECA stimulated CREB activation in 7F2 
cells and after their differentiation into adipocytes. Serum starved (16 
hours) 7F2 osteoblasts (A) or adipocytes (B) were treated with NECA (10' 6 M) 
for 0, 5, 10, 15, 30 and 60 minutes. Cells were lysed in RIPA buffer and 
analysed for phospho-CREB by Western blotting. Data were normalised to 
total CREB and compared with the unstimulated controls. Representative 
blots and densitometric values from at least three separate experiments are 
shown above. **P < 0.01 and ***P < 0.001 when compared with zero (basal 
values).
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Figure 5.4.8 Involvement of signal pathways downstream of adenosine 
receptors on CREB phosphorylation in 7F2 cells. Serum-starved 7F2 cells 
were pre-treated at 37°C for 30 minutes with 20 pM RO-32-0432, 4 pM LI- 
73122, 10 pM PD 98059, 0.2 pM Wortmannin or 50 pM DDA. Subsequently, 
the cells were stimulated with NECA (10"6 M) for 5 minutes and CREB 
phosphorylation was determined by Western analysis. Representative blots 
and densitometric values from at least two separate experiments are shown 
above.
Inhibitors Site of action ERK CREB
RO-32-0432 PKC - 1
U-73122 PLC 11 11
PD 98059 MEK1/2 11 11
Wortmannin PI3K - -
DDA Adenylate cyclase 1 1
Table 5.4.1 Summary illustrating the sites of action and the effects of the 
different inhibitors on NECA induced ERK or CREB activation.
| |  = High inhibition of ERK or CREB; |  = Low inhibition of ERK or CREB.
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5.4.2 Role of adenosine receptors on 7F2 cell proliferation and 
maturation
5.4.2.1 Effects of adenosine receptors agonists on cell number and ALP 
activity in 7F2 cells.
Expression of adenosine receptors on 7F2 cells suggested that adenosine 
might play a physiological role in these cells. Dose response and time course 
experiments using the adenosine receptor agonists (NECA, CCPA and CGS 
21680) were investigated in 5% FCS containing medium. As shown in figures 
5.4.9 and 10, treatment with adenosine receptor agonists for 2 and 5 days 
had no effects on cell number or ALP activity.
5.4.2.2 Effects of adenosine receptors agonists on mineralisation of 7F2 
cells.
7F2 cells are considered as differentiated osteoblasts as they express 
osteoblast markers and have the capacity to mineralise. Optimal p-GP 
concentration for mineralisation were determined by comparing the effects of 
2 to 8 mM p-GP on mineral deposition. As shown in figure 5.4.11 A, culturing 
with 2 - 4  mM p-GP resulted in minor mineral matrix deposition, whereas 8 
mM p-GP induced widespread deposition. Sub-maximal (6 mM) p-GP was 
used in all subsequent experiments. Treatment with adenosine receptor 
agonists for 10 days, however did not modify the mineral matrix deposition 
figure 5.4.11 B&C.
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Figure 5.4.9 Effects of adenosine receptor agonists on 7F2 cell number.
7F2 cell numbers following 2 and 5 days of treatment with the indicated 
concentrations of adenosine, NECA, CCPA and CGS 21680 in 5% FCS 
containing medium (n=2; total of 24 replicates).
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Figure 5.4.10 Effects of adenosine receptor agonists on ALP activity in 
7F2 cells. 7F2 cells treated with the indicated concentrations of adenosine, 
NECA, CCPA and CGS 21680. ALP activity was measured after 2 and 5 days 
(n=2; total of 24 replicates).
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Figure 5.4.11 Effect of adenosine receptor agonists on mineralisation of 
7F2 osteoblasts. (A) 7F2 cells were incubated with mineralisation medium 
containing varying concentration of p-GP for 10 days and calcified 
extracellular matrix was visualised by Alizarin Red S staining. (B and C) Effect 
of adenosine receptor agonists at 10' 5 M after 12 days of treatment on 
mineralisation. (C) Mineralisation was quantified by extracting the dye and 
measured at 490 nm (n=3; total of 12 replicates).
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5.4.3 Transdifferentiation of 7F2 osteoblast cells to adipocytes
5.4.3.1 Evaluation of adipogenesis
7F2 cells were induced to transdifferentiate into adipocytes using a cocktail of 
culture media additives (Dex, indomethacin, and AA) as described previously 
(Thompson et al., 1998). Under these conditions, adipocytic cells containing 
intracellular lipid droplets were detectable microscopically after 3 days and the 
number of adipocytes and the size of their lipid vesicles increased 
progressively up to day 7 post differentiation. Figures 5.4.12 A shows Oil Red 
O staining of 7F2 cells and after 7 days of adipocyte differentiation. Beyond 7 
days some adipocytes became detached and floating cells with large 
intracellular lipid vacuoles were visible. Flow cytometry analysis demonstrated 
that up to 50% of the cells stained positive for Nile red and following 7 days of 
adipocyte transdifferentiation Figures 5.4.12 B.
Expression of adipocyte (PPARy, C/EBPp, LPL and GPDH) and osteoblast 
(osteocalcin) lineage markers were also assessed in 7F2 adipocyte 
differentiated cultures. Consistent with the increased adipocyte morphology 
after differentiation all adipocyte markers, as determined by q-RTPCR, 
showed an increase up to 7 days before falling back but still remained above 
that of undifferentiated 7F2 cells after 9 and 12 days (figure 5.4.17). Adipocyte 
differentiated 7F2 cells also showed marked reduction in osteocalcin 
expression within 1 day of adipocyte differentiation (figure 5.4.19).
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Figure 5.4.12 Transdifferentiation of 7F2 cells into adipocytes. 7F2 cells 
and adipocytes (7 days of differentiation) were stained with Oil Red O (A) and 
subjected to flow cytometery analysis following Nile red staining (B). Flow 
cytometery data analysis is presented using the FL2 (fluorescent emission) 
versus FSC (size of the cells) plot. The plot was divided into quadrants using 
the undifferentiated cells (lower quadrants) as the base line of fluorescent 
emission. The lower quadrants (red dots) therefore display events that are 
negative for Nile red fluorescent emission and represent undifferentiated cells. 
The upper quadrants (green dots) on the other hand contain events that are 
positive for Nile red fluorescent emission and therefore represent the 
adipocyte population.
219
Adipocytes
Chapter 5 Osteoblasts to adipocytes
5.4.3.2 Adenosine receptor expression during transdifferentiation of 7F2 
cells into adipocytes
Previous investigations examining the expression and function of adenosine 
receptors during differentiation of MSCs into adipocytes demonstrated 
upregulation and involvement of Ai and A2A receptors. q-RTPCR was used to 
determine whether these changes also occurred during transdifferentiation of 
7F2 cells into adipocytes, mRNA expression in individual samples post 
differentiation, was normalised to a housekeeping gene (ARP) and compared 
to that in undifferentiated 7F2 cells. As shown in figure 5.4.13 A, the A1 
receptor was dramatically increased during differentiation and its pattern of 
expression mirrored exactly the adipogenic marker genes (figure 5.4.17). A1 
receptor mRNA expression peaked at day 7 with >1500 (P < 0.001) fold 
increase above that in undifferentiated 7F2 cells.
In contrast to that seen during adipocyte differentiation of MSC, expression of 
the A2A receptor was diminished significantly by about 75% (P < 0.001) as 
early as 24 hours after adipogenic induction and stayed at more or less the 
same level throughout the differentiation process (figure 5.4.13 B). A similar 
inhibition of expression of up to 80% (P < 0.001) was also seen with the A2B 
receptor and the A3 receptor only showed inhibition 12 days after 
differentiation (figure 5.4.13 C&D).
The expression of CD73 and ADA during adipocyte differentiation was also 
investigated, these enzymes are particularly important for regulating 
extracellular levels of adenosine. Changes in CD73 expression followed that
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Figure 5.4.13 Adenosine receptor and adenosine metabolic enzyme 
mRNA expression during the transdifferentiation of 7F2 into adipocytes.
Cells were cultured in adipogenic medium for the indicated times and q- 
RTPCR used to determine gene expression. Expression of A<\ (A), A2a (B), A2b 
(C) and A3 (D) receptors and (E) CD73 and (F) ADA were normalised to ARP 
and compared with undifferentiated cells (day 0 ); the day 0  was assigned a 
value of 1 (n=3; total of 6  replicates). **P < 0.01 and ***P < 0.001 when 
compared with day 0 .
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of the adipocyte marker genes and the Ai receptor with an increase of up to 6  
fold (P < 0.001) at day 4 of differentiation (figure 5.4.13 E). ADA, on the other 
hand, showed a marked reduction of more than 80% at a similar time point 
(day 4) (P < 0.001) (figure 5.4.13 F). These data suggest that there is a net 
accumulation of adenosine in the extracellular space during adipocyte 
differentiation of 7F2 cells.
Changes in adenosine receptors during differentiation were also assessed at 
the protein level. Representative Western blots figure 5.4.14 A showed that 
the Ai receptor increased while A2A receptor expression decreased during 
differentiation. The relative level of protein change for the Ai receptor was 
much smaller when compared with the observed changes in mRNA. Western 
blotting for the A 2b receptor showed two bands, the smaller size band is of a 
much higher intensity. On differentiation the expression of this band 
decreased with concomitant increase in expression of the higher molecular 
weight band. This higher molecular weight band may represent a 
phosphorylated form of the A 2b receptor and thus its phosphorylation status 
was investigated. Labelling with Pro-Q or detection using a phospho-threonine 
antibody showed bands which co-eluted with the higher molecular weight 
band. These bands were not detectable in the 7F2 undifferentiated cells but 
only after adipocyte differentiation (figure 5.4.14 B). The A3 receptor protein 
was not detectable in 7F2 cells or after adipocyte differentiation.
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Figure 5.4.14 Adenosine receptor protein expression during the 
transdifferentiation of 7F2 cells into adipocytes. 7F2 cells were cultured 
for the indicated times in adipogenic medium. Cells were lysed in RIPA buffer 
and equal amount of protein lysates were separated on 10% SDS-PAGE. (A) 
The expression of adenosine receptors were detected by probing with specific 
antibody for each adenosine receptor. Representative blots are shown above. 
(B) A representative Western blot analysis of A2b receptor, phospho-threonine 
and Pro-Q staining in 7F2 cells and after 12 days of adipocyte differentiation. 
Figures on the left indicate sizes (KDa) of protein molecular weight markers.
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5.4.3.3 Adenosine mediated cAMP expression in 7F2 cells and after 
adipocyte differentiation
Studies of adenosine receptor mRNA and protein expression during the 
differentiation of 7F2 cells into adipocytes indicate an increase in Ai, a 
decrease in A2A and an inactivation of A2B receptors. To assess if the 
alterations in adenosine receptor expression during differentiation reflect 
changes in adenosine receptor mediated cAMP expression cultures before 
and after differentiation (7 days) were treated with different concentrations of 
adenosine receptor agonists. When compared to undifferentiated 7F2 cells 
stimulation of cAMP accumulation by adenosine and NECA was markedly 
reduced in the adipocyte cultures (figure 5.4.15 A&B). Following adipogenesis 
cAMP accumulation by adenosine and NECA (10‘4 M) was significantly 
reduced respectively from 4 and 16 fold to 2.5 (P < 0.001) and 5 fold (P < 
0.001). CGS 21680 was only a weak stimulator of cAMP in both 7F2 cells and 
7F2 adipocyte cultures (figure 5.4.15 D). The Ai receptor agonist CCPA 
(figure 5.4.15 C) failed to inhibit forskolin stimulated cAMP levels in 7F2 and 
adipocyte cultures and at 1CT4 M it caused an apparent stimulation. These 
findings overall indicate a loss of adenosine receptor mediated cAMP 
signalling as 7F2 cells are induced to differentiate to adipocytes. Such data is 
consistent with the loss of A2 receptors (both mRNA and protein) as 
previously described. The weak or lack of effect of CCPA suggests that the Ai 
receptor is lowly expressed in 7F2 and adipocyte cultures when compared 
with levels of A2 and in particular the A2B receptor. It is, of course, possible 
that the large increase in Ai receptor mRNA on differentiation is not translated 
to protein.
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Figure 5.4.15 Effect of adenosine receptor agonists on the accumulation 
of cAMP in 7F2 cells and after transdifferentiation into adipocytes. Cells 
were cultured for 9 days in the adipogenic differentiation medium. At the end 
of the incubation period cells were treated with the indicated concentrations of 
(A) adenosine, (B) NECA, (C) CCPA and (D) CGS 21680 for 15 minutes in 
the presence of RO 20-1724 (10'4M) and cAMP was measured using RIA 
(n=3; total of 12 replicates). *P < 0.05, **P < 0.01, and ***P < 0.001 when 
compared with untreated cells; ###P < 0.001 when compared with adipocytes 
treated with agonist at the same concentration.
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5.4.3.4 Effects of adenosine receptor signalling on transdifferentiation of 
7F2 cells
The increase in Ai receptor expression on adipocyte differentiation suggests 
that adenosine itself may be important in the differentiation or function of 
adipocytes. Adenosine (after 12 days of exposure) had only a weak 
stimulatory effect on lipid accumulation and this may reflect its short half-life 
and stability. When the stable agonist, NECA was used stimulated lipid 
accumulation was observed at a much lower concentration of agonist (10'6 M 
for NECA compared with 10-4 M for adenosine) and after 9 days of treatment 
(P < 0.01) (figure 5.4.16). Surprisingly, CGS 21680 also induced 
adipogenesis; this was rather unexpected since it was only a weak stimulator 
of cAMP in both 7F2 and adipocyte cultures. The Ai receptor agonist CCPA 
also resulted in a dose dependent increase in lipid accumulation after 7 days 
of differentiation (P < 0.001), yet its antagonist, PSB 36, failed to inhibit 
adipogenesis when added to the differentiation media alone (figure 5.4.18 A).
5.4.3.5 Effect of adenosine receptor signalling on the expression of 
adipocyte marker genes during the transdifferentiation of 7F2 cells
As previously described (section 5.4.3.1) the adipogenic marker genes, 
PPARy, C/EBPp, LPL and GPDH were upregulated in 7F2 cells as they were 
induced to differentiate to adipocytes. Whether these markers could be 
influenced further by adenosine receptor activation was also investigated 
particularly since a stimulatory effect on lipid accumulation was observed. 
Surprisingly, NECA failed to have effects on any of the adipocyte markers 
above any increases seen with differentiation media alone figure 5.4.17.
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Figure 5.4.16 Effect of adenosine receptor agonists on adipogenesis of 
7F2. 7F2 cells were incubated with adipogenic differentiation medium in the 
presence of the indicated concentrations of adenosine, NECA, CCPA and 
CGS 21680 for 7, 9 and 12 days. Extracted Oil Red O was measured at 490 
nm (n=3; total of 9 replicates). *P < 0.05, **P < 0.01, and ***P < 0.001 when 
compared with the control at the same time point.
227
Chapter 5 Osteoblasts to adipocytes
A lack of effect was also seen with the Ai receptor agonist (CCPA) and its 
antagonist (PSB 36) (figure 5.4.18 B). Adipogenic differentiation of 7F2 cells 
also resulted in reduced osteocalcin mRNA expression, again addition of 
NECA for up to 12 days had no further effect (figure 5.4.19).
5.4.3.6 Stable transfection of Ai and A2B receptors in 7F2 cells
My data indicates that the Ai receptor is important in adipogenesis and the 
A2b receptor is important for osteoblastogenesis. These receptors were thus 
over expressed in 7F2 cells by stable transfection, subsequently named 
7F2Ai and 7F2A2b- Expression of adipocyte and osteoblast markers were 
compared in these cells with cells transfected with only plasmid (pcDNA3.1) 
(7F2c). 7F2Ai cells showed increased L P L  and GPDH mRNA expression (P < 
0.01) (figure 5.4.20 B&C) and reduced A L P  enzyme activity (P < 0.001) when 
compared to 7F2c cells (figure 5.4.21 A). P P A R y  expression in these cells, 
also tended to increase, although statistical significance was not reached 
(figure 5.4.20 A). Surprisingly, enhanced Ai receptor expression also induced 
the expression of osteocalcin (P < 0.01) (figure 5.4.21 B). Overexpression of 
the A2b receptor on the other hand, did not modify LP L , GPDH or P P A R y 
expression (figure 5.4.20 A - C), but did significantly increase A L P  activity (P < 
0.05) and osteocalcin expression (P < 0.001) (figure 5.4.21 A&B).
Morphologically, 7F2Ai and 7F2A2b cells showed respectively increased and 
decreased adipogenesis when compared with 7F2c cells (figure 5.4.22 A). 
Overexpressing the Ai receptor also induced adipogenesis in relation to both
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Figure 5.4.17 Adipogenic gene expression in the presence or absence of 
NECA during the differentiation of 7F2 cells into adipocytes. Cells were 
treated with NECA (10*5 M) for the indicated times in adipogenic media. 
PPARy, C/EBPa, LPL and GPDH mRNA were determined by q-RTPCR and 
compared with undifferentiated cells after normalisation to ARP (n=3; total of 6 
replicates). *P < 0.05, **P < 0.01, and ***P < 0.001 when compared with day 
0.
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Figure 5.4.18 Effect of an Ai receptor agonist and antagonist on 
adipogenesis of 7F2 cells. Cells were treated with CCPA or PSB 36 for the 
indicated times in adipogenic medium. (A) Lipid accumulation quantified by Oil 
Red O (n=4; total of 8  replicates) and (B) LPL mRNA expression determined 
by q-RTPCR and compared with undifferentiated cells after normalisation to 
ARP (n=3; total of 6  replicates).
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Figure 5.4.19 Osteocalcin mRNA expression in the presence or absence 
of NECA during differentiation of 7F2 cells into adipocytes. Cells were 
treated with NECA (10'5 M) for the indicated times in adipogenic media. 
Osteocalcin mRNA expression determined by q-RTPCR and compared with 
undifferentiated cells after normalisation to ARP (n=3; total of 6 replicates). 
**P < 0.01 and ***P < 0.001 when compared with day 0.
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an increase in the number and size of lipid droplets and the number of 
individual adipocytes in the culture. In contrast, cells overexpressing the A2B 
receptor showed reduced adipocyte numbers when assessed microscopically. 
Quantitative analysis of the Oil Red O dye extract showed a significant 
reduction in 7F2A2b cells and a significant increase (P < 0.001) in 7F2Ai cells 
at 5 and 7 day of adipogenic differentiation (figure 5.4.22 B). Similar findings 
were obtained when flow cytometry analysis of Nile red stained cells (figure 
5.4.23 A) was carried out. In addition to an increase in number of adipocytes, 
the mean Nile red fluorescence per unit cell was also upregulated in 7F2Ai 
cultures, suggesting that these cells also contained on average more 
intracellular lipid. Conversely, 7F2A2b cells showed a decrease in Nile red 
fluorescence emission and thus a reduction in the number of adipocytes. The 
amount of lipid accumulated per cell was unaltered (figure 5.4.23 A&B).
5.4.4 Transdifferentiation of HOB cells to adipocytes
5.4.4.1 Evaluation of adipogenesis
HOB cells were induced to differentiate towards the adipocyte lineage using 
insulin, Dex and indomethacin. During 17 days of differentiation, only a small 
number of cells (about 1 - 2%) acquired morphological characteristics of 
adipocytes (figure 5.4.24 B). Lipid droplets were detectable after 14 days and 
increased in size upon longer incubation. HOB cells in basal medium 
expressed high levels of osteocalcin mRNA, however within 2 days of 
inducing adipocyte differentiation expression was reduced by 80% and 
remained at this level thereafter (figure 5.4.25 C).
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Figure 5.4.20 Expression of adipogenic markers in 7F2 cells stably 
transfected with Ai and A2B receptors. (A) PPARy, (B) LPL and (C) GPDH 
mRNA expression was determined by q-RTPCR and compared with 
pcDNA3.1 alone (7F2c) cells after normalisation to ARP (n=3; total of 6 
replicates). **P < 0.01 when compared with 7F2c.
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Figure 5.4.21 ALP enzyme activity and osteocalcin mRNA expression in 
7F2 cells stably transfected with Ai and A2b receptors. (A) ALP activity 
was measured and normalised to cell number (n=3; total of 36 replicates). (B) 
Osteocalcin was determined by q-RTPCR and compared with pcDNA3.1 
alone (7F2c) cells after normalisation to ARP (n=3; total of 6 replicates). *P < 
0.05, **P < 0.01, and ***P < 0.001 when compared with 7F2c
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Figure 5.4.22 Adipogenesis as determined by Oil Red O staining in 7F2 
cells stably transfected with Ai and A2B receptors. Cells were incubated 
with adipogenic medium for 5 and 7 days. Lipid accumulation was (A) 
visualised after 7 days by staining with Oil Red O and (B) quantified by 
measuring the amount of retained dye in lipid vacuoles at 490 nm (n=3; total 
of 9 replicates). ***P < 0.001 when compared with the 7F2c.
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Figure 5.4.23 Adipogenesis as determined by Nile red staining in 7F2 
cells stably transfected with Ai and A 2b receptors. Cells were incubated 
with adipogenic medium for 5 days. (A) Number of Nile red positive cells and 
(B) mean Nile red fluorescence emission was quantified with flow cytometry 
(n=3; total of 6 replicates). *P < 0.05 and ***P < 0.001 when compared with 
the 7F2c.
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HOB cells also expressed PPARy mRNA, which increased progressively 
during the transdifferentiation process (15 - 20 fold after 17 days) (figure
5.4.25 A). In contrast, expression of LPL mRNA was undetectable in HOB 
cells and was only detectable after 17 days of adipocyte differentiation (figure
5.4.25 B).
5.4.4.2 Adenosine receptor expression during adipocytic 
transdifferentiation of HOB cells
In contrast to adipogenesis of MSCs and 7F2 cells where there were marked 
upregulation in expression of Ai adenosine receptor, adipogenic 
transdifferentiation of HOB cells was associated with a reduction in Ai 
receptor expression. As shown in figure 5.4.24 C, A1 receptor mRNA was 
reduced within 2 days and remained low during 17 days of differentiation; 
there was however, no effect on Ai receptor protein expression (figure 5.4.24 
F). Induced transdifferentiation of HOB cells did not affect A2A and A2b 
receptor mRNA or protein expression (figure 5.4.24 D - F).
5.4.4.3 Effects of NECA on adipogenic transdifferentiation of HOB cells
Treatment with NECA stimulated adipocyte formation of HOB cells when 
compared to untreated controls. This effect was apparent by an increase in 
the number of lipid containing adipocytes seen microscopically in NECA 
treated cultures. However, due to a limited number of cells the analysis by Oil 
Red O staining was not possible. In addition, PPARy expression tended to 
increase in NECA treated cells, although statistical significance was not 
reached (figure 5.4.25 A). Similar to untreated HOB cells, the expression of
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LPL mRNA was undetectable after 12 days of adipocyte differentiation; at day 
17 LPL was clearly detectable and significantly induced by NECA (figure
5.4.25 B).
5.4.4.4 Effects of NECA on osteoblast marker expression in HOB cells in 
the absence of differentiating media
HOB cells were cultured in the presence or absence of NECA (10'5 M) for the 
indicated times and ALP and osteocalcin expression was analysed by q- 
RTPCR. When normalised and compared to untreated cells, the expression of 
both ALP and osteocalcin was found significantly reduced in NECA treated 
cells (figure 5.4.26 A and 5.4.27 A respectively). The relative mRNA 
expression for ALP was reduced by 40% and 45% and for osteocalcin by 14% 
and 30% after 2 and 7 days treatment with NECA respectively. Similar data 
were observed when NECA treated cells were analysed for ALP enzyme 
activity (figure 5.4.26 B). NECA and adenosine also inhibited mineralisation of 
HOB cells as determined by Alizarin Red S staining (figure 5.4.27 B). 
Treatment with adenosine (10-4 M) and NECA (10'5 M) respectively also 
resulted in a reduction in mineralisation in presence of AA and p-GP.
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Figure 5.4.24 Differentiation of HOB cells to adipocytes and expression 
of adenosine receptors. Oil Red O staining of (A) HOB cells and after (B) 17 
days of adipogenesis (Magnification x100, inset x200). (C - E) q-RTPCR 
shows adenosine receptor mRNA expression, relative to the housekeeping 
gene, APRT (n=3; total of 6  replicates). ***P < 0.001 when compared with day 
0. (F) A representative Western blot showing expression of Ai and A 2b 
receptor proteins in HOB cells and after 17 days of adipocyte differentiation. 
The A 2a and A3 receptors were not detectable. Left margin indicates the sizes 
(kDa) of protein marker.
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Figure 5.4.25 Expression of PPARy, LPL and osteocalcin mRNA in the 
presence or absence of NECA during the differentiation of HOB cells 
into adipocytes. Cells were treated with NECA for the indicated times in 
adipogenic medium. mRNA expression for (A) PPARy, (B) LPL (for 17 days) 
and (C) osteocalcin was determined by q-RTPCR and presented as the 
relative mRNA expression level to undifferentiated cells after normalisation to 
APRT (n=3; total of 6 replicates). *P < 0.05, **P < 0.01, and ***P < 0.001 
when compared with day 0.
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Figure 5.4.26 Effect of NECA on ALP mRNA expression and enzyme 
activity in HOB cells. Cells were treated with NECA (10'5 M) for 2 and 7 
days. (A) ALP mRNA was determined by q-RTPCR and presented as relative 
expression to that of undifferentiated cells after normalisation to APRT (n=3; 
total of 6 replicates). ***P < 0.001 when compared with vehicle control. (B) 
ALP activity was measured and normalised to protein content (n=2; total of 24 
replicates). Data are expressed as mean ± SDM.
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Figure 5.4.27 Effects of adenosine and NECA on osteocalcin mRNA 
expression and mineralisation in HOB cells. Cells were treated with NECA 
(10‘5 M) for 2 and 7 days and (A) osteocalcin mRNA was determined by q- 
RTPCR and presented as relative expression to undifferentiated cells after 
normalisation to APRT (n=3; total of 6 replicates). **P < 0.01 when compared 
with vehicle control. (B) Cells were treated with adenosine (10'4 M) and NECA 
(10"5 M) or appropriate vehicle control in mineralisation medium and calcium 
deposition was determined.
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5.5 Discussion
5.5.1 Expression of adenosine receptors in 7F2 and HOB cells
In the previous chapters, adenosine receptors were shown to be differentially 
expressed and functionally involved in the differentiation of MSCs into 
osteoblasts and adipocytes. The goal of this chapter was to determine the 
expression profile and functional properties of adenosine receptors in primary 
HOB and mouse 7F2 osteoblasts and during their transdifferentiation into 
adipocytes. In agreement with earlier findings in rat MSCs and human 
osteoprogenitor cells, mRNA expression for all four adenosine receptors was 
present in both cell types. Similar findings were obtained by Russel et al 
(2007), however they were unable to detect expression of the A3 receptor in 
MG-63 osteoblastic cells. In both 7F2 and HOB cells the A3 receptor was 
detectable using qRT-PCR but the protein was not evident, at least on 
Western blotting analysis.
Protein bands for the Ai, A2A and A2B receptors were easily detectable in 7F2 
cells. The sizes of the Ai and A2A receptors in rat MSC and mouse 7F2 cells 
were similar but the A2B receptor appeared as a band with apparent molecular 
mass of 36 kDa in both 7F2 and HOB cells, in contrast to the 52 kDa 
observed in rat. This correlates with the predicted molecular mass of A2B 
receptors and is consistent with those reported by other groups in many cell 
types including a human osteoblast cell lines (Linden et al., 1999; Russell et 
al., 2007). The larger mass for the A2b receptor in rat MSCs could be 
attributed to tissue or species specific differences as shown by other 
investigators (Puffinbarger et al., 1995). Ai but not A2A receptor proteins were
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also detectable in HOB cells. The lack of A2A receptor expression is consistent 
with the low level of mRNA expression observed in HOB cells.
The cAMP data obtained from 7F2 cells indicates a predominance of A2B 
receptors. In the presence of adenosine, NECA and CGS 21680, the cAMP 
accumulation was increased with a rank order of potency of NECA > 
adenosine > CGS 21680. These findings were also found in MSCs and are 
compatible with cells expressing recombinant or endogenous adenosine A2B 
receptors (Feoktistov and Biaggioni, 1998; Klotz et al., 1997; Linden et al., 
1999).
Besides coupling to the adenylate cyclase dependent signal cascade, 
adenosine receptors have been demonstrated to be able to couple to at least 
one subfamily of MAPK in a variety of cell types, including rat smooth muscle, 
human endothelial cells, embryonic kidney (HEK-293) cells, mast cells and 
melanoma cells (Feoktistov et al., 1999; Gao et al., 1999; Merighi et al., 
2002a; Robinson and Dickenson, 2001; Sexl et al., 1997). The data reported 
in this chapter shows that adenosine receptors can also be coupled to the 
MAPK pathway in osteoblasts.
In 7F2 cells, NECA caused time and dose dependent ERK phosphorylation, 
which was rapid and transient, peaking at 5 minutes, and returning to the 
basal level after 60 minutes; a similar transient stimulation has been reported 
in HEK-293 cells (Gao et al., 1999). The duration of the ERK signal is 
regulated by different upstream events in the ERK signal cascade and is
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thought to be linked to different cellular responses (Ebisuya et al., 2005). The 
concentrations of NECA used to stimulate ERK phosphorylation were 
comparable to those used in the activation of cAMP suggesting that the ERK 
is also an important signalling pathway for adenosine receptors. These 
observations were in agreement with other findings showing that the EC5o for 
NECA induced ERK activation is in the lower micro-molar range (Gao et al., 
1999; Grant et al., 2001). As with the cAMP responses in 7F2 cells, NECA 
induced ERK activation also appears to be mediated through the A2B receptor 
as selective agonists for the Ai and A2A receptors failed to have an effect and 
NECA activation of ERK was inhibited by a selective A2b receptor, but not by 
an Ai or A2A receptor, antagonist. The coupling of A2b receptors to ERK 
signalling have been demonstrated in HEK-293 cells, mast cells and retinal 
endothelial cells (Feoktistov et al., 1999; Gao et al., 1999; Grant et al., 2001; 
Schulte and Fredholm, 2003a).
A2b receptor linked ERK activation can be mediated through multiple 
signalling cascades that are either cAMP dependent (Gs/cAMP/PKA -> B-Raf 
MEK1/2 ERK1/2) and (Gs/cAMP PI3K MEK1/2-* ERK1/2) or 
cAMP independent (Gq11 —> PLC/Ca2+/DAG ->• tyrosine kinase -> Ras^ B- 
Raf/C-Raf-> MEK1/2 ERK1/2) and (Gq11-> PLC/Ca2+/DAG -> PKC-> 
MEK1/2 ERK1/2). The precise pathways involved may depend on the cell 
type (Feoktistov et al., 1999; Gao et al., 1999; Grant et al., 2001; Schulte and 
Fredholm, 2000; Schulte and Fredholm, 2003a). Although it is clear that the 
A2b receptor acts through cAMP in 7F2 cells, the adenylate cyclase inhibitor, 
DDA, only partially reduced the NECA stimulation of ERK activation. The
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incomplete inhibition of the ERK response suggests that a pathway 
independent of cAMP is also involved. This suggestion is supported by 
experiments that showed the PLC inhibitor, U-73122, inhibited NECA induced 
ERK1/2 phosphorylation. Such findings are in agreement with that of Gao et 
al who demonstrated that A2B induced ERK activation in HEK-293 cells 
required PLC (Gao et al., 1999). Moreover, as expected, the MEK inhibitor, 
PD 98059 completely abolished ERK activation. Ras/B-Raf has been 
described previously to be intermediate signal molecules in the PLC/MEK 
induction of ERK activation via the A2B adenosine receptor in HEK-293 cells 
(Gao et al., 1999). This pathway may also be important in osteoblasts. The 
PKC inhibitor RO-32-0432 and the PI3K inhibitor, Wortmannin failed to inhibit 
NECA stimulated ERK phosphorylation. The inhibitory action of RO-32-0432 
on PKC was confirmed by demonstrating the loss of PMA induced ERK 
activation, whereas the PLC inhibitor U-73122 was without effect. Together 
these data demonstrate that NECA induces phosphorylation of ERK 2 in 7F2 
cells by a pathway that is most likely coupled to Gs, and Gq/11 proteins but is 
independent of PKC and PI3K. Similar findings has been previously described 
by Gao (1999) and colleagues in HEK-293 cells.
An important target that is activated by both ERK and cAMP/PKA pathways is 
the transcription factor CREB (Johannessen et al., 2004). Since A2B receptor 
is shown here to activate both cAMP and ERK pathways in 7F2 cells, it is 
likely that one or both of these pathways subsequently activate the 
phosphorylation of CREB in these cells. NECA caused a rapid and transient 
increase in CREB phosphorylation which was inhibited by PD 98059 and U-
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73122, consistent with its inhibitory actions on NECA induced ERK signalling. 
A similar effect was seen with the PKC inhibitor, RO-32-0432, suggesting that 
PKC may be an intermediate step downstream of ERK and upstream of 
CREB signalling. The weak or lack of effect of DDA and Wortmannin on 
CREB signalling was in agreement with that seen on ERK phosphorylation. 
Given the complexity of interactions between the cAMP, ERK and CREB, no 
firm conclusions can be drawn about the signal pathways associated with 
NECA activation of 7F2 cells. Nevertheless, my experiments do indicate a 
possible involvement of the A 2b receptor that is linked to PLC, MEK, ERK, 
PKC and CREB but less likely with PI3K (figure 5.5.1).
Adenylate cyclase PLC
cAMP Ras/B-Raf (?)
PKA
CREB PKC ERK2
Figure 5.5.1 Possible pathways of ERK and CREB activation by A 2b 
receptor in 7F2 cells.
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5.5.2 Adenosine receptor expression and function in the
transdifferentiation of 7F2 and HOB cells to adipocytes
Both HOB and 7F2 cells correspond to mature osteoblasts as evidenced here 
by expression of ALP and osteocalcin and positive staining for extracellular 
matrix mineralisation. Induction of adipogenesis in 7F2 cells resulted in the 
formation of lipid droplets in at least 50% of the cells and strong expression of 
adipogenic markers PPARy, C/EBP, LPL and GPDH and loss of the late 
osteogenic marker, osteocalcin. These findings are in agreement with those 
reported by Thompson et al (1998). An interesting observation was the 
progressive reduction in the expression of adipocyte markers (and indeed of 
the Ai receptor and the enzyme, CD73) after reaching a peak after 7 days of 
differentiation. This could be explained by the loss of mature adipocytes from 
the cell monolayer surface, as they are filled with lipid and can become easily 
detached. Similar observations have been reported by others and are 
attributed to the reduction in production of matrix proteins as well as 
morphologic changes due to lipid accumulation (van Harmelen et al., 2005).
In contrast to 7F2 cells, transdifferentiation of HOB cells was slow and only 
resulted in conversion of about 1 - 2  % of the cells into lipid containing 
adipocytes. Furthermore, the loss of osteoblastic genotype i.e. osteocalcin 
expression occurred well before any increase in expression of adipogenic 
associated genes was observed. This may suggest that cells might have 
dedifferentiated to a progenitor cell stage prior to redifferentiation into 
adipocytes. Dedifferentiation prior to transdifferentiation of osteoblasts has 
been previously reported by Song et al (2004 and 2006) who showed that fully
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differentiated MSCs (i.e. mature osteoblasts, adipocytes, and chondrocytes) 
lose their characteristic markers prior to transdifferentiation upon withdrawal of 
the inducing stimulus. Park et al (1999) also showed that mature human 
adipocytes were able to dedifferentiate and redifferentiate into osteoblasts.
The observation that HOB cells, in our hands, could only be weakly induced to 
adipocytes may somehow account for the reduced Ai adenosine receptor 
expression. Adipocyte transdifferentiation of 7F2 cells was associated with a 
marked increase in Ai receptor mRNA expression and an increase (albeit at a 
lower level) in protein expression. In chapter 4, I also showed that Ai mRNA 
expression was increased as rat MSCs were induced to differentiate to 
adipocytes and this also occurs during the maturation of preadipocytes 
(Borglum et al., 1996). The apparent reduction in Ai receptor expression 
during adipogenesis of HOB cells is unlikely to be related to the media used 
for adipocyte induction as the same media was used for HOBs and MSCs. It 
is possible that HOB cells undergo dedifferentiation with a loss of Ai receptors 
prior to undergoing differentiation to adipocytes. In addition weak staining with 
Oil Red O could suggest that during induced adipogenic differentiation HOB 
cells only reach the preadipocyte stage and such cells only have low 
expression of Ai receptors (Borglum et al., 1996; Fatholahi et al., 2006; 
Johansson et al., 2008; Vassaux et al., 1993). This is consistent with the 
finding that the late adipogenic marker (LPL) was only observed after 17 days 
of differentiation and even then at a low level in contrast to that seen in 7F2 
adipocyte differentiation. Thus the majority of cells in the HOB differentiation 
experiments were not mature adipocytes.
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Transdifferentiation of 7F2 cells was also accompanied with a loss of the A2a 
and A2b receptors at both the mRNA and protein level and putative 
inactivation (phosphorylation) of the A2b receptor. Although 
immunoprecipitation experiments were unsuccessful, possibly due to low 
expression of the A2b receptor after adipogenesis, I was able to show co­
elution of the putative phosphorylated band with bands labelled with anti- 
phosphothreonine and Pro Q. Loss of A2 receptors were also demonstrated, 
mechanistically, by losses in cAMP, ERK and CREB activation. Similar to 
these data, Borglum and colleagues (Borglum et al., 1996) also demonstrated 
a reduction in A2 receptors during the adipogenesis of Ob1771 preadipocytes. 
Such findings could suggest that A2 receptors are associated with an 
osteoblast phenotype and this was demonstrated when MSCs were induced 
to differentiate to adipocytes (chapter 3) and on the transfection of A2B 
receptors into 7F2 cells. The loss of A2 receptors (particularly the A2b 
receptor) is also likely to be associated with an inhibitory role for these 
receptors in the transdifferentiation of osteoblasts into adipocytes. Similar 
observation have been reported for other inhibitors of adipogenesis (such as 
TAZ) that are downregulated during the adipogenesis process (Hong and 
Yaffe, 2006).
The increase in Ai receptor expression during adipogenesis may suggest that 
adenosine itself is important in the differentiation process. In support of this 
was the observation that CD73 is upregulated and ADA is downregulated 
during differentiation. Interestingly these changes also peaked around days 4 
- 7 which mirrored changes in adipocyte marker expression. The increase in
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CD73 with a concomitant decrease in ADA expression suggests that 
adenosine levels accumulate on adipocyte differentiation. The presence of 
increased endogenous adenosine levels may limit the effects of adding 
exogenous adenosine and could explain the lack of effects of NECA on 
adipocyte marker expression seen in our experiments. In addition, it should be 
noted that 7F2 cells undergo strong adipogenesis in the presence of 
adipogenic inducing agents and this may overshadow any additional effects of 
adenosine. Nevertheless, adenosine receptor agonists did have moderate 
effects on differentiation of 7F2 cells in the presence of differentiating media 
and NECA similarly stimulated an increase in LPL mRNA expression in HOB 
cells undergoing differentiation. Additional experiments in HOB cells indicated 
that NECA could inhibit markers of osteoblastogenesis (ALP and osteocalcin) 
in the absence of adipocyte differentiation media as well as inhibiting 
mineralisation. These data could also imply that activating adenosine 
receptors could stimulate adipogenesis.
Overall my data on 7F2 and HOB differentiation as well as that on MSC 
differentiation to osteoblasts and adipocytes suggest that the Ai and A2b 
receptors are particularly important in the adipogenesis and 
osteoblastogenesis processes respectively. The Ai receptor in adipocytes has 
been extensively studied (see section 1.4.9) and is shown to increase 
lipogenesis and reduce lipolysis (Cheng et al., 2000; Dhalla et al., 2007b; 
Johansson et al., 2008; Rice et al., 2000; Sollevi and Fredholm, 1981; 
Vannucci et al., 1989). Stable transfection of the Ai and A2b receptors into 
7F2 cells respectively increased and decreased adipogenesis as determined
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by lipid accumulation. Tatsis-Kotsidis and Erlanger (1999) similarly reported 
that Ai receptor overexpression in murine preadipocytes (ob17) also 
stimulated adipocyte differentiation. Enhanced Ai but not A2b receptor 
expression also increased markers of adipogenesis. ALP and osteocalcin 
were also upregulated with the A2b receptor and overexpression of the Ai 
receptor decreased ALP but surprisingly stimulated osteocalcin expression. 
This could suggest that the Ai receptor may be linked to other signal 
pathways which may indirectly affect osteocalcin expression. One possibility is 
the activation of K+ channels that has been previously shown by our lab to be 
involved in the mineralisation of osteoblasts (Henney et al., 2009). To 
determine whether the Ai receptor was a necessary factor for adipogenic 
transdifferentiation, I have also tried to use an siRNA approach to knockdown 
the Ai receptors in 7F2 cells. However the effort was hampered by its low 
expression level even following adipogenesis.
Together the data from this chapter suggest a possible role for Ai receptors in 
the differentiation of adipocytes and for A2B receptors in maintaining the 
osteoblastic phenotype.
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6.1 Summary and discussion
There has been increasing interest in recent years in determining the factors 
that regulate the differentiation of MSCs into osteoblasts and adipocytes. 
Such information would enable the development of strategies for treating 
diseases such as osteoporosis that are associated with an imbalance in the 
differentiation and function of these lineages. Drugs that are in therapeutic 
use for bone loss target predominantly inhibition of osteoclast activity. PTH is 
the only anabolic drug currently in clinical use for osteoporosis. Based on 
previous data which showed that adenosine receptors are important for the 
function of human osteoprogenitor cells, the data presented here describe the 
expression and function of adenosine receptors in MSCs and during their 
differentiation to osteoblasts and adipocytes, as well as in osteoblasts and 
during their transdifferentiation to adipocytes.
Adenosine exists in all cells as part of the ATP metabolic pathway and 
concentrations fluctuate on cellular activity, stress and inflammation indicating 
that the different adenosine receptors which have different Km values can be 
activated according to the nature of the microenvironment. In addition, 
activation of specific adenosine receptors to either stimulate (A2a and A2b 
receptors) or inhibit (Ai and A3 receptors) cAMP could suggest that reciprocal 
changes in cAMP levels may be important for lineage specific differentiation. 
The findings presented here show that Ai receptors play a dominant role in 
the differentiation and function of adipocytes and that A2 receptors seem to be 
important in MSCs and osteoblasts.
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Although all four adenosine receptors were detectable (at least at the level of 
the gene) in MSCs, the A2b receptor was dominantly expressed and their 
activation was sufficient to promote differentiation towards the osteoblast 
lineage as evidenced by increased ALP expression. Interestingly, the A2b 
receptor gene and protein expression appeared to be transiently unregulated 
as cells differentiated into osteoblasts, suggesting this receptor may have a 
role in early osteoblastic differentiation. On the other hand the A ^  receptor 
gene and protein expression appeared to increase during later stages of 
osteoblastic differentiation. From this data one can speculate that A2B 
receptors are more important for commitment and differentiation to 
osteoblasts, and that the A 2a receptors are important for osteoblast maturation 
and maintenance of the osteoblast phenotype. There was also a progressive 
increase in A ^  receptor mediated cAMP expression as MSCs were induced 
to differentiate to osteoblasts which may also support a role for the receptor in 
later differentiation. Nevertheless, the A2b receptor remained the dominant 
receptor throughout the differentiation process and its activation leads to a 
stimulation of osteoblast associated genes.
The A2b receptor was also dominantly expressed in 7F2 osteoblasts and 
shown to be coupled to cAMP, ERK and CREB signalling molecules. 
Activation of these pathways has been previously implicated in differentiation 
and function of osteoblasts (Ge et al., 2007; Lai et al., 2001; Pearman et al., 
1996; Pekkinen et al., 2008; Siddappa et al., 2008). Overexpression of human 
A2B receptors in 7F2 cells resulted in increased expression of osteoblastic 
markers i.e. osteocalcin and ALP, whilst limiting the ability of 7F2 cells to
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differentiate to adipocytes (down regulation of lipid accumulation). On the 
basis of these findings this work proposes that A2 receptors are important for 
bone homeostasis by stimulating differentiation towards an osteoblast lineage 
and the maintenance of an osteoblast phenotype.
The Ai receptor, in contrast to A2 receptors, was found to be involved in 
adipogenesis and adipocyte function. Ai receptor expression is reported to be 
low in preadipocytes, but increases on adipogenesis and remains at high 
levels in mature adipocytes (Borglum et al., 1996; Fatholahi et al., 2006; 
Vassaux et al., 1993). My data concur with these findings. I showed that the 
expression of the Ai receptor in rat MSCs and 7F2 cells was low and that it 
increased markedly on differentiation to adipocytes. Ai mRNA expression 
increased respectively > 800 and 1600 fold as MSCs and 7F2 cells were 
induced to differentiate to adipocytes; this was accompanied by increases in 
protein expression. On the other hand when MSCs were differentiating to 
osteoblasts there was < 5 fold increase in Ai mRNA and no change in protein 
expression. The importance of the Ai receptor in adipogenesis was also 
supported by over expression experiments in 7F2 cells; this led to an 
upregulation of lipid accumulation and an increase in adipocyte marker 
expression.
Surprisingly this appeared not to be borne out in HOB cell differentiation to 
adipocytes, where the Ai receptor appeared to be reduced. These findings 
have to be treated with caution as only 1 - 2 % of cells differentiated to 
adipocytes. In contrast, over 50% of the cells were found to be adipocytes
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when 7F2 cells underwent adipogenesis. The importance of the Ai receptor in 
adipocytes has been previously described by several groups (see section 
1.6.3). Its overexpression in murine preadipocytes (ob1771) was shown to 
enhance adipogenesis and treatment with universal adenosine receptor 
agonists to increase corticosterone-induced differentiation of preadipocytes 
suggested that Ai receptors are important for adipocyte differentiation 
(Borglum et al., 1996; Tatsis-Kotsidis and Erlanger, 1999).
It appears that adenosine can be important for both osteoblast and adipocyte 
differentiation. When MSCs were induced to differentiate to osteoblasts 
adenosine stimulated osteoblast marker expression and similarly it also 
stimulated adipocyte marker expression during induced adipogenesis. 
Transdifferentiation experiments in 7F2 and HOB cells also showed that 
adenosine receptors mediate adipogenesis in an adipogenic environment. 
Which cells dominate will depend on the nature of the microenvironment, the 
level of adenosine and the type of adenosine receptors expressed. It has also 
been previously reported that osteoblasts undergo a dedifferentiation step to a 
more primitive cell prior to transdifferentiation to a cell of a different lineage 
(Song and Tuan, 2004; Song et al., 2006); whether this occurs in the 7F2 and 
HOB cell adipogenic experiments is not known.
6.2 Future studies
The prime aim of these studies was to demonstrate the importance of 
adenosine receptor signalling pathways in the differentiation and function of 
osteoblasts and adipocytes and to identify putative targets which could be
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considered for therapeutic intervention. My data thus far clearly show that A2b 
and A2A receptors are important for osteoblasts and Ai receptors are 
important for adipogenesis.
Some concerns do however need to be noted, for example rat MSCs may 
behave differently to human MSCs and experiments in vitro may not replicate 
the in vivo situation. This is borne out by the studies of Siddappa et al (2008 
and 2009) who showed that cAMP increased human osteoblast differentiation 
in vitro and bone formation in vivo, whereas in rodent cells, it inhibited ALP, 
osteocalcin, and collagen type I expression. In my experiments HOB cells, in 
comparison to murine 7F2 cells only, showed poor adipogenesis so these 
experiments need to be corroborated. The use of human primary cells, 
however, could also be problematic due to cell heterogeneity. There may well 
be differences in growth and differentiation capacity which is further 
compounded by the age of donors and the cell passage number. In addition 
cultures after induced differentiation still possessed multiple cell types which 
may make data interpretation difficult. This could perhaps be overcome by 
separating out the different cell types either by FACS analysis or magnetic 
bead separation.
Co-expression of several adenosine receptors in MSCs and osteoblasts make 
it difficult to determine precisely which receptor/s are involved in differentiation 
processes and cell specific function. Studies are also hampered by the lack of 
specific adenosine receptor agonists particularly those that target the A2b 
receptor. Specificity may also be lost when compounds are used at high 
concentration or during prolonged exposure which could lead to receptor
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desensitisation. Thus as well as pharmacological intervention of receptor 
action a number of other experimental models should be considered, these 
include receptor overexpression and inhibition (siRNA) as well as gene 
knockout animals.
Some of my findings also need further clarification: although the Ai receptor 
seemed to be only lowly expressed in MSCs and 7F2 cells, incubation with 
the Ai receptor agonist CCPA markedly stimulated adipogenesis. In my 
experiments, a rather surprising finding was the observation that Ai receptor 
overexpression in 7F2 cells increased osteocalcin expression. These findings 
could relate to up or down regulation of other signal molecules, for example Ai 
receptors might mediate osteoblast mineralisation through activation of K+ 
channels (Henney et al., 2009). Ai receptors are also involved in lipolysis and 
lipogenesis (Dhalla et al., 2007b; Johansson et al., 2008; Vannucci et al., 
1989) and this needs to be addressed in the context of adipogenesis of MSCs 
and osteoblasts.
It would also be interesting to assess the concentrations of adenosine 
produced in the microenvironment during cellular differentiation to either 
osteoblasts or adipocytes, and whether such concentration alone can 
influence differentiation or stimulate adenosine receptor expression. This may 
be particularly pertinent as CD73 appeared to increase, and ADA appeared to 
decrease, during adipogenesis of 7F2 cells.
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The precise role of adenosine receptors in osteoblast or adipocyte 
differentiation needs to be clarified and this can be potentially addressed by 
using pure cell populations and if possible of human origin. In the context of 
osteoblastogenesis, adenosine receptor expression and function in 
osteoclasts should provide interesting information particularly since bone 
homeostasis requires a balance in the activities of osteoblasts and 
osteoclasts. Adenosine receptors have been shown to mediate the release of 
hormones, growth factors and cytokines from MSCs, adipocytes and 
osteoblasts (Hasko et al., 2009; Hasko et al., 2008). Such compounds could 
have both autocrine and paracrine effects and could affect both adipocytes 
and osteoblasts. Ai receptors mediate leptin secretion from adipocytes (Rice 
et al., 2 0 0 0 ) and leptin has complex actions on bone, including stimulating 
differentiation and inducing apoptosis (see section 1.5.2). Expression of these 
molecules during osteoblast or adipocyte differentiation in response to 
adenosine receptor stimulation needs to be investigated.
6.3 Clinical importance
To date, targeting adenosine receptors for stimulating bone formation has not 
been considered. The data obtained in this study suggest that stimulation of 
A2 and inhibition of Ai receptors could potentially be useful for stimulating 
osteoblastogenesis. In terms of therapy involving adenosine receptors there 
are several compounds in clinical trials that act mainly at the A2a and A3 
receptors. Many of these compounds rely on their anti-inflammatory properties 
and aimed at a variety of diseases that include diabetes, cancer, psoriasis, 
asthma and RA. RA is particularly interesting since MTX, the most commonly
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used anti-rheumatic drug induces increased levels of adenosine and a 
reduction in inflammation. Combination therapy of MTX and CF101 (A3 
receptor antagonist) is more effective than either drug alone (Ochaion et al., 
2006). The action of adenosine or which adenosine receptors are expressed 
in bone in the setting of RA is unknown.
Antagonism of the A2B receptor has also been considered for diseases such 
as asthma, diabetes and inflammatory bowel disease. Targeting A 2b receptors 
is particularly challenging due to the lack of agonist selectivity; two 
compounds have been recently developed (LUF5835 and BAY 60-6583) that 
claim to show good specificity but there is no information available on their 
effectiveness in a clinical setting (Beukers et al., 2004; Chen et al., 2009). The 
use of adenosine receptor agonists and antagonists need to be approached 
with caution as receptors are widely distributed and mediate a diverse range 
of actions. For example the Ai receptor agonist, selodenoson, and the mixed 
Ai/A2a agonist, AMP579, have been removed from clinical trials due to side 
effects (Jacobson and Gao, 2006). In spite of this the development of more 
specific agonists and antagonists for adenosine receptors by several 
pharmaceutical companies is still ongoing.
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